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Zusammenfassung 
Von Bakterien produzierte Sekundärmetabolite weisen enorme strukturelle Diversität und 
erstaunliche biologische Aktivitäten auf. Diese Arbeit gewährt neue Einblicke in die 
Biosynthese der myxobakteriellen Sekundärmetabolitfamilie der Tubulysine durch in vitro 
und in vivo Experimente zusammen mit der Identifizierung und Charakterisierung neuer 
struktureller Varianten.  
Die komplizierte Biosynthese der Aurachine in Stigmatella aurantiaca Sg a15 wurde 
aufgeklärt. In vitro Experimente legten einen einmaligen Mechanismus zur Bereitstellung der 
Anthranilsäure Startereinheit offen und in vivo Inaktivierungsexperimente resultierten in der 
Identifizierung der modifizierenden Enzyme, die für die schrittweise Umwandlung von 
Aurachin D zu Aurachin A verantwortlich sind. 
Ein weiterer Gegenstand dieser Arbeit war die Untersuchung der Biosynthese von 
2-Heptyl-4(1H)-chinolin (HHQ), ein wichtiges Quorum sensing Molekül in 
Pseudomonas aeruginosa. Die Rekonstruktion der HHQ-Biosynthese in vitro mittels 
rekombinantem PqsD Protein gab Aufschluss über dieses Enzym und seine Substrate und 
führte zur Entwicklung eines in vitro Testsystems zur Identifizierung von Inhibitoren der 
Biosynthese von HHQ, ein vielverspechendes alternatives Angriffsziel für die Therapie von 
Infektionen mit P. aeruginosa. 
Das kürzlich sequenzierte Genom von S. aurantiaca Sg a15 wurde für einen „Genome 
mining“ Ansatz genutzt. Dieser setzt sich zusammen aus der gezielten Inaktivierung 
bestimmter Gene und einer statistikgestützten vergleichenden Analyse der 
Sekundärmetabolitprofile. Dadurch konnte der Biosynthesegencluster von Rhizopodin 
identifiziert und charakterisiert werden. 
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Summary 
Bacterial secondary metabolites display enormous structural diversity with astonishing 
biological activities. This thesis confers new insights into the biosynthesis of the 
myxobacterial secondary metabolites tubulysins by both in vitro and in vivo experiments, 
along with the identification and characterization of new structural variants. 
The cryptic biosynthetic pathway of the aurachins in Stigmatella aurantiaca Sg a15 was 
elucidated. In vitro experiments revealed an unparalleled priming mechanism for the 
anthranilate starter unit. In vivo gene inactivation experiments resulted in the identification of 
the tailoring functionalities responsible for the successive transformations from aurachin D to 
aurachin A. 
Another topic of this thesis was the investigation of the biosynthesis of 2-heptyl-4(1H)-
quinolone (HHQ), an important quorum sensing molecule in Pseudomonas aeruginosa. In 
vitro reconstitution of HHQ biosynthesis by employing recombinant PqsD protein has shed 
light on this enzyme and its substrates, leading to the development of an in vitro test system 
for the identification of HHQ biosynthesis inhibitors, a promising alternative target in 
P. aeruginosa therapy.  
Exploiting the newly sequenced genome of S. aurantiaca Sg a15 a genome mining 
approach, combining targeted gene inactivation with a statistics based comparative secondary 
metabolite profile analysis, was adapted and employed. This culminated in the identification 
and characterization of the rhizopodin biosynthetic gene cluster. 
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A. Introduction 
1. The importance of natural products in drug discovery  
– From the past to the future 
1.1 The past 
Natural products have had and still have an invaluable impact on modern-day medicine. 
Natural products are defined as chemical substances produced by living organisms - plants, 
microorganisms, or animals. Since this definition holds true for almost every cellular matter, 
the term natural product usually refers to compounds that exhibit distinct pharmacological or 
biological activities. A synonymously used term is secondary metabolites, implying that these 
organic compounds are not directly involved in normal growth, development, or reproduction 
and are therefore not absolutely essential for the survival of its producer. Mankind’s use of 
plants for the treatment of ailments can be traced back to the prehistoric times. Through the 
course of time, this knowledge has grown immensely and led to the development of a number 
of traditional medicines based on the use of indigenous medicinal plants. The identification of 
the active components of these medicinal plants was very fruitful for the pioneering days of 
drug discovery. More than 200 years ago, Friedrich Sertürner isolated morphine from 
Papaver somniferum, an event often regarded as the birth of modern natural product 
research.[1]  
An astonishing number of the drugs in clinical use today are either derived from, inspired 
by, or natural products themselves. A remarkable 52% of all new chemical entities approved 
between 1981 and 2006 can be attributed to natural products (Figure A-1).[2] 5% are natural 
products themselves, 23% are semisynthetic derivatives of natural products, and another 24% 
are somehow derived from a natural product pharmacophore. When considering specific 
indications, the numbers become even more impressive. For drugs with anticancer activity or 
antibacterial activity, a combined 63% and 69%, respectively, can be traced back to natural 
products. 
A. Introduction 
 
2 
 
 
Figure A-1. Origin of all new chemical entities approved in between 1981 – 2006 (modified from 
Newman et al. [1]) 
Nowadays, regulatory agencies request highly detailed knowledge of the chemical structure of 
the active pharmaceutical ingredient (API), pharmacodynamic and pharmacokinetic 
parameters, along with proof of efficacy, safety, purity, and content for every single drug 
submitted for approval. Classic herbal remedies usually present crude mixtures containing, in 
addition to the active component(s), a jumble of uncharacterized compounds, some exhibiting 
adverse pharmacological or toxicological properties. A further roadblock to the 
standardization of these remedies is the questionable content of the active component in the 
mixture.  
Early natural product research focused on the isolation of biologically active compounds 
from the alkaloid family from plants. It wasn’t until the 1930´s that researchers noticed that 
certain microorganisms, too, were prolific producers of antibacterial and antifungal 
compounds.These antimicrobials were desperately needed at a time when, despite rapid 
industrialization, infectious diseases were still the leading cause of death. The most prominent 
example is certainly the discovery of the β-lactam antibiotic penicillin from Penicillium 
notatum by A. Fleming, H. W. Florey and E. B. Chain.[3] Massive screening programs of 
microorganisms in the search for new antibiotics and antifungals culminated in a “golden era” 
in anti-infective research, yielding many antibiotics that are still in use today (Figure A-2). 
A. Introduction
 
   3 
 
Figure A-2. Examples of microbial natural products representing important antibiotics in clinical use. 
Name, activity, native producer, year of first isolation, and trade name (where applicable) are indicated 
below the respective structure. 
The investigation of their modes of action revealed bacterial cellular functions that could be 
targeted without having toxic effects in humans, known as the principle of selective toxicity. 
Among these targets are the bacterial cell wall synthesis (inhibited by β-lactams and 
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glycopeptides), protein synthesis (inhibited by tetracyclines, chloramphenicol, macrolides, 
and aminoglycosides), and bacterial RNA polymerase (inhibited by rifamycins). The 
identification of these targets made them also accessible for further drug development.  
At the beginning, antibiotic and antifungal agents were the focus of microbial derived 
natural product research, but this field has also rapidly proven to be a valuable source of 
secondary metabolites with a vast array of biological activities, finding their way into the 
clinics as anticancer and antiparasitic agents, as well as immunosuppressives and 
cholesterol-reducing drugs (Figure A-3). 
 
Figure A-3. Examples of microbial natural products with various biological activities. Name, activity, 
native producer, year of first isolation, and trade name (where applicable) are indicated below the 
respective structure. 
1.2 The present and the future 
The presented structures provide only a glimpse of the enormous structural diversity covered 
by microbial secondary metabolites. Although synthetic approaches may provide deeper 
access to the chemical space, the profit of such an approach might be limited. With an 
estimated more than 1060 different molecules spanning the drug-like chemical space, 
comprehensive exploitation is nowhere near feasible.[4] The challenge is rather to identify 
areas within the chemical space containing a high percentage of biologically active 
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compounds. In this context, it is of particular interest that the vast number of possible primary 
protein sequences is greatly reduced by the spatial arrangement of secondary structure 
elements like α-helices and β-sheets. This leads to a predicted 1000 – 8000 different fold 
types for proteins in nature.[5] Natural products can be considered as privileged structures for 
specific interactions with diverse biological targets due to their evolutionary selection over a 
multitude of generations.[6] Statistical evaluation of ~18000 protein cavities, normally 
representing the most promising targets for small molecule-protein interactions, revealed 
mainly volumes in the range of 300 to 800 Å3.[7] This value is in very good agreement with 
the calculated volumes of most of NP scaffolds.  
Another major requirement in modern drug development is oral bioavailability. A 
retrospective evaluation of chemical properties of drugs on the market led to the 
establishment of Lipinski´s Rule of Five.[8] The bottom line is that most orally active drugs do 
feature no more than 5 hydrogen bond donors or more than 10 hydrogen bond acceptors in 
combination with a molecular weight below 500 daltons and an octanol-water partition 
coefficient (log P) below 5. The fact that the majority of natural products disobey this rule of 
thumb while still exhibiting, in many cases, reasonable bioavailability led to the establishment 
of Lipinski´s fifth rule which states that the first four rules do not apply to natural products or 
any molecule recognized by an active transport system.  
The high expectations of discovery of drug leads from libraries based on unfocused 
combinatorial chemistry have not met with success. Today, most industrial drug discovery 
programs rely on high-throughput screening (HTS) of focused synthetic libraries. The 
advantages, usually easy access and modifiability of the hits, carry the steep price tag of a 
perilously low hit rate. Taking the ~7000 known polyketide secondary metabolites into 
account, natural product library screening has yielded more than 20 approved drugs, 
corresponding to a hit rate of 0.3% and several orders of magnitude higher than the <0.001% 
usually obtained from synthetic compound libraries.[9] In return, exploitation of this potential 
is complicated by the labor intensive identification and purification of microbial secondary 
metabolites. One approach to bypass this bottleneck is the testing of either fractionated or 
crude extracts from microbial fermentation in HTS. While a tremendous increase in 
throughput is achieved, the reliability and robustness of the results might suffer due to a 
number of problems. The concentration, stability, or solubility of a bioactive compound in the 
extract may be too low to be detected by assays, leading to missed hits. Furthermore, 
interpretation of the results may be complicated by synergistic or antagonistic effects of the 
A. Introduction 
 
6 
complex mixture of compounds. Some antibiotics (e.g. members of the aminoglycosides) 
occur in a high percentage of soil actinomycetes. The activity of these known compounds can 
mask that of other antimicrobial compounds present in the crude extract. Lastly, every 
confirmed activity must be correlated to its bioactive compound, requiring labor-intensive 
processes such as dereplication, upscaling, isolation, and structure elucidation.  
As bacterial antibiotic resistance continues to exhaust our supply of effective antibiotics, 
there is high demand for the discovery of new lead structures in order to prevent the antibiotic 
pipeline from drying up. The emergence of multiresistant nosocomial pathogens is especially 
alarming; a group of six bacteria, termed the ESKAPE pathogens, is responsible for two thirds 
of all health care associated infections. These ESKAPE pathogens (Enterococcus faecium, 
Staphylococcus aureus, Klebsiella pneumonia, Acinetobacter baumanii, 
Pseudomonas aeruginosa, and Enterobacter species) escape most antibiotic therapies due to 
their resistance against a large number of antibiotics. Therefore, new drugs are needed to fight 
them effectively. 
Over the last 50 years, streptomycetes have emerged as the major source of antibiotic 
secondary metabolites. Of the ~12000 antibiotic compounds known by 1995, 55% were 
derived from streptomycetes and another 11% from other actinomycetes.[10] The genesis for 
this prolific production of secondary metabolites is the enormous competition in their natural 
soil habitat. The continuous exploitation of this repository elicits difficulties as there is 
frequent rediscovery and reisolation of known structures. Within the fungal and bacterial 
kingdoms, there remain enormous numbers of species that have not been thoroughly 
investigated for their potential to produce bioactive secondary metabolites. In the barely 
exploited marine environments alone, around 3x1030 microorganisms are estimated to be 
present, giving rise to a gigantic pool of natural products.[11] Unfortunately, there are also 
estimates that more than 99% of all bacteria cannot be cultured under standard laboratory 
conditions. It is therefore of utmost importance to exploit the most promising and accessible 
microbial resources. In this framework, myxobacteria have attracted attention as prolific 
producers of novel secondary metabolites. 
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2. Myxobacteria as novel source for bioactive natural products 
The bulk of myxobacteria have been isolated from soil, decaying wood, and the dung of 
herbivores,[12] although recently novel isolates from marine and moderate halophilic 
environments have also been reported.[13;14] Myxobacteria are Gram-negative, obligate 
aerobic mesophiles belonging to the δ-group of proteobacteria. The typically rod-shaped 
vegetative cells exhibit dimensions of 3-12 µm in length and 0.7-1.2 µm in width 
(Figure A-4A).[15] Their lifestyle is rather “micropredatory”, preying on other 
microorganisms than being saprotrophic. Myxobacteria are taxonomically contained in the 
order Myxococcales, which comprises the three suborders Cystobacterineae, Sorangineae, 
and Nannocystineae.[16] They are characterized by outstanding nutrient exploitation, motility 
and life cycle behaviours which differ again distinctively between the members of the 
different suborders or families. Myxococcus xanthus (a member of the Myxococcaceae family 
within the suborder Cystobacterineae) is, for example, is able to swarm on solid surfaces such 
as agar by chemotaxis, hunting out nutrients not within its immediate proximity 
(Figure A-4B). These “nutrients” are often other bacteria or yeast digested by M. xanthus 
through secretion of a variety of lytic enzymes that break open the cells of the prey.[17] The 
high concentration of these extracellular lytic enzymes required for cell lysis is achieved by 
the coordinated action of many individual cells, leading to the perception of “wolf pack 
bacteria”. The released proteins, lipids and nucleic acids are then further digested and 
consumed as monomeric building blocks. This lifestyle is also mirrored in liquid culture, 
where M. xanthus, like most myxobacteria, grows preferentially in media containing small 
peptides from protein digestions in comparison to media containing mainly carbohydrates as 
carbon and energy sources. Sorangium cellulosum deserves special mention as, aside from a 
characteristic micropredatory lifestyle, they exhibit the unique ability of cellulose 
degradation, even using it as a sole carbon and energy source.[18] Under low nutrient 
conditions, myxobacteria can aggregate and undergo differentiation into specialized cell 
types, a process that finally culminates in characteristic multi-cellular structures called 
fruiting bodies (Figure A-4C). These fruiting bodies house so called myxospores 
(Figure A-4D), which are highly resistant to environmental stress factors as temperature 
extremes, desiccation, and UV radiation. These myxospores allow the bacteria to outlast 
periods of starvation and to return to a monocellular vegetative growth lifestyle upon 
restoration of favorable nutritional and environmental conditions. The shape, size, and 
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morphology of myxobacterial fruiting bodies vary greatly between members of the different 
genera and range from spherical cell clusters (e.g. Stigmatella) to sophisticated tree-like 
structures (e.g. Chondromyces). Due to these developmental and morphological 
characteristics of myxobacteria, they have been the subject of microbiological studies for 
several decades.  
 
 
Figure A-4. Developmental growth stages of S. aurantiaca Sg a32. A) Vegetative cells taken from a 
swarm colony. B) Swarming colony on agar plate showing the rippling and radial vein pattern.  
C) Cluster of fruiting bodies on agar surface. D) Arrangement of myxospores in a  sporangiole. 
Pictures A) and D) are obtained from phase contrast microscopy and pictures B) and C) from 
stereoscopic microscopy. 
Another special feature of myxobacteria, revealed recently through enormous progress in 
sequencing technology, are their very large genomes, comprising 9 – 13 million base pairs 
(Mb). Sorangium cellulosum So ce56, with a size of 13.0 Mb, has the largest genome of all 
sequenced bacteria[19], although other members of the genus Sorangium, such as So ce38, 
appear to be even larger, with an estimated genome size of 14.5 Mb (unpublished results). 
The myxobacterial genomes exhibit a high average GC-content of 67 – 72%.[15] Of particular 
interest is the fact that myxobacteria dedicate a high percentage of their sequence information 
(usually around 8 – 10%) to genes encoding enzymes involved in secondary metabolism.[19;20] 
The number of secondary metabolite gene clusters found in one myxobacterial strain can 
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range from around 10 up to 20. Thereby, their biosynthetic potential clearly outcompetes that 
of sequenced streptomycetes.[21-23] 
Even without the benefit of genetic background knowledge, the potential of myxobacteria 
as prolific producers of bioactive secondary metabolites was recognized in the early 1980s, 
leading to the establishment of a program for the systematical exploitation of this yet 
untapped source at the German Research Center for Biotechnology (GBF). This continuing 
success story has led to the isolation and structure elucidation of more than 100 new core 
structures and approximately 500 structural variants.[24] Intriguingly, many of these 
myxobacterial secondary metabolites exhibit exceptional structural features and 
modes-of-action not employed by secondary metabolites isolated from other bacterial 
sources.[25;26]  
The most prominent myxobacterial secondary metabolites by far are the epothilones, 
produced by several Sorangium strains.[27] The mode of action of the cytostatic epothilones is 
identical to that of paclitaxel (Taxol®), approved in 1992 for the treatment of various cancers. 
Both agents bind β-tubulin and promote tubulin polymerization, disturbing the natural 
dynamics between polymerization and dissociation of the microtubule network essential for 
vital cellular functions and finally causing apoptosis. [28] Interestingly, epothilones retain their 
cytotoxic activity against a number of paclitaxel resistant tumor cell lines and show low 
susceptibility to multiple tumor resistance mechanisms.[29] Combined with a reasonable side 
effect profile and pharmacokinetic properties, ixabepilone (Ixempra®), a semisynthetic 
epothilone B derivative (Figure A-5), was approved by the American Food and Drug 
Administration (FDA) for the treatment of breast cancer in 2007.[30] Because cancer cells 
divide at an accelerated rate in comparison to normal cells, a process dependent on proper 
microtubule function, the eukaryotic cytoskeleton is a validated target for anticancer 
therapy.[31] A cytotoxic effect through interference with the microtubule network can be 
caused by both the induction and the inhibition of tubulin polymerization. The latter 
mechanism is employed by the vinca alkaloids vinblastine (Velbe®) and vincristine 
(Oncovin®), which have been in use in clinical oncology for almost 50 years. Two families of 
myxobacterial secondary metabolites, the tubulysins and the disorazols, show an identical 
mode of action as the vinca alkoids.[32;33] The tubulysins inhibit tubulin polymerization and 
induce microtubule depolymerization and are the most potent tubulin polymerization 
inhibitors described to date. 
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Figure A-5. Myxobacterial secondary metabolites that target the eukaryotic cytoskeleton. Name, mode 
of action, and native producer are indicated below the respective structure. 
In general, the eukaryotic cytoskeleton is rarely targeted by natural products of bacterial 
origin. However, in addition to those acting on microtubules, three other myxobacterial 
secondary metabolites interact with actin filaments. Once again, both polymerization inducers 
and inhibitors are represented. The chondramides, produced by several Chondromyces strains, 
enhance actin polymerization.[34] Rhizopodin, a C2-symmetric dilactone, bears two enamide 
side chains, each of which binds a single G-actin molecule, resulting in a ternary 
rhizopodin/G-actin complex and inhibiting actin polymerization.[35] The chivosazoles also 
inhibit actin polymerization, though incubation with eukaryotic cells suggests a slightly 
different mode of action from rhizopodin, which itself still has to be elucidated in detail.[36] 
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There are several other myxobacterial secondary metabolites with rare modes of action 
(Figure A-6). Argyrin A, another compound of potential value in cancer therapy, acts as a 
proteasome inhibitor.[37] The target of the fungicide soraphen A is the fungal acetyl-CoA 
carboxylase, blocking de novo fatty acid biosynthesis.[38-40] Several myxobacterial secondary 
metabolites like sorangicin A,[41] corallopyronin A,[42] and ripostatin A[43] inhibit bacterial 
RNA polymerase. Notably, the latter two retain their activity against rifamycin-resistant rpoB 
mutants of Staphylococcus aureus, potentially making them very valuable in therapy.[44] Yet 
another common target among myxobacterial secondary metabolites is the electron transport 
chain, which is inhibited by the aurachins,[45] myxalamids,[46] myxothiazoles,[47] and the 
stigmatellins.[48] 
 
Figure A-6. Myxobacterial secondary metabolites with rare targets. Name, mode of action, and native 
producer are indicated below the respective structure. 
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3. Biosynthesis of secondary metabolites 
3.1 Nonribosomal peptide and polyketide biochemistry 
Most of the bacterial secondary metabolites are assembled by nonribosomal peptide 
synthethases (NRPSs), polyketide synthases (PKSs) or hybrids of the two.[49;50] Both NRPS 
and modular type I PKS are “biosynthetic assembly lines”, consisting of giant multifunctional 
enzymes containing several repeated functional units known as modules. By definition, each 
module is responsible for the incorporation of one monomeric building block and thereby for 
chain extension of the nascent natural product. PKSs are further categorized as iterative or 
noniterative, depending on whether or not each module catalyzes more than one round of 
chain extension.[51;52] The modules are further split up into domains that catalyze one of 
several successive reactions during one extension step. In NRPS, the building blocks are 
proteinogenic as well as nonproteinogenic amino acids; coenzyme A (CoA) thioesters of short 
dicarboxylic acids are the building blocks of choice in PKS. Despite differences in building 
blocks and the chemical reactions catalyzed, there are striking similarities between the NRPS 
and PKS biosynthetic logics.[53;54] Both systems utilize analogous elongation strategies in 
which the growing chain is tethered through thioester linkage to the 4´-phosphopantetheine 
(Ppant) prosthetic group of dedicated carrier proteins (CPs).[54] Post-translational attachment 
of this non-protein organic molecule to a highly conserved serine residue is catalyzed by 
dedicated Ppant transferases (PPTases) that convert the catalytically inactive apo-CPs to the 
catalytically active holo-CPs.[55] The flexible nature and length (~20 Å) of the Ppant 
prosthetic group allows for efficient positioning of the tethered intermediates for processing 
by the spatially distinct domains within a module and transfer of the growing intermediate by 
interaction with the domain catalyzing the condensation reaction in the downstream module. 
The covalent linkage to the CP makes these processes far more efficient than simple diffusion 
of dissolved intermediates between the single domains. Further, the building blocks and the 
intermediates are activated by the energy-rich thioester linkage which is crucial for the 
condensation steps.[56] The offloading of the final product from the assembly line NRPS and 
PKS also employ analogous strategies. Both have evolved dedicated chain-terminating 
thioesterase (TE) domains responsible for detachment of the fully extended product from the 
terminal CP modules and off-loading of the final secondary metabolite. In this process, the TE 
can catalyze either hydrolysis, leading to the release of a linear product, or macrolactonization 
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by intramolecular nucleophilic attack of a specific amino or hydroxyl moiety on the terminal 
acyl group of the covalent TE-O-intermediate, leading to the formation of lactames or 
lactones, respectively.[57] 
3.2 NRPS biochemistry 
NRPS and PKS differ, however, in the core domains liable for building block selection (and 
activation), building block condensation and downstream processing. The minimal NRPS 
module required for one extension step consists of an adenylation (A) domain, a peptidyl 
carrier protein (PCP; also referred to as thiolation (T) domain), and a condensation (C) 
domain.[58] A typical loading module lacks a C domain.[59] Every cycle of chain extension is 
initiated by the action of an A domain, which successsively selects, activats and transfers an 
amino acid to the PCP within the same module. The efficiency with which a specific amino 
acid building block is selected is crucial for the formation of a natural product with a defined 
peptide sequence, which is in turn crucial for biological activity. Sequence alignments of A 
domains with known amino acid specificity, combined with structural data information, led to 
the identification of 8-10 pivotal residues within the substrate binding pocket that determine 
the substrate specificity.[60-62] These indicative residues, referred to as the nonribosomal code, 
present a powerful tool for in silico prediction of A domain substrate specificity. The variety 
of employed building blocks does not only include the pool of proteinogenic amino acids but 
also nonproteinogenic amino acids and even aryl carboxylic acids.[59] After the specific 
selection of an amino acid, the A domain catalyzes the formation of the respective aminoacyl-
adenylate intermediate with the consumption of ATP. The adenylate, a high-energy acid 
anhydride, provides the energy for the thioester-forming step, covalently linking the amino 
acid to the terminal sulfhydryl group of the PCPs Ppant co-factor via its carboxyl function.[63] 
The C domain catalyzes peptide bond formation between amino acid building blocks tethered 
to the PCPs of adjacent modules by nucleophilic attack of the amino group of the downstream 
aminoacyl-S-PCP on the acyl group of the upstream peptidyl-S-PCP.[64] This condensation 
reaction yields an extended peptide intermediate covalently linked to the PCP of the 
downstream module, allowing for further elongation steps (Figure A-7).  
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Figure A-7. Schematic overview of NRPS biosynthesis of a hypothetical nonribosomal polypeptide 
product and illustration of the discrete reactions within one elongation cycle. 
In addition, optional domains that are responsible for methyl transfer (MT), epimerization (E), 
heterocyclization (HC) and oxidation (Ox) can increase the structural diversity of the 
product.[65] These tailoring functionalities are embedded in the modular context and fulfill 
their actions either on the PCP bound building blocks or intermediates. The MT domains 
catalyze N- or C-methylation of the building blocks using S-adenosyl-L-methionine (SAM) as 
cofactor. This modification is performed on the aminoacyl-S-PCP intermediate prior to the 
condensation reaction.[65] N-methylation is a structural feature found in many NRP products 
(e. g. ciclosporin) which reduces the proteolytic liability of the compound and thereby 
enhances its biological activity.[66] A similar effect can be achieved by incorporation of 
D-amino acids into the product. In most cases, this is realized by incorporation of the 
respective L-amino acid that is epimerized by an E domain acting on the peptidyl-S-PCP 
intermediate after peptide bond formation.[67] HC domains act on intermediates with 
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C-terminal cysteine, serine, or threonine residues to yield five-membered thiazoline or 
oxazoline heterocycles. These HC domains replace the C domain in the respective module 
and thus catalyze peptide formation and heterocyclization of the nucleophilic amino acid side 
chains with the C-penultimate acyl group.[68] The resulting heterocycles are often further 
transformed by Ox domains catalyzing flavin mononucleotide (FMN)-dependent oxidation to 
thiazoles or oxazoles.[69] 
3.3 PKS biochemistry 
3.3.1 Modular type I PKS 
The minimal set of domains within a PKS module consists of an acyltransferase (AT), an acyl 
carrier protein (ACP), and a β-ketoacylsynthase (KS) domain. The AT is responsible for 
extender unit selection and transfer to the Ppant co-factor of the ACP. Unlike NRPS, where a 
low reactivity building block is activated in situ by a dedicated domain via consumption of 
ATP, the AT domain selects pre-activated CoA thioesters of short dicarboxylic acids. 
Analogous to A domains, AT domains can specifically select particular building blocks and 
their substrate specificity can be predicted in silico based on sequence alignments.[70;71] The 
commonly used extender units are malonyl-CoA and methylmalonyl-CoA. In addition, the 
AT can show specificity for one of the more unusual extender units such as 
ethylmalonyl-CoA, hydroxymalonyl-CoA, methoxymalonyl-CoA, or aminomalonyl-CoA.[72-
74] For chain extension, the polyketide intermediate must first be transferred from the ACP of 
the upstream module to a conserved active site cysteine of the KS by transthioesterification. 
The KS catalyzes a decarboxylative Claisen thioester condensation between the extender unit 
and the acyl-S-KS intermediate, leading to a C2 extended β-keto-acyl-S-ACP intermediate 
(Figure A-8A).[75] The structural diversity of the product can be increased by processing of 
the β-keto function by a series of optional reductive domains within the module 
(Figure A-8A). A complete so-called “reductive loop” consists of ketoreductase (KR), 
dehydratase (DH) and enoylreductase (ER). The KR reduces the β-keto function with 
NADPH as cofactor, resulting in a β-hydroxy function.[76] This can, in turn, be dehydrated by 
the DH to yield a α,β-enoyl moiety which can finally be reduced to a methylene function by 
the ER with the consumption of NADPH. As not all of these domains have to be present 
within a module, the final product can contain hydroxyl- as well as enoyl- or fully reduced 
methylene functions.[77] Additional diversity can be introduced by MT domains introducing 
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either O- or C-methyl groups. Selection of the starter unit in type I PKS biosynthesis is 
accomplished by dedicated loading modules. This can be a module of KS-AT-ACP 
architecture with selection and ACP priming of either malonyl-CoA or methylmalonyl-CoA, 
followed by KS mediated decarboxylation to yield either acetyl- or propinyl-starter units. In 
this type of module, the KS is disabled for condensation by the exchange of the active site 
cysteine against glutamine, and is therefore referred to as a KSQ domain.[78] Alternatively, the 
loading module can consist of an AT-ACP didomain in which the AT selects and transfers 
short straight-chain, branched-chain or aromatic monocarboxylic acids immediately.[79-81] 
3.3.2 Special cases of modular type I PKS 
In contrast to classical cis-AT (or canonical) type I PKSs, there are also trans-AT type I PKSs 
which lack integral AT domains and complement the AT functionality by freestanding 
enzymes.[82] In addition to the exceptional acyl transfer mechanism, these systems quite often 
exhibit highly aberrant architectures with unprecedented functionalities, novel domain orders 
or apparently superfluous functions. Whereas NRPSs and textbook cis-AT PKSs show strong 
correlation between the organization of modules and domains in the megasynthases and the 
structural elements found in the final product, also known as colinearity rule,[83] this does not 
hold true for trans-AT PKSs. The colinearity rule allows for prediction of metabolite 
structures from enzyme architectures which can again be predicted from DNA sequences and 
vice versa, and is an effective tool in the genome mining context. Recently, an innovative 
approach based on phylogenetic clustering of KS sequences in relationship to their substrate 
specificity was developed and allowed prediction of core structures from trans-AT systems 
with a significantly improved reliability.[84] 
The structural diversity of natural products assembled by NRPS or PKS can further be 
increased by the cooperation of both systems, resulting in mixed polyketide-polypeptide 
compounds.[81;85] 
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Figure A-8. Schematic overview of the different types of PKS systems and their respective biochemistry. 
A) Biosynthesis of a hypothetical polyketide product build up by a modular type I PKS system and 
illustration of the discrete reactions within one elongation cycle. B) Type II PKS consisting of 
iteratively acting subunits exemplified for tetracenomycin biosynthesis. C) Type III PKS consisting of 
one iteratively acting homodimer subunit as exemplified for flaviolin biosynthesis. 
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3.3.3 Type II PKS 
Aside from these classes of modular and non-iteratively acting multifunctional enzymes, there 
are two other classes of biosynthetic enzymes that use discrete, iteratively acting 
monofunctional enzymes for polyketide assembly, the type II PKSs and type III PKSs. Type 
II PKSs are found almost exclusively in Gram-positive actinomycetes (with only two known 
examples from Gram-negative bacteria[86;87]) where they are involved in the biosynthesis of 
aromatic polycyclic polyketides, also called polyphenols.[88] The “minimal type II PKS” is 
composed of two ketosynthase units, KSα and KSβ (also referred to as chain length factor 
(CLF)) and an ACP, which serves to tether the growing intermediate and extender unit 
supplier (Figure A-8B).[89] There is ongoing debate in the literature whether or not a 
malonyl-CoA:ACP transacylase (MCAT), which is usually recruited from fatty acid synthases 
and serves for rapid malonyl-ACP priming, should be added to the minimal type II PKS 
functionalities. This set of proteins employs identical overall biochemical logic for the 
iterative decarboxylative condensation of malonyl-CoA building blocks as type I PKSs. The 
two KS subunits KSα and KSβ show high sequence homologies to each other, but only KSα 
possesses the active site cysteine crucial for transient covalent tethering of the intermediate 
and thereby polyketide assembly.[90] However, both subunits are absolutely required for 
polyketide biosynthesis. The KSβ subunit is involved in malonyl-CoA loading and generation 
of acetyl-KS from decarboxylation of malonyl-ACP.[78] Further, the KSβ subunit dictates the 
carbon chain length of the final product and thereby the number of iterative condensation 
steps.[91] During polyketide assembly, the growing intermediate is shuttled between the KSα 
and the ACP. Since there is no intercyclic reductive processing, the nascent chain consists of 
highly unstable poly-β-keto functions, which should be prone to spontaneous cyclisation. 
From a structural study, it was deduced that KSα/KSβ form a heterodimer with a cleft that 
keeping the nascent polyketide chain extended.[92] Spatial separation of the ketide groups is 
therefore achieved, allowing for stabilization of the intermediate until the final number of 
elongation steps is completed to yield octaketides (as actinorhodin), decaketides (as 
tetracenomycin), or dodecaketides (as pradimicin), in the majority of cases. Additional 
discrete functionalities as ketoreductases, cyclases, and aromatases influence the folding 
pattern of the final polycyclic product. Further modifications by tailoring enzymes as P450 
monooxygenases, methyltransferases, and glycosyltransferases contribute to the huge 
structural diversity of polyphenolic polyketides found in nature.  
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3.3.4 Type III PKS 
Type III PKS were long thought to derive only from plants, where they are also referred to as 
chalcone synthases (CHSs) or stilbene synthases (STSs), depending on the generated 
products. CHSs are found ubiquitously in plants and catalyse the condensation of three 
malonyl-CoA building blocks with a phenylpropanoid-derived p-coumaroyl-CoA starter unit. 
Subsequent cyclisation leads to the formation of the final product chalcone.[93] It was only in 
the last decade that a number of homologous enzymes have been discovered in bacteria.[94;95] 
These bacterial type III PKSs share only weak sequence homology to plant CHSs (typically 
~25% identity), and are therefore unsurprisingly involved in the formation of products other 
than chalcones.  
Type III PKSs are structurally and mechanistically quite distinct from type I and type II 
PKSs. Instead of using CP-Ppant-tethered dicarboxylic acid building blocks, type III PKSs 
employ free CoA thioesters as a building block supply and anchoring of the polyketide 
intermediate. They act as homodimeric proteins and utilize a single active site to iteratively 
perform loading of the acyl-CoA intermediate to the active site cysteine and chain extension 
via decarboxylative condensation of malonyl-CoA extender units (Figure A-8C). In addition, 
they catalyze intramolecular cyclization to release the final product. 
3.4 Further classes of secondary metabolites 
Aromatic amino acids, benzoic acids, and cinnamic acids are produced via the shikimate 
pathway. Further modifications of these starting compounds lead to the formation of lignans 
and lignin, phenylpropenes, and coumarins.[96] The phenazines are another large class of 
secondary metabolites whose biosynthetic pathway branches off from the shikimate pathway 
before anthranilate formation.[97] They share a dibenzo-annulated pyrazine core structure that 
can be highly diversified by various substituents. Another large and structurally diverse 
family of natural products is the terpenoids, which are classified according to the number of 
incorporated isoprenoid units. They are generated by head-to-tail condensation of C5 
dimethylallyl pyrophosphate (DMAPP) and isopentenyl pyrophosphate (IPP) units[98], formed 
through the mevalonate or deoxyxylulose pathways. “True alkaloids” are defined by a 
nitrogen-containing heterocycle derived from an amino acid. Although classified mainly 
based on the nature of their heterocycle, a uniform classification is not feasible due to their 
enormous structural diversity. Glycosinolates are a group of highly water soluble anions that 
incorporate sulfur and nitrogen atoms and are derived from glucose and an amino acid. In 
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contrast to nonribosomal peptides and polyketides (formed by type I PKS) assembled by the 
previously described multifunctional gigantic enzymes, all secondary metabolites discussed in 
this section arise from successive reactions catalyzed by mostly monofunctional enzymes. 
3.5 Functions of secondary metabolites in the natural context 
The exact roles of many if not most secondary metabolites in their original biological context 
remain unknown. It is likely most confer a selection benefit for the producing organism or 
serve in their producer’s defense. These effects can also be embedded in a symbiotic context. 
For example, there are reports of Streptomyces living in symbiosis with leaf-cutting ants and 
thus serve to control parasites in the ants’ fungus garden. The leaf-cutting ants grow special 
fungi on harvested leaf material, which serves as their major food source. These fungus 
gardens can be infected by a specialized pathogenic fungus which is controlled by the ants via 
symbiosis with antibiotic-producing bacteria. This symbiosis between Streptomyces and the 
ants is highly sophisticated, as the fungicide produced by the bacteria, recently identified as 
the macrolide candicidin, exhibits strong activity against the pathogenic fungus but does not 
affect the fungus serving as ants’ food source.[99] Secondary metabolites can aid the 
acquisition of iron from the environment for its producer. These so-called siderophores are 
small, high-affinity iron chelating compounds secreted into the extracellular compartment and 
actively taken up again once Fe3+-bound.[100] Others act as virulence factors (rhizoxin,[101] 
pyocyanin), pigments, or infochemicals. The extent of both inter- and inner-species signaling 
in bacteria has just recently been revealed. Numerous species of bacteria use elaborate 
regulatory mechanisms, referred to as quorum sensing (QS), to control the expression of 
specific genes used in the coordination of activities of a population. QS is based on the 
production and release of small signaling molecules, autoinducers, that increase in 
concentration as a function of cell density and activate corresponding transcriptional 
regulators after a threshold concentration has been reached.[102] Gram-positive bacteria 
employ mainly small post-translationally modified peptides as autoinducers, whereas 
Gram-negative bacteria mainly make use of N-acyl-L-homoserine lactones (AHLs). These 
AHL signaling molecules are often produced as mixtures with one species-specific main 
constituent and variable N-acyl chains. By definition, these autoinducers are also regarded as 
secondary metabolites, although they are not derived from one of the previously discussed 
biosynthetic machines. AHLs are synthesized by monofunctional enzymes, termed LuxI 
homologues after the first characterized member of this class. LuxI homologues use 
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ACP-bound fatty acyl derivatives and SAM as substrates for the production of AHL 
molecules.[103] Another rather unique QS system, restricted to particular Pseudomonas and 
Burkholderia strains, utilises 2-alkyl-4(1H)-quinolone (AQ) autoinducers such as 
2-heptyl-3-hydroxy-4(1H)-quinolone (the Pseudomonas quinolone signal, PQS) and its direct 
precursor 2-heptyl-4(1H)-quinolone (HHQ).[104] The biosynthesis of HHQ is mediated by a 
four-gene operon (pqsABCD) encoding an anthranilate:CoA ligase (pqsA) and three 
β-ketoacyl-acyl carrier protein synthase III (KAS III) homologues.[105] Logically, this 
biosynthetic operon resembles PKS biosynthesis; however, the molecular details were 
unknown before this study. 
4. Outline of the dissertation 
The aim of this thesis was to increase the body of knowledge of bacterial secondary 
metabolite biosynthesis. In doing so, pathways of different biosynthetic classes as well as 
tailoring modifications were examined and characterised. A detailed biosynthetic background 
is the basis for tapping the full potential of the microbial secondary metabolome uncovered by 
the genomic era. The same applies to the discovery of innovative targets for therapeutic 
intervention that might be represented by key biosynthetic reactions in the pathway of a 
secondary metabolite crucial to a pathogen´s virulence. In particular, tubulysin biosynthesis in 
Angiococcus disciformis and Cystobacter sp. SBCb004, aurachin and rhizopodin biosynthesis 
in Stigmatella aurantiaca Sg a15 and 2-heptyl-4(1H)-quinolone (HHQ) biosynthesis in 
Pseudomonas aeruginosa were investigated. 
The existence of the previously postulated biosynthetic precursor pretubulysin, lacking 
the acetoxy and acyl N,O-acetal substituents found in mature tubulysin, was confirmed by 
chemical synthesis and comparison of the reference material with extracts from the natural 
producer. Furthermore, the cytotoxic activity of this more synthetically accessible, simplified 
tubulysin derivative was assessed in Section B Chapter 1. An d48, one of our novel isolates 
classified as Cystobacter SBCb004, was also shown to produce tubulysins. While An d48 
produces D-type tubulysins containing a phenylalanine building block, SBCb004 produces 
A-type tubulysins containing instead a tyrosine building block.  
In depth analysis of extracts from both strains by high performance liquid 
chromatography coupled to high resolution mass spectrometry (HPLC-HRMS) and 
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HRMS/MS was performed to search for new tubulysin derivatives. The identification and 
partial characterization of a multitude of structural variants of A- and D-type tubulysins along 
with the comparison of the tubulysin biosynthetic gene clusters from An d48 and SBCb004 is 
reported in Section B Chapter 2. Interstrain comparison enabled assignment of cluster 
boundaries due to conserved architecture. Interestingly, orf17 and orf18, located downstream 
of the last PKS-gene tubF, encode for patatin-like proteins and are present in both clusters. 
The involvement of these ORFs in tubulysin biosynthesis was investigated by targeted gene 
inactivation. The mutants accumulated a thus far unknown tubulysin derivative whose 
structure was studied by stable isotope labeled precursors feeding and HR-MS/MS 
experiments in combination with compound isolation and NMR-based structure isolation. 
Further, the biochemical functions of the patatin-like proteins were analyzed by in vitro 
experiments with heterologously expressed proteins, as described in Section B Chapter 3. 
Details of the biosynthesis of the aurachin quinoline alkaloids from 
Stigmatella aurantiaca Sg a15 have remained elusive so far. The postulated formulation 
mechanism of the quinoline core comprises the elongation of activated anthranilate with two 
malonyl-CoA extender units catalyzed by a type II PKS followed by decarboxylation and 
heterocycle formation.[86] It is of special interest to understand the channeling mechanisms of 
non-acetate starter units into polyketide biosynthesis due to the associated potential for 
metabolic engineering. Therefore, the goal was to identify the molecular mechanisms 
underlying anthranilate priming in aurachin biosynthesis. In vitro experiments with 
recombinant ACP and aryl:CoA ligase proteins were conducted with the previously identified 
auaABCDE operon. These experiments yielded inconclusive results, promting the exploration 
of genes in the wider genetic neighbourhood of the auaABCDE operon for their involvement 
in anthranilate priming. The discovery of an additional required functionality and the 
elucidation of an unprecedented mechanism for starter unit priming in polyketide biosynthesis 
are presented in Section B Chapter 4. Further, the functionalities responsible for the 
successive transformations of the aurachins were identified and characterized to decipher the 
complete biosynthetic pathway. These results are described in Section B Chapter 5. 
The aurachins are structurally related to the members of the 4-hydroxy-2-alkylquinoline 
family (HAQs) produced by Pseudomonas aeruginosa. The Pseudomonas quinolone signal 
(PQS) and its direct precursor, 2-heptyl-4(1H)-quinolone (HHQ), are important quorum 
sensing (QS) signalling molecules in P. aeruginosa. Due to the structural similarities between 
the aurachins and the HAQs, possible analogies between their biosynthetic pathways were 
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investigated. The essential functionalities for the formation of HHQ (pqsABCD) are 
known,[105] but a detailed biosynthesis mechanism has not been established. Recombinant 
PqsD protein was used to elucidate its function and to identify its substrates. P. aeruginosa is 
an opportunistic pathogen that causes many nosocomial infections, especially in cystic 
fibrosis (CF) patients.[106] These infections are difficult to treat due to specific resistances and 
P. aeruginosa´s ability to form biofilms that exhibit a low susceptibility to all types of 
antibiotics. The formation of biofilms and the production of the bulk of virulence factors 
excreted by P. aeruginosa are controlled by QS, which is based on formation and detection of 
diffusible signal molecules that accumulate as a function of cell density.[107] Interference with 
QS has been proven to be a promising target in virulence attenuation. The knowledge gained 
in this study could be employed to investigate the inhibition of HHQ biosynthesis as a 
potential target for alternative therapeutic approaches against P. aeruginosa. The results of 
this project are summarized in Section B Chapter 6.   
The field of microbial natural product research is on the verge of a new era as the 
increasing availability of genome sequences provides enormous potential for the discovery of 
new natural compounds by so-called genome mining approaches. These approaches may, in 
the future, replace isolation campaigns based on physico-chemical properties or the tracking 
of bioactivity, as they show drawbacks in sensitivity and implementation range. The 
examination of biosynthetic gene clusters that are easily accessible from sequence 
information can further prevent rediscovery of known compounds. The recently in-house 
sequenced genome of the myxobacterium S. aurantiaca Sg a15 should be screened in silico 
for unknown biosynthetic gene clusters and hits investigated by an approach based on 
targeted gene inactivation and comparative analysis of the secondary metabolome between 
mutants and wild type by HPLC-HRMS and data processing with statistical tools. The results 
of these efforts that led to the identification and characterization of a thus far unknown trans-
AT PKS/NRPS gene cluster and the correlation of the respective secondary metabolite are 
illustrated in Section B Chapter 7. 
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Introduction 
The tubulysins are a family of nonribosomally synthesized peptides with promising cytotoxic 
activity,[1] even against multi-drug-resistant tumors. The cytotoxic effect is mediated by 
inhibition of tubulin polymerization, inducing a depletion of cell microtubules and finally 
triggering the apoptotic process.[2] The tubulysin core structure consists of the five amino 
acids, N-methyl pipecolic acid (Mep), isoleucine (Ile), valine, cysteine and either 
phenylalanine or tyrosine, and two acetate units. The fragment consisting of valine and 
cysteine connected by one acetate unit has been grouped into a structural unit referred to as 
tubuvaline (Tuv), while the acetate chain-extended forms of phenylalanine or tyrosine are 
designated as tubuphenylalaline (Tup) and tubutyrosine (Tut), respectively (Figure 1).  
 
Figure 1. Chemical structures of tubulysin A and tubulysin D with division into structural subunits 
The core of the corresponding PKS/NRPS hybrid gene cluster for tubulysin biosynthesis was 
first identified in Angiococcus disciformis An d48.[3] Recently, we reported another tubulysin 
producing strain, Cystobacter sp. SBCb004, and compared the tubulysin biosynthetic gene 
clusters in An d48 and SBCb004. By identification of the gene set common to both strains, it 
was possible to define the cluster boundaries.[4]  
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Results and discussion 
Conservation of patatin-like proteins  
The comparison of the tubulysin biosynthetic gene clusters in An d48 and SBCb004 revealed 
the presence of two conserved open reading frames (ORFs), orf17 and orf18, downstream of 
the last PKS gene tubF (Figure 2). The ORFs further downstream did not show any 
correlation between the strains. orf17 and orf18 both encode patatin-like proteins, which show 
high mutual sequence homology (in the range of 60% identity and 70% similarity) and 
suggest evolution by gene duplication. 
 
Figure 2. Comparison of the genetic organizations of the tubulysin biosynthetic gene clusters in 
Angiococcus disciformis and Cystobacter sp. SBCb004. 
Patatin-like proteins are known to exhibit lipid acyl hydrolase activity,[5] a function apparently 
not required in the tubulysin pathway. However, it is worth mentioning that genes encoding 
patatin-like proteins are also present in the DKxanthene gene clusters of the myxobacteria 
Myxococcus xanthus DK1622 and Stigmatella aurantiaca DW 4/3-1,[6] as well as in the 
leupyrrin gene cluster of Sorangium cellulosum So ce690,[7] suggesting that these enzymes 
may play a unexpected role in natural product biosynthesis.  
Characterization of patatin-like protein knockout mutants 
To investigate the involvement of the patatin-like proteins in tubulysin biosynthesis, the 
corresponding genes were inactivated by targeted gene disruption based on homologous 
recombination. The first mutant obtained and verified was an An d48-orf18- mutant 
(generated by Yi Chai). HPLC-MS analysis of the extract of this mutant revealed more than a 
B. Publications – Chapter 3
 
   31 
50-fold decrease in production of tubulysin D, a surprising and extreme result considering 
patatin-like proteins were not expected to be involved in tubulysin biosynthesis. Detailed 
analysis of the HPLC-MS data revealed that the An d48-orf18- mutant accumulated an 
unknown compound not present in wild-type strain extracts. This compound, m/z [M+H]+ = 
902.5, was bigger than tubulysin D, with m/z [M+H]+ = 828.5 (Figure 3). 
 
Figure 3. Extracted ion chromatograms (EICs) for m/z 828.5 (blue) and 902.5 (red) of HPLC-MS 
analysis of extracts from A) An d48 wild type and B) An d48-orf18- mutant.  
Compound characterization by MS experiments 
Ensuing HRMS experiments produced a monoisotopic mass of m/z [M+H]+ = 828.4566 for 
tubulysin D (calculated m/z [M+H]+ = 828.4576). The deduced molecular formula of 
C43H66N5O9S+ matched the reported elemental composition. The monoisotopic mass of the 
unknown compound was determined to m/z [M+H]+ = 902.4947, leading to the prediction of 
a molecular formula of C46H72N5O11S+. Based on similarities between both molecular 
formulae, it was logical to conclude the unknown compound was a new tubulysin derivative. 
MS/MS fragmentation based on collision induced dissociation (CID) was employed to 
investigate this hypothesis. MS/MS data revealed mostly identical fragmentation losses 
between tubulysin D and the unknown compound (Figure 4). 
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Figure 4. HRMS/MS spectra of A) tubulysin D and B) the unknown compound accumulating in the 
An d48-orf18- mutant. The fragments are connected to the mother ion by dashed lines and the italic 
numbers in the upper corners of the respective connection indicate the loss in m/z upon fragmentation. 
For clarity, only the first two decimal places are given.  
Both compounds exhibit common fragmentation losses of 102.07, 340.23 and 400.25 Da. 
Furthermore, they share a fragment of m/z = 410.19. For the unknown compound, there is 
another fragment of m/z = 544.25 which, neither itself or the corresponding fragmentation 
loss of 358.24 Da, is found in the MS/MS-spectra of tubulysin D. Mapping of the most likely 
fragmentation breaking points of tubulysin D allowed assignment of the four main fragments. 
These four fragments show a sequential relationship to each other. The fragment of 
m/z = 726.3891 arises from tubulysin D by elimination of 3-methylbutanoic acid from the 
bis-acyl N,O-acetal substituent attached to the tubuvaline moiety. The fragment of 
m/z = 488.2208 has, in addition, eliminated the N-terminal dipeptide consisting of N-methyl 
pipecolic acid (Mep) and isoleucine (Ile). This fragment can further eliminate acetic acid from 
the acetoxy substituent of tubuvaline to yield the fragment of m/z = 428.2001. The smallest 
fragment of m/z = 410.1895 arises from additional elimination of water from the C-terminal 
carboxyl group of the tubuphenylalanine moiety (Figure 5). Since this fragment was also 
found in the unknown compound it could be concluded that an additional substituent is linked 
to the carboxyl group of tubulysin D and, upon elimination of the entire moiety, the common 
fragment of m/z = 410.1895 is formed. 
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Figure 5. Postulated structural assignments for CID fragments obtained for tubulysin D. Calculated 
(calcd) and the observed (obsvd) m/z-values for the charged species are given below the structures. 
Based on a difference to the accurate mass of 74.0371 Da as well as a difference in predicted 
molecular formula to tubulysin D, the unknown compound was predicted to contain an 
additional C3H6O2. Taking into account the high relative amount of oxygen in C3H6O2 and 
that this moiety would have to be attached in a biosynthetically comprehensible way to the 
C-terminal carboxyl group of tubulysin D greatly reduced the pool of possible structures. The 
most likely candidate was a glycerol moiety hypothesized to be attached to tubulysin D via 
ester bond formation. In order to support this hypothesis, the An d48-orf18- mutant was fed 
with labeled 13C3-glycerol (experiment performed by Yi Chai). HPLC-HRMS analysis 
revealed the incorporation of one glycerol molecule by peak intensities at +3 Da and the 
successive isotope signals (Figure 6).  
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Figure 6. Isotope patterns of the unknown compound accumulating in An d48-orf18- mutant. Patterns 
were obtained by HPLC-HRMS measurements of extracts from A) An d48-orf18- mutant control and 
B) An d48-orf18- mutant fed with stable isotope-labeled 13C3-glycerol. For clarity, only the first two 
decimal places are given. 
Based on these results, we correlated the MS/MS fragments obtained for the unknown 
compound to the structural proposal of tubulysin D glycerol ester and were able to rationalize 
all differences between masses of fragments of tubulysin D and the new compound. The 
common fragment of m/z = 410.1895 arises, in this case, from the elimination of glycerol 
instead of water. The structural proposal also explains the presence of a fragment of 
m/z = 544.2474, found in the new compound as a result of a loss of 3-methylbutanoic acid, 
the N-terminal Ile-Mep dipeptide and one molecule of water from the C-terminal glycerol 
moiety (Figure 7). 
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Figure 7. Postulated structural assignments for the CID fragments obtained for the unknown compound 
accumulating in the An d48-orf18- mutant based on the structural proposal of  tubulysin D glycerol 
ester. Calculated (calcd) and the observed (obsvd) m/z-values for the charged species are given below 
the structures. 
Compound isolation and structure elucidation by NMR 
To confirm the MS-based proposed structure of the tubulysin D glycerol ester, the compound 
was isolated for more conclusive structural elucidation by nuclear magnetic resonance (NMR) 
spectroscopy. The purification procedure is described in detail in the experimental section. 
0.6 mg of a slightly beige amorphous solid were obtained after final purification and analysed 
by one-dimensional and two-dimensional NMR experiments. Table 1 lists the observed 
1H NMR signals and their assignments to the respective positions.  
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Table 1. 1H NMR spectroscopic data from tubulysin D glycerol ester 
Position (H) δH [ppm] Multiplicity JH [Hz] 
2 2.48 under DMSO signal  
3 1.86 m  
4 4.21 m  
5 7.97 d 9.1 
8 8.18 s  
11 5.74 dd 11.3; 1.6 
12 2.41 m  
13 4.20 m  
16 4.40 t 9.1 
17 7.93 d 8.8 
19 2.47 dd 10.7; 3.2 
20a 1.37 m  
20b 1.56 m  
21a 1.15 m  
21b 1.63 m  
22a 1.42 m  
22b 1.51 m  
23a 1.92 m  
23b 2.82 m  
25 2.04 s  
26 1.07 d 7.3 
27a 2.80 dd 13.6; 6.3 
27b 2.87 dd 13.6; 7.6 
29 7.19 AA´  
30 7.24 BB´  
31 7.16 C   
32 7.24 BB´  
33 7.19 AA´  
35 2.10 s  
36 1.81 m  
37 0.67 d 6.6 
38 0.98 d 6.3 
39a 5.25 d 12.0 
39b 6.19 brd 11.7 
40 1.91 m  
41 1.47 m  
42 0.81 m  
43 0.81 m  
45a 2.08  m  
45b 2.13 m  
46 1.92 m  
47 0.81 m  
48 0.81 m  
49a 3.87 dd 11.0; 6.3 
49b 4.01 dd 11.0; 4.7 
50 3.62 m  
51a 3.33 under water signal  
51b 3.67 m  
 
The observed 1H NMR signals further support the proposed structure and correlate quite well 
with those reported for tubulysin A.[1] Evaluation of the [1H, 1H]-COSY couplings resulted in 
the successful assignment of all alkyl- and aryl-moieties present in tubulysin D glycerol ester 
(Figure 8). 
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Figure 8.Chemical structure of tubulysin D glycerol ester with numbering used for 1H NMR 
assignments and observed [1H, 1H]-COSY couplings indicated by bold bonds. 
Combination of the 1H NMR and [1H, 1H]-COSY data prove the chemical structure of 
tubulysin D glycerol ester and further suggest linkage of the glycerol moiety to the carboxylic 
acid of tubulysin D via the primary and not the secondary alcohol function. In the case of 
ester bond formation with the secondary alcohol, the signals of the protons at the two 
neighboring primary alcohol functions would not be split due to the fact that they are 
chemically and magnetically identical; in this case, one duplet with an intensity equaling four 
protons would be expected. The proton of the carbon carrying the secondary alcohol function 
should then give a triplet with an intensity of one. However, this situation is not observed in 
the spectrum. Instead, the signals for the primary alcohol functions were split up. The 
observation of distinct chemical shifts for the protons of one of the primary alcohol functions 
(assigned as 49a and 49b) and the most downfield shifted signals for the glycerol moiety 
indicates its participation in the ester bond. This is further confirmed by reciprocal couplings 
of the protons 49a and 49b in the [1H, 1H]-COSY experiment. Due to the separated proton 
pairs 49a and 49b, and 51a and 51b, the signal for the proton at position 50 should 
theoretically exhibit a multiplicity of dddd with an intensity of one. Although the multiplicity 
of the signal is not completely resolved, proton 50 is most likely represented by the multiplet 
at 3.62 ppm. Thereby, the chemical nature of the glycerol ester is resolved. 
A compound with a mass (m/z [M+H]+ = 760.4) consistent with pretubulysin A glycerol ester 
was identified in the crude extract obtained from fermentation of the SBCb004 tubZ- mutant 
from which pretubulysin A was purified (described in Chapter 2). Analogous HRMS and 
HRMS/MS experiments as those performed for tubulysin D glycerol ester substantiated this 
assumption. Since the compound was present in reasonable amounts, it was also purified to 
provide structural proof by NMR. Successive chromatographic purification steps yielded 
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7.5 mg pure compound to be analysed by NMR. Table 2 lists the obtained 1H NMR signals 
and their assignments to the respective atoms.  
Table 2. 1H NMR signals for pretubulysin A glycerol ester 
Position (H) δH [ppm] Multiplicity JH [Hz] 
2 2.63 m  
3a 1.73  m  
3b 1.99 m  
4 4.30 m  
8 7.97 s  
11a 2.86 m  
11b 2.96 m  
12a 1.99 m  
12b 2.17 m  
13    -   
16 4.73 d 8.5 
19 2.57 m  
20a 1.81 m  
20b 1.91 m  
21 1.52 m  
22a 1.68 m  
22b 1.72 m  
23a 2.62 m  
23b 3.25 m  
25 2.49 s  
26 1.17 d 8.7 
27 2.80 m  
29 7.03 d 8.2 
30 6.67 d 8.2 
32 6.67 d 8.2 
33 7.03 d 8.2 
36 1.80 m  
373 0.79 d 6.5 
38 0.97 d 6.5 
39 3.09 s  
40 1.93 m  
41a 1.22 m  
41b 1.54 m  
42 0.91 t 7.4 
43 1.00 d 6.8 
49a 3.98 dd 6.3 
49b 4.19 dd 4.4 
50 3.82 m  
51a 3.54 m  
51b 3.88 m  
 
Evaluation of the 1H NMR data strengthens the structural proposal of a pretubulysin A 
glycerol ester. The quality of the data is, likely due to residual impurities, inferior to that of 
pretubulysin A, making assignment of all proton signals very difficult. Most of the signals are 
in very good accordance with those for pretubulysin A (reported in Chapter 2). However, for 
some parts of the molecule, especially for the piperazin heterocycle, some signals show a 
strong shift compared to the spectrum of pretubulysin A. Strong overlap with other signals 
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compounded our elucidation efforts. However, the signals for the glycerol moiety were 
clearly identified and confirmed the structural proposal of the ester bond between the carboxyl 
group and one of the primary alcohol functions of glycerol. 
 
Figure 9. Chemical structure of pretubulysin A glycerol ester with numbering used for 1H NMR 
assignments and observed [1H, 1H]-COSY couplings indicated by bold bonds. 
Evaluation of the [1H, 1H]-COSY couplings resulted in the assignment of most alkyl- and 
aryl-moieties present in pretubulysin A glycerol ester (Figure 9). 
Characterization of recombinant patatin-like proteins 
The fact that tubulysin D glycerol ester accumulates in the An d48-orf18- mutant implicates 
that ORF18 hydrolyzes the ester bond between the C-terminal tubulysin carboxyl group and 
the glycerol moiety. Inactivation of orf17 in An d48 resulted in a mutant which also 
accumulated tubulysin D glycerol ester. Inactivations of both genes in SBCb004 yielded 
mutants with analogous tubulysin A glycerol ester-accumulating phenotypes (experiments 
performed by Yi Chai, data not shown). To support and further investigate this hypothesis, 
ORF17 and ORF18 from both An d48 and SBCb004 were heterologously expressed and 
employed in in vitro assays. 
Initial expression constructs were designed using a pET-29 b (+) backbone, resulting in 
heterologous proteins with a C-terminal fused hexahistidine tag for convenient purification by 
Ni2+ immobilized metal ion affinity chromatography (IMAC). Expression and purification of 
ORF18 from both An d48 and SBCb004 was straightforward and yielded reasonably pure 
preparations (Figure 9). However, expression and purification of ORF17 from both strains 
proved to be very challenging. Even though ORF17 and ORF18 show high mutual homology 
in both strains, heterologous expression of ORF17 yielded only insoluble protein. To 
overcome this problem, a number of different affinity tags as glutathione S-transferase 
(GST),[8] maltose-binding protein (MBP),[9] and small ubquitin-like modifier (SUMO)[10] 
protein were screened in order to improve the yield of soluble protein. Unfortunately, none of 
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these tags conferred satisfactory improvements concerning the solubility. Therefore, the 
C-terminal hexahistidine tagged version of ORF17 was co-expressed with several chaperone 
systems.[11-13] Plasmid pGro7 (encoding for E. coli GroEs-GroEL) proved to have the best 
effect on the amount of soluble heterologous protein and was therefore chosen for 
co-expression. Preparations of ORF17 obtained from co-expression and one-step Ni2+-IMAC 
purification were still quite heterogeneous but bands corresponding to the respective 
heterologous proteins could be clearly identified (Figure 10) and verified by matrix assisted 
laser desorption ionization time-of-flight mass spectrometry (MALDI-ToF-MS) of tryptic 
in-gel digests. 
 
Figure 10. SDS-PAGE of heterologously expressed patatin-like proteins. 1: An d48 ORF17, indicated 
by arrow (calc. size 41.5 kDa), 2: An d48 ORF18 (calc. size 40.0 kDa), 3: SBCb004 ORF17, indicated 
by arrow (calc. size 39.3 kDa), 4: SBCb004 ORF18 (calc. size 41.6 kDa), M: Marker (sizes descending 
in kDa: 160 – 110 – 90 – 70 (red) – 55 – 45 – 35 – 25) 
The availability of the recombinant patatin-like proteins as well as their putative substrates 
tubulysin D glycerol ester and pretubulysin D glycerol ester (synthesized by Angelika Ullrich 
from AK Kazmaier) allowed for investigation of the proteins’ capacities in vitro. The 
patatin-like proteins were incubated with tubulysin glycerol esters in 20 mM Tris-HCl pH 7.5 
at 30°C for 1 h and the assays analysed by HPLC-MS. Evaluation of these experiments 
revealed that, in presence of patatin-like proteins, tubulysin glycerol esters were turned over 
to “free” tubulysin, as exemplified in tubulysin D glycerol ester incubated with recombinant 
ORF18 protein from An d48 (Figure 11).  
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Figure 11. Representative HPLC-MS analysis (EICs for m/z 828.5 [blue] and 902.5 [red]) of purified 
tubulysin D glycerol ester before (upper chromatogram) and after (lower chromatogram) incubation 
with recombinant patatin-like proteins (in this case, ORF18 from An d48). 
These experiments therefore confirmed the postulated function of the patatin-like proteins 
ORF17 and ORF18, hydrolytic cleavage of the ester bond between the carboxyl group of 
tubuphenylalanine (or tubutyrosine) and glycerol. This reaction was strictly 
enzyme-dependent, as negative controls containing either no or heat-inactivated protein did 
not exhibit any turnover of tubulysin D glycerol ester to tubulysin D, nor did incubation with 
crude cell extract of the expression strain harbouring the empty expression plasmid. To 
investigate differences between the patatin-like proteins and their tentative preferences for 
mature tubulysin D glycerol ester versus pretubulysin D glycerol ester, all possible 
combinations of recombinant proteins and substrates were tested. The accomplishment of 
well-executed kinetic studies was hampered by the lack of homogeneous fractions of 
recombinant ORF17 from both An d48 and SBCb004, hindering the precise measurement of 
enzyme concentrations, and the limited substrate availability. Therefore equimolar 
concentrations of recombinant patatin-like proteins (assessed as precisely as possible) were 
incubated for a defined period of time with one defined concentration of either tubulysin D 
glycerol ester or pretubulysin D glycerol ester. From these experiments, conversion rates 
based on the integrals of “free” tubulysins and tubulysin glycerol esters were calculated 
(listed in Table 3). 
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Table 3. Conversion rates of substrates by recombinant patatin-like proteins 
Protein 
Conversion of   
pretubulysin 
glycerol ester 
Conversion of     
tubulysin D 
glycerol ester 
ORF17 (An d48) 54.2 % 96.4 % 
ORF18 (An d48) 90.0 % 86.3 % 
ORF17 (SBCb004) 57.0 % 89.0 % 
ORF18 (SBCb004) 1.1 % 1.7 % 
 
Incubation of pretubulysin D glycerol ester with ORF17 from An d48 resulted in 54.2% 
cleavage whereas 96.4% tubulysin D glycerol ester was converted.  Incubation with ORF18 
from An d48 revealed 90.0% pretubulysin D glycerol ester cleavage and 86.3% tubulysin D 
glycerol ester cleavage. These results suggest that ORF17 from An d48 is acting preferentially 
on mature tubulysin D glycerol ester whereas ORF18 from An d48 does not appear to 
discriminate between the two substrates. Preferences for mature tubulysins may be 
reasonable, assuming the glycerol moiety might fulfil some purpose in post-NRPS/PKS 
tailoring reactions. To confirm these presumed functions, detailed kinetic studies with pure 
protein fractions are required. From the assay performed with ORF17 from SBCb004, 
conversion rates of 57.0% for pretubulysin D glycerol ester and 89.0% for tubulysin D 
glycerol ester were obtained. These results are in good agreement with those of ORF17 from 
An d48 and reinforces the hypothesis that tubulysin D glycerol ester is the favoured substrate 
for ORF17 from both organisms. Surprisingly, incubation of ORF18 from SBCb004 revealed 
neither turnover for pretubulysin D glycerol ester nor for tubulysin D glycerol ester. 
Sequence analysis of the patatin-like proteins 
To explain the inactivity of ORF18 from SBCb004, the corresponding patatin-like proteins 
from both strains were compared and a detailed sequence analysis was performed (Table 4). 
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Table 4. Results from sequence comparisons among the patatin-like proteins from both strains 
Protein sequences to be compared Identity [%] Similarity [%] 
ORF17 (An d48) vs. ORF18 (An d48) 78 86 
ORF17 (SBCb004) vs. ORF18 (SBCb004) 67 78 
ORF17 (An d48) vs. ORF17 (SBCb004) 61 74 
ORF18 (An d48) vs. ORF18 (SBCb004) 70 84 
ORF17 (An d48) vs. ORF18 (SBCb004) 62 77 
ORF18 (An d48) vs. ORF17 (SBCb004) 62 77 
 
Both ORF17 and ORF18 from An d48 have a size of 351 amino acids and show a high mutual 
sequence homology (78% identity, 86% similarity), suggesting evolution by gene duplication. 
ORF17 from SBCb004 has a size of 337 amino acids, whereas ORF18, with 368 amino acids, 
is a little bigger. Their mutual sequence homology among each other 
(67% identity/78% similarity) is lower than that observed for the patatin-like proteins from 
An d48. Comparison of the patatin-like proteins from both strains revealed ORF18 from 
An d48 as the closest homolog to both ORF17 and ORF18 in SBCb004, perhaps implying 
that orf17 of An d48 has diverged from the other sequences. 
The term “lipolytic enzymes” characterizes enzymes that hydrolyze hydrophobic 
carboxylic acid esters to release fatty acids and glycerol and these enzymes comprise the 
families of lipases and esterases. The addition of the family of patatin-like proteins to the 
lipolytic enzymes has recently been proposed. The potato patatin B2, after which this family 
has been named, is the major soluble storage protein in potato tubers and has been shown to 
exhibit lipid acyl hydrolase activity.[14] Whereas lipases and esterases usually contain a 
Ser-His-Asp catalytic triad, the active site of patatin B2 consists of a Ser-Asp catalytic 
dyad.[15] ORFs coding for patatin-like proteins have been identified in almost half of all 
sequenced bacterial genomes sequenced and are highly represented in the genomes of 
pathogens/symbionts, suggesting that they confer an advantage, although their exact function 
is not known for the majority of cases. Bacterial patatin-like proteins have been shown to 
contain four conserved domains (blocks I-IV)[5;16]. The first block consists of a Gly rich 
region with a conserved Arg or Lys, which is assumed to function as an oxyanion hole. The 
second block neighbours block I (usually 10 to 20 amino acids distance) and includes the 
hydrolase motif G-X-S-X-G with the putative active-site Ser. Block III features a conserved 
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Ser with vaguely described function (both roles as hydrogen bond donor and as potential 
phosphorylation site are conceivable). The highly conserved Pro residues in blocks III and IV 
may be important for proper conformation of the protein. Block IV contains, in addition, the 
second member of the catalytic dyad, an Asp residue.  
 
Figure 12. Sequence alignment of the patatin-like proteins from the tubulysin biosynthetic gene clusters 
with other myxobacterial patatin-like proteins and patatin B2 from Solanum tuberosum. The alignment 
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was performed with ClustalW2 and formatted with Boxshade 3.21. The consensus sequences of the 
conserved blocks are given on top of the alignment. Abbreviations: DkxK: patatin-like protein 
associated with DKxanthene biosynthetic gene cluster in Stigmatella aurantiaca DW4/3-1, accession no. 
BN001209; Leu 11: patatin-like protein associated with leupyrrin biosynthetic gene cluster in 
Sorangium cellulosum So ce690, accession no. HM639990; MXAN_3852: patatin-like protein from 
Myxococcus xanthus DK1622 involved in development, accession no. ABF93087; PatB2: patatin B2 
from Solanum tuberosum, accession no. P15477. 
These four blocks are generally well-conserved for the patatin-like proteins ORF17 and 
ORF18 from both strains (Figure 12). Detailed analysis of the most crucial residues within 
the single blocks revealed perfect conservation of all residues for ORF17 (An d48), ORF18 
(An d48) and ORF18 (SBCb004). The conserved Lys residue in block I is uniformly 
exchanged for an Arg, thereby retaining the positive net charge required for formation of the 
oxyanion hole. Only ORF17 (SBCb004) is missing this residue (replaced by Gly). Since 
ORF17 (SBCb004) retains its activity, this exchange is probably compensated by other 
residues. The region of +12 to -12 aa around the conserved Arg (Lys in patatin B2 from 
Solanum tuberosum) contains four more basic residues conserved in both ORF17 and ORF18 
(from both strains; two Arg and two Lys) that are most likely also involved in the formation 
of the oxyanion hole and can seemingly retain the functionality of the enzyme. Based on 
sequence analysis, there are no obvious reasons for the inactivity of ORF18 (SBCb004). All 
active-site residues are conserved and only two minor sequence variations compared to highly 
conserved regions in ORF18 (An d48) and both ORF17s (An d48 and SBCb004) are found. 
At position 82, directly after the G-X-S-X-G motif, the Ala residue common to all the three 
other proteins is exchanged for Ser. In block IV at position 214, directly preceding the 
active-site Asp, the consensus Val is substituted by an Ala. However, there is no evident 
rationale why these substitutions should lead to an inactive enzyme. 
The sequences of the proteins DkxK and Leu11, associated with the biosynthetic gene 
clusters for DKxanthene and leupyrrin respectively, also show good conservation of the four 
blocks. However, the Gly rich region within block I (a GGG-motif is conserved for all other 
aligned patatin-like proteins) is not particularly well conserved in both DkxK and Leu11. 
Their involvement or putative functions in the biosynthesis of DKxanthene or leupyrrin are 
unknown. A dkxK knockout mutant of Myxococcos xanthus DK1622 did not reveal any 
differences regarding DKxanthene production in comparison to the wild type strain nor did 
this mutant accumulate any compounds with masses corresponding to glycerol esters of 
DKxanthenes (Thorsten Klefisch, unpublished results). 
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Sequence analysis of the thioesterase domains 
The biochemistry underlying the formation of tubulysin D glycerol ester is still unknown. 
There are no obvious functionalities encoded in the core gene cluster predicted to catalyze this 
reaction. Therefore, the thioesterase (TE) domain situated in the last module of TubF was 
postulated as most likely responsible candidate. TE domains belong to the α/β hydrolase 
family and contain an active site triad comprised of Ser, Asp, and His. Thioesterases can be 
divided into two groups: type I TEs exist as integral domains within a PKS or NRPS subunit 
and catalyze the controlled off-loading of the final product from the assembly line[17], whereas 
type II TEs are discrete proteins that hydrolyze the acyl thioesters of incorrectly acylated 
carrier proteins to maintain the functionality of the assembly line;[18] the following discussion 
focuses on type I TEs. While some of these TEs act as true hydrolases, e. g., those for 
vancomycin or daunomycin, others catalyze regio- and stereospecific macrolactonization or 
macrolactamization.[19] In case of tubulysin release from the assembly line, the TE should, 
rather than employ one molecule of water as nucleophile for hydrolysis of the TE-O-acyl 
intermediate, select one molecule of glycerol. Phylogenetic analyses of thioesterase domains 
revealed a clustering of the sequences according to the class of secondary metabolites released 
(either polyketides, nonribosomal polypeptides or polypeptide/polyketide hybrids).[20] To 
check for obvious special features in the sequence of the tubulysin TEs that might explain for 
the special  postulated reactions catalysed, the sequences of the tubulysin TE domains from 
An d48 and SBCb004 were aligned with TE domains from other myxobacterial 
polypeptide/polyketide hybrids (i. e. epothilone, chondramide, DKxanthene, leupyrrin, and 
myxothiazol; Figure 13) 
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Figure 13. Sequence alignment of the thioesterase domains from the tubulysin biosynthetic gene 
clusters and selected thioesterase domains from myxobacterial biosynthetic gene clusters of mixed 
polypeptide-polyketide secondary metabolites. Domain boundaries were predicted by using the TIGR 
PKS/NRPS prediction tool (http://nrps.igs.umaryland.edu/nrps/). Alignment was performed with 
ClustalW2 and formatted with Boxshade 3.21. Active site residues are indicated in bold letters on top of 
the alignment. Abbreviations: EpoE TE: thioesterase domain from epothilone biosynthetic gene cluster 
in Sorangium cellulosum So ce90, accession no. AAF26925; CmdD TE: thioesterase domain from 
chondramide biosynthetic gene cluster in Chondromyces crocatus Cm c5, accession no. CAJ46692; 
DkxJ TE: thioesterase domain from DKxanthene biosynthetic gene cluster in Stigmatella aurantiaca 
DW4/3-1, accession no. BN001209; LeuE TE: thioesterase domain fromh leupyrrin biosynthetic gene 
cluster in Sorangium cellulosum So ce690, accession no. HM639990; MtaG TE: thioesterase domain 
from myxothiazol biosynthetic gene cluster in Stigmatella aurantiaca DW4/3-1, accession no. 
AAF19815. 
The first distinctive feature is the difference in sequence length of the particular TE domains. 
The epothilone TE exhibits the shortest sequence with 223 aa, while the myxothiazol TE 
(249 aa), leupyrrin TE (256 aa), chondramide TE (257 aa) and DKxanthene TE (261 aa) are 
all in the range of 255 aa; the tubulysin TE (An d48) with 275 aa and the tubulysin TE 
(SBCb004 ) with 276 aa are around 20 aa residues longer. The N-terminal region leading up 
to the Asp active site residue (~ position 100) shows good mutual agreement for all aligned 
sequences. The difference in length between the tubulysin and the remaining TE domains is 
due mainly to aa insertions in the regions directly after the Asp active site residue and halfway 
between the Asp and the His active site residues. This region between the Asp and the His 
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active site residues shows lower mutual agreement between all TE domains, whereas the 
C-terminal block around the His active site residue is more highly conserved. Examination of 
the crystal structure of the DEBS TE (catalyzing macrolactonization in 6-deoxyerythronolide 
B biosynthesis) revealed that several residues downstream of the Asp active site residue are 
involved in the lining of the substrate channel.[21] The additional amino acids inserted in the 
tubulysin TEs in this region might therefore be involved in formation of a pocket to 
accommodate the glycerol moiety suspected to replace water as the attacking nucleophile. 
However, this speculation still requires experimental verification. Initial attempts to 
heterologously express the tubulysin TE domain for investigation of the postulated capacity of 
tubulysin D glycerol ester formation in vitro have not been successful and require additional 
work. 
Biochemical purpose of the glycerol moiety 
The purpose of the attachment of glycerol to tubulysin D and the existence of special enzymes 
dedicated to the cleavage of this moiety is unclear. One idea was that the tubulysin D glycerol 
ester might be further modified by esterification of the glycerol moiety with two fatty acid 
molecules. This tubulysin diacyl glycerol might then be situated in the cell membrane thereby 
serving as storage for tubulysin. If this was true, this fraction of tubulysin would not be 
extracted by the standard procedure of stirring with methanol. Therefore, cell mass of 
An d48-orf18- mutant was first extracted according to the normal procedure (to remove 
tubulysins present in the cells) and the remaining cell pellet was hydrolyzed, extracted and 
analyzed. In order to investigate the impact of the hydrolysis on tubulysin D glycerol ester 
and other tubulysin derivatives (possible breakdown of the backbone), the extract obtained 
from initial extraction of the An d48-orf18- mutant was treated the same way. Comparison of 
the hydrolyzed extract with the original extract revealed the disappearance of all glycerol ester 
derivatives of tubulysins as well as all acylated and N-formylated tubulysin derivatives. 
12-keto N-desmethyl pretubulysin and pretubulysin levels remained unchanged. Instead, a 
peak with m/z = 672.4, present only at very low levels in the original extract, increased in the 
hydrolyzed extract. This compound was identified as 11-hydroxy N-desmethyl pretubulysin 
(reported in Chapter 2) on the basis of retention time and fragmentation pattern comparisons. 
It was therefore confirmed that the conditions used for hydrolysis do not cause a breakdown 
of the tubulysin backbone. Based on these results, there should be an increase of 11-hydroxy 
N-desmethyl pretubulysin in the hydrolysed cell mass sample if the storage theory was 
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correct. However analysis of the hydrolyzed cell mass did not reveal the presence of 
11-hydroxy N-desmethyl pretubulysin and therefore contradicts the storage theory, leaving 
the actual role of the glycerol moiety unknown. 
Experimental procedures 
Culture conditions 
For analysis of secondary metabolite production, A. discoformis An d48, An d48-orf17- and 
An d48-orf18- mutants were grown in 50 mL M7 medium (0.5% probion,0.1% CaCl2·2H2O, 
0.1% MgSO4·7H2O, 0.1% yeast extract, 0.5% soluble starch, 1% HEPES (pH 7.4)) at 30°C in 
presence of 1% adsorber resin (Amberlite XAD-16, Sigma-Aldrich) for 7 days. Mutants 
An d48-orf17- and An d48-orf18- were grown in the presence of kanamycin (50 µg/mL). 
Cystobacter SBCb004, SBCb004-orf17- and SBCb004-orf18- mutants were cultivated in 
50 mL M-medium (1% papaic digest of soybean meal, 1% maltose, 0.1% CaCl2·2H2O, 
0.1 % MgSO4·7H2O, 8 mg/L NaFe-EDTA, 1.19% HEPES, adjusted to pH 7.2) at 30°C in 
presence of 1% adsorber resin for 7 days. Mutants SBCb004-orf17- and SBCb004-orf18- were 
grown in the presence of kanamycin (100 μg/mL).  
Chromatography and mass spectrometry 
For analysis of secondary metabolites, the adsorber resin was separated from the medium and 
extracted with methanol. The extracts were evaporated to dryness and resuspended in 1 mL 
methanol before analysis by mass spectrometry. Standard analysis of crude extracts was 
performed on an HPLC-DAD system from the Agilent 1100 series, coupled to a HCTultra 
ESI-MS ion trap mass spectrometer (Bruker Daltonics) operating in positive ionization mode. 
Compounds were separated on a Luna RP-C18 column (125  2 mm; 2.5 μm particle diameter; 
flow rate 0.4 mL/min (Phenomenex)), with a mobile phase of water/acetonitrile each 
containing 0.1% formic acid, using a gradient from 5–95% acetonitrile over 20 min. Detection 
was by both diode array and ESI-MS. High-resolution mass spectrometry was performed on 
an Accela UPLC-system (Thermo-Fisher) coupled to a linear trap-FT-Orbitrap combination 
(LTQ-Orbitrap), operating in positive ionization mode. Separation was achieved using a BEH 
RP-C18 column (50  2 mm; 1.7 μm particle diameter; flow rate 0.6 mL/min (Waters)), with a 
mobile phase of water/acetonitrile each containing 0.1% formic acid, using a gradient from 
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5-95% acetonitrile over 9 min. The UPLC-system was coupled to the LTQ-Orbitrap by a 
Triversa Nanomate (Advion), a chip-based nano-ESI interface. 
Isolation and structure elucidation of tubulysin glycerol esters 
A fermentation batch culture (8.5 L) of An d48-orf18- mutant was grown in M7 medium in 
the presence of kanamycin (50 µg/mL) and 2% XAD adsorber resin. During cultivation, 
10 mL 20% glycerol per day were added to increase the yield of tubulysin D glycerol ester. 
The production was monitored and the fermenter was harvested after 8 days when it 
plateaued. XAD and cells were extracted with 3 L of methanol and the solvent was removed 
by in vacuo, yielding 15.3 g of crude extract. Initial purification was performed by flash 
chromatography on silica gel using a stepwise gradient of nonpolar to polar solvents: hexane, 
chloroform, chloroform/methanol (3:1, 2:1 and 1:1), and methanol. Fractions containing 
significant amounts of tubulysin D glycerol ester were combined and evaporated to dryness. 
Pure tubulysin D glycerol ester was obtained by purification in a preparative HPLC 
instrument (Waters), equipped with a 2545 binary gradient module, 515 HPLC pump, SFO 
system fluidics organizer, 2998 PDA, 3100 mass detector, and 2767 sample manager. An 
X-Bridge RP-C18 column (19  100 mm, 5 µm, Waters) was used for separation with a 
solvent system of H2O (A) and methanol (B), each containing 0.1% formic acid. The 
following gradient was applied:  0–1 min, 35% B; 1–6 min 35–55% B; 6–10 min 55–70% B. 
Fractions were collected using mass-guided fraction collection, with a trigger mass of 
902.5 Da. This purification procedure yielded 0.6 mg of a slightly beige amorphous solid. The 
compound was dissolved in DMSO d6 and analyzed by one-dimensional and two-
dimensional NMR experiments. NMR spectra were recorded on a Bruker Avance 500 
spectrometer. 
The SBCb004-tubZ– mutant was cultivated in M medium in the presence of kanamycin 
(50 µg/mL) and 2% XAD adsorber resin at 30°C for 6 days. Cultivation was implemented in a 
17 L fermenter and shaking flasks (9 L; 150 rpm), for a total volume of 26 L. Fermentation 
was performed with stirring at 300 rpm, oxygen saturation of 35%, and at pH of 7.2–7.4. 
XAD was separated from the supernatant and extracted with 6 L of methanol. This procedure 
yielded 18.4 g crude extract after solvent evaporation. Purification of pretubulysin A glycerol 
ester was performed analogously to the protocol described above and yielded 7.5 mg pure 
compound. 
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Cloning, expression and purification of ORF17 and ORF18 
Orf17 and orf18 were amplified from genomic DNA of An d48 and SBCb004 using Phusion 
DNA polymerase (Finnzymes) with primers orf17_An d48_NdeI_for (5´-CTA GCA TAT GGC 
CGC AGC TGC GGC ATC T-3´) and orf17_An d48_HindIII_rev (5´-CTA GAA GCT TGC TCC GCG 
CCT CTC CCG ACT-3´), orf18_An d48_NdeI_for (5´-CTA GCA TAT GAC TTC GGG CAC TCG GAA A-
3´) and orf18_An d48_HindIII_rev (5´-CTA GAA GCT TGC TCC GCG CCT CTC CCG ACT-3´), 
orf17_SBCb004_NdeI_for (5´-CTA GCA TAT GGC CGC GGG TCG CCC T-3´) and 
orf17_SBCb004_HindIII_rev (5´-CTA GAA GCT TAC GGG GAG ACG TCT CGT GGG-3´), 
orf18_SBCb004_NdeI_for (5´-CTA GCA TAT GGC CAC CGG TTC GAC GCC CAA-3´) and 
orf18_SBCb004_HindIII_rev (5´-CTA GAA GCT TAC CTG GAG AGG CCT CGG CTG TCT-3´). The 
resulting PCR products were purified, digested with NdeI and HindIII, and ligated into NdeI/ 
HindIII-digested pET-29 b (+), generating pET-29 b (+)-orf17-An d48, 
pET-29 b (+)-orf18-An d48, pET-29 b (+)-orf17-SBCb004, and pET-29 b (+)-
orf18-SBCb004. The ligations were electroporated into E. coli DH10B and positive clones 
were selected on LB agar plates containing kanamycin (50 µg/mL). The identity of the 
plasmids was confirmed by restriction analysis and sequencing. For production of C-terminal 
His-tagged fusion proteins, E. coli BL21(DE3) harbouring the respective expression plasmid 
was grown at 37°C in 250 mL LB medium containing kanamycin (50 µg/mL) to an OD600 of 
approximately 0.8 units. For protein expression, the culture was induced with 0.2 mM 
isopropyl β-D-thiogalactopyranoside (IPTG) and incubated at 16°C for 16 h. For co-
expression of ORF17 from both strains with GroES-GroEL chaperones from E. coli, the 
plasmid pGro7 was co-transformed into the expression strain and maintained by addition of 
chloramphenicol (20 µg/mL). The chaperones were induced by addition of L-arabinose to a 
final concentration of 2 mM 30 min prior to induction of the proteins of interest. The cells 
were harvested by centrifugation at 7300 g for 12 min at 4°C in a Beckman Coulter Avanti 
J-E centrifuge. All subsequent steps were carried out at 4°C. The cell pellet was resuspended 
in 25 mL binding buffer (50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 20 mM imidazole, 
glycerol 10 % (v/v)) and lysed with a French pressure cell press. Cell debris was removed by 
centrifugation at 25000 g for 45 min. The supernatant was filtered through 1.2 µm Acrodisc 
syringe filters (PALL Life Sciences) before loading onto a 1 mL Hi-Trap His column using 
the Äkta purifier system (both from GE Healthcare) at a flow rate of 1 mL/min. The unbound 
sample was washed away with 5 column volumes binding buffer. To elute the His-tagged 
heterologous proteins, a stepwise gradient with 7%, 16%, 40% and 100% elution buffer 
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(50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 500 mM imidazole, glycerol 10% (v/v)) with 
6 column volumes for each step was applied. Buffer in fractions containing heterologous 
protein were exchanged for 50 mM Tris-HCl, pH 8.0, 150 mM NaCl, glycerol 10% (v/v) 
using PD10 columns (Amersham Biosciences) and further concentrated using Amicon 
ultracentrifugal filter devices. Concentrated protein solutions were frozen in liquid nitrogen 
and stored at -80°C. Protein concentrations were determined with the Bio-Rad protein assay 
kit according to the manufacturer’s instructions using bovine serum albumin (BSA) as a 
standard (0.5 – 8 µg/mL). Protein fractions were separated on a 15% sodium dodecyl sulfate 
(SDS)-polyacrylamide gel by electrophoresis. Proteins were visualized in the gel by staining 
with Coomassie Brilliant Blue R-250. For matrix assisted laser desorption ionisation 
time-of-flight mass spectrometry (MALDI-ToF-MS), protein bands were excised from the 
SDS-polyacrylamide gel and in-gel digestion with trypsin was performed. Samples were 
prepared using Zip-Tips (Milipore). 
Characterization of activity of patatin-like proteins 
Assays were performed in 50 mM phosphate buffer, pH 7.0 containing one of the 
recombinant patatin-like proteins (100 nM) and either pretubulysin D glycerol ester or 
tubulysin D glycerol ester (25 µM) in a total volume of 100 µL. Control incubations were 
performed with heat-inactivated patatin-like proteins (10 min at 99°C), cell lysate of E. coli 
BL21(DE3) pET-29 b (+), and without addition of enzyme. Reactions were incubated at 30°C 
for 1 h and quenched by the addition of 100 µL methanol prior to analysis by HPLC-MS 
according to the conditions stated above.  
Hydrolysis of An d48 cell mass 
A portion of cell mass from An d48 was extracted once with acetone and twice with 
methanol. The remaining cell pellet was divided into two equal portions. The first portion was 
boiled under reflux in KOH (pH 13.5) for two hours, neutralized, freeze-dried, extracted with 
methanol, filtered, and evaporated to dryness before HPLC-MS analysis. The second portion 
was extracted a third time with methanol, filtered, evaporated to dryness, and analysed by 
HPLC-MS.  Another portion of the extract obtained from the first extraction was also 
hydrolysed and processed as described.  
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Abstract  
 The field of bacterial natural product research is currently undergoing a paradigm change 
concerning the discovery of natural products. Previously most isolation efforts were based on 
isolation of the most abundant compound in an extract or on the tracking of bioactivity. 
However, traditional activity guided approaches are limited by the available test panels and 
frequently lead to the rediscovery of already known compounds. The constantly increasing 
availability of bacterial genome sequences provides the potential for the discovery of a huge 
number of new natural compounds by in silico identification of biosynthetic gene clusters. 
Examination of the information on the biosynthetic machinery can further prevent rediscovery 
of known compounds and identify so far unknown biosynthetic pathways of known 
compounds. By in silico screening of the genome of the myxobacterium Stigmatella 
aurantiaca Sg a15 a trans-AT polyketide synthase/non-ribosomal peptide synthetase 
(PKS/NRPS) gene cluster was identified that could not be correlated to any secondary 
metabolite known to be produced by this strain. Targeted gene inactivation and analysis of 
extracts from the resulting mutants by high performance liquid chromatography coupled to 
high resolution mass spectrometry (HPLC-HRMS) in combination with the use of statistical 
tools resulted in the identification of a compound which was absent in the mutants extracts. 
By matching with our in house database of myxobacterial secondary metabolites this 
compound was identified as rhizopodin. A detailed analysis of the rhizopodin biosynthetic 
machinery is presented in this manuscript. 
Introduction 
Myxobacteria are soil-dwelling, Gram-negative bacteria which are a rich source of secondary 
metabolites (SMs) with multifaceted biological activities, such as antibacterial or antifungal 
mode of action and cytotoxic or cytostatic effects against eukaryotic cell lines.[1] In general 
one strain produces not only one but several SMs. This is also the case for the subject of this 
study - Stigmatella aurantiaca Sg a15 which is known to produce aurachins,[2] myxochelins,[3] 
stigmatellins,[4] myxalamids,[5] myxochromides,[6] and DK-xanthenes.[7] Most of these SMs 
are built up by non-ribosomal peptide synthethases (NRPSs), polyketide synthases (PKSs) or 
hybrids of both.[8;9] These systems are giant multifunctional enzymes that are composed of 
modules. Each module is responsible for one cycle of chain extension of the nascent product, 
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consisting of a set of domains which dictate the chemical functionalities of the incorporated 
building block. The minimal NRPS module is composed of an adenylation (A), a 
condensation (C) and a peptidyl carrier protein (PCP) domain. The A domain activates a 
specific amino acid that is subsequently linked via its carboxyl function to the 
4´-phosphopantetheine (Ppant) cofactor of the PCP, whereas the C domain catalyzes peptide 
bond formation with the growing chain tethered to the upstream PCP. In addition, optional 
domains that are responsible for methyl transfer (MT), epimerization (E), heterocyclization 
(HC) and oxidation (Ox) can raise the structural diversity.[10] In analogy to NRPS, the 
minimal set of domains within a PKS module consists of an acyltransferase (AT) which loads 
a coenzyme A activated dicarboxylic acid extender unit onto an acyl carrier protein (ACP), 
where it undergoes condensation with the nascent polyketide intermediate catalyzed by the 
upstream ketosynthase (KS) domain. The resulting β-keto function can be further processed 
by a number of optional functionalities, including ketoreductase (KR), dehydratase (DH) and 
enoylreductase (ER) domains, to yield hydroxyl, enoyl or fully reduced methylene functions 
in β-position.[11] Besides these “classical” cis-AT PKSs, there exist trans-AT PKSs which 
stand out by a lack of integral AT domains which is complemented freestanding AT 
enzymes.[12]  
NRPS and textbook cis-PKS show strong correlation in both the number and the order of 
modules in the megasynthases and the building blocks incorporated into the final product, 
also known as colinearity rule.[13] The fact that all of the above mentioned domains show 
significant sequence conservation with retention of active site motifs and that the genes 
responsible for the biosynthesis of a SM are usually clustered in the genome, allow for 
straightforward identification of these biosynthetic gene clusters from complete microbial 
genome sequences by homology searches. The recent increase of available genome sequences 
from bacterial SM producers, including several myxobacteria, revealed in all cases a higher 
biosynthetic potential encoded at the DNA-level, compared to the number of known 
SMs.[14-18] In some cases the gene clusters may be “silent” under the chosen cultivation 
conditions, or the amounts of the correlated SM are so low that it escapes detection. Besides 
screening of new bacterial isolates as novel SM producers, the future of bacterial natural 
product research lies in the exploitation of this untapped biosynthetic potential by making use 
of the increasing sequence data, in order to find new chemical entities with potentially novel 
modes of action, and to identify biosynthetic pathways of known secondary metabolites. To 
attain this goal a multitude of different approaches has been developed in recent years.[19;20] 
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Here, we present how the application of targeted gene inactivation in combination with 
sophisticated analytical and statistical tools led to the identification of rhizopodin as another 
SM produced by Sg a15 and provide a detailed characterization of the corresponding 
biosynthetic gene cluster. 
Results  
Identification of rhizopodin from S. aurantiaca Sg a15 
The draft genome of S.aurantiaca Sg a15 has been obtained by 454 sequencing and was 
subjected to analysis by a genome scanning pipeline for PKS and NRPS biosynthetic gene 
clusters.[21] The limited average length of contiguous DNA stretches in the draft genome 
(approximately 7.8 kb) complicated straightforward genome mining of SM biosynthetic gene 
clusters, which often exhibit sizes between 30 to 80 kb. In addition to the gene clusters related 
to the production of known SMs from Sg a15, several fragments of gene clusters were found 
that could not be correlated to known biosynthetic pathways. Among these two fragments of 
trans-AT PKS-NRPS hybrids. Both of them were obviously exceeding the borders of their 
respective contigs, with one truncated at the 3’-end the other at the 5’-end.  However, in both 
cases, the essential trans-AT functionalities were present. In order to correlate these clusters 
to their SMs, two single-crossover gene disruption mutants,[22] targeting KS domains in both 
fragments, were generated. The secondary metabolite profiles of resulting mutants were 
analyzed by high performance liquid chromatography coupled to mass spectrometry 
(HPLC-MS) and compared to that of the wild type. In depth manual inspection of 
chromatograms and MS spectra did not reveal any obvious differences. Consequently, we set 
out to use statistical tools for identifying minor variations in the mutants’ metabolic 
profiles.[23] Mutants and the wild type were grown and worked up under identical conditions, 
in quintuplicates. The resulting extracts were measured on a HPLC system coupled to an 
Orbitrap mass spectrometer. In brief, the obtained HPLC-high resolution (HR)MS data were 
used to generate a molecular feature inventory. Based on the combination of m/z values of 
molecular features and the respective retention time, so called buckets are created. These 
buckets present the input values for the statistical evaluation of the data sets. Using the 
statistical tool of principle component analysis (PCA), implemented in the ProfileAnalysis 
software (Bruker Daltonics), we were able to identify two hits with masses of 735.4428 and 
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1469.8783 m/z missing in both the inactivation mutants but present in the wild type 
(Figure 1B). Both masses were recorded at identical retention time. Closer investigation of 
the isotopic patterns revealed that 735.4428 m/z is doubly charged and thus equivalent to the 
singly charged m/z 1469.8783 m/z. Computation of the molecular formula based on the 
neutral mass of 1468.8705 Da resulted in a number of hits due to the high molecular weight. 
The most likely molecular formulas, based on biosynthetic considerations, were used in 
combination with the obtained chromatographic and MS data to scan our in-house 
myxobacterial SM database. Thereby the compound was identified as rhizopodin. This 
finding was confirmed by comparative HPLC-MS analysis of extracts of Sg a15 wild type 
with authentic rhizopodin reference. 
 
 
Figure 1. HPLC-MS chromatograms of Sg a15 extracts. A) Base peak chromatogram (BPC) from 200-
2000 Da in positive ionisation mode (dashed line) and combined extracted ion chromatograms (EIC) of 
735.44 and 1469.88 ± 0.01 Da (mass of [rhizopodin + 2H]2+ and [rhizopodin + H]+, solid line) of 
extracts from Sg a15 wild type. The rhizopodin signal is highlighted. B) EICs of 735.44 and 1469.88 ± 
0.01 m/z of extracts from Sg a15 wild type, rizB KS1 mutant, rizB KS7 mutant, rizA mutant, rizF mutant 
and orf5 mutant. 
The very low amounts of rhizopodin produced by Sg a15 (Figure 1A) and the fact that it is 
“hidden” by co-elution with myxalamide B,[5] which is present in the spectra at a 100-fold 
higher level, have so far prevented the identification of Sg a15 as a producer of rhizopodin 
B. Publications – Chapter 7 
 
62 
(Figure S1). Rhizopodin is a myxobacterial SM with potent cytostatic activity. It was first 
isolated and structurally elucidated in the early nineties from Myxococcus stipitatus.[24] 
Fifteen years later it became apparent, during the course of extensive NMR studies,[25;26] that 
rhizopodin, instead of the originally proposed monolactone, is a C2-symmetric dilactone. At 
the same time, the absolute configuration of rhizopodin and its mode of action via inhibition 
of actin polymerization by dimerization were elucidated by X-ray crystallography.[27] To date, 
molecular details regarding the biosynthesis of rhizopodin remain unknown.  
Sequence analysis of the rhizopodin biosynthetic gene cluster  
The results obtained from the inactivation experiments indicate that the two partial DNA 
sequences coding for trans-AT NRPS-PKS hybrids present components of the rhizopodin 
biosynthetic gene cluster. In order to obtain the whole gene cluster (designated as riz cluster), 
gaps between the two identified contigs were closed by PCR followed by sequencing. Thus 
92.2 kb of continuous DNA sequence were obtained that contain 13 genes, among which two 
encode for hybrid PKS-NRPSs (rizB and rizD) and two encode PKSs (rizC and rizE). None of 
the PKS gene products harbours integral AT domains. Instead, three genes encoding 
free-standing ATs (rizA, rizF and orf5) were found in the same gene locus. Targeted 
disruption by insertion mutagenesis of rizF located immediately downstream of the last PKS 
gene (rizE) led to an approximately 50-fold decrease in rhizopodin production, indicating that 
RizF plays a role in the biosynthesis (Figure 1B). On the contrary, inactivation of orf5 
located downstream of rizF did not significantly affect the production of rhizopodin, and thus 
allowed to define one of the boundaries of the riz cluster. Inactivation of rizA completely 
abolished rhizopodin production. However, a polar effect in this mutant is likely, as rizA 
seems to form an operon with the downstream PKS-NRPS and PKS genes. Regarding the 
genes (orf1-4) upstream of rizA no putative functions in the biosynthesis of rhizopodin could 
be assigned.  
The megasynthases RizBCDE encoded in the riz cluster are organized into 21 modules 
(19 PKSs and 2 NRPSs). In order to gain insight into the biosynthetic pathway, all domains 
were analyzed for the conservation of characteristic motifs and key active site residues. 
Among the 19 KS domains, seven (KS3, KS7, KS10, KS12, KS14, KS18 and KS20) lack part 
of or the complete HGTGT motif that is essential for the decarboxylative condensation 
activity[28] (Figure 2). 
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Figure 2. Alignment of the KS domain core regions of KS1-KS20 of RizBCDE. Highly conserved amino 
acids are highlighted by black background, deviations from the core motifs are marked in bold. 
Therefore the corresponding modules are likely not elongating and may be involved in 
channeling the polyketide chain to downstream modules as postulated earlier.[29] The presence 
of 12 active KS domains is in agreement with the retrobiosynthetic analysis that predicts 
incorporation of 12 acetate-derived C2 building blocks to form one part of the rhizopodin 
dimer. The N-terminus of RizB contains a typical NRPS loading module, composed of an A 
and a PCP domain together with two additional tailoring domains. The last domain of RizE is 
a thioesterase (TE) commonly involved in the release of polyketide or polypeptide chains 
from the megasynthase. These features strongly indicate that RizBCDE are arranged in a 
colinear manner to the biosynthetic assembly. A domains within the NRPS modules in RizB 
and RizD show good conservation of the amino acids lining the binding pockets that are 
predicted to recognize glycine and serine, respectively (Table 1).[30] 
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Table 1. Comparison of the specificity-conferring code of the A domains in rhizopodin biosynthesis with 
consensus sequences.[a] 
Residues
 235 236 239 278 299 301 322 330 331 517 
Glyconsensus D I L Q V G L I W K 
RizB 
ALoad 
D I L Q C G V I W K 
Serconsensus D V W H L S L I D K 
RizD A11 D V W H F S L V D K 
[a] Residue numbering according to the GrsA L-phenylalanine activating A domain.[31] 
 
Analysis of the ten KR domains confirmed in all cases the presence of the Rosmann fold 
motif GXGXXG and the Lys-Ser-Tyr catalytic triad.[32] The four DH domains show good 
agreement with the conserved HXXXGXXXXP and DXXX(Q/H) motifs required for 
activity.[33] The sole ER domain encoded in the rhizopodin gene cluster deviates from the 
consensus sequence LXHXXXGGVGXXAXXXA in two positions 
(LIQTAAGGVGLFGMQMA), but the functionality is likely to be retained. The methyl 
transferase (MT) domains present could be classified into three categories according to their 
conserved motifs:[34] N-MT (in the loading module), C-MTs (in modules 2, 5, 8) and O-MTs 
(in modules 3, 7, 14, 18). The NRPS module 11 on RizD contains a tandem HC-domain as 
distinctive feature. When compared to the eight core motifs of standard HCs (Cy1-Cy7 and 
C3),[35] both HC domains from the rhizopodin gene cluster showed good agreement for the 
conserved motifs Cy1, Cy2, Cy6, Cy7 and C3 but only poor to moderate agreement  for Cy3, 
Cy4 and Cy5. The Ox domain downstream of the tandem HCs is in good agreement with the 
conserved motifs Ox1-3.[36] Based on these results, a detailed model of rhizopodin assembly 
was proposed (Table 2 and Scheme 1). 
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Model of rhizopodin biosynthesis 
Biosynthesis starts with activation and tethering of glycine to the PCP of the loading module, 
followed by formylation and N-methylation to yield the unusual methylformamide starter 
unit. The formyltransferase (FT) in the loading module is a rather exceptional feature in 
NRPS. Examples can be found in the biosynthetic pathways of linear gramicidin,[37] the 
anabaenopeptilides,[38] and oxazolomycin.[39] The first two rounds of extension are carried out 
by the successive two PKS modules, whose modular architectures correspond exactly to the 
degree of β-keto processing, i. e. module 1 generates an acrylyl intermediate while module 2 
results in an α-methylated β-hydroxy functionality. Module 3 (KS0-(O-MT)-ACP) does not 
account for chain extension , due to its inactive KS domain, but mediates O-methylation of 
the β-hydroxy group. Module 4 (KS-ACP) presents the minimal module of trans-AT systems 
and incorporates a malonyl-CoA unit without further reductive processing. Module 5 
(KS-DH-KR-(C-MT)-ACP-ER) presents an unusual domain organization, with the ER 
located downstream of the ACP. Nonetheless, the present activities fit with the expected 
aliphatic α-methylated intermediate. Module 6 (KS-KR-ACP) accounts for a two carbon 
extension, giving rise to a β-hydroxy intermediate. Module 7 (KS0-(O-MT)-ACP) features  a 
non-elongating KS and thus, like module 3, is solely responsible for O-methylation of the 
β-hydroxyl group. The next module (module 8) is split with KS-KR-(C-MT) on RizB and its 
ACP located on RizC. The C-MT is predicted to act twice on the α-carbon thereby installing a 
dimethyl functionality at  thisposition. To the best of our knowledge this unusual course of 
reaction has only been reported from other trans-AT systems (e. g. pederin,[40] onamide,[41] 
bryostatin,[42] disorazol,[43] oxazolomycin,[39] and elansoloid[44]). For SMs built up by cis-AT 
systems (e. g. epothilone),[45] geminal dimethyl groups are introduced by incorporation of a 
methylmalonyl-CoA building block followed by a single C-methylation. Therefore, the 
C-MTs acting twice seem to be a special feature of trans-AT PKS. However, sequence 
alignment of such C-MTs with “classical” C-MTs in the cis-AT systems did not reveal any 
obvious differences (data not shown). The assembly continues with one functional PKS 
module followed by the second NRPS module in the assembly line. The NRPS module 
(HC-HC-A-PCP-Ox) in RizD attaches a serine to the acyl chain which is subsequently 
cyclized and oxidized by the concerted action of HC and Ox domains to result in an oxazole 
moiety. The growing intermediate is then passed through module 12 (KS0-ACP), extended by 
module 13 (KS-KR-ACP) and modified by the O-MT in module 14 (KS0-(O-MT)-ACP) in 
analogy to modules 3 and 7. The successive module (module 15) (KS-DH-ACP) lacks the KR 
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domain needed to act prior to the DH to produce the expected α, β-double bond. Thus, the 
nascent β-keto group is likely not processed by this module; instead, the acyl chain is 
transferred to the ACP of module 16 followed by reduction and dehydration to result in the 
required α,β double bond. Subsequent transfer of this intermediate to KS16 for further 
extension would be expected. Such reaction sequence has been proposed for the biosynthesis 
of several myxobacterial SMs including thuggacins,[46] adjudazols,[47] spirangienes,[48] and 
stigmatellins.[4] However, the detailed mechanisms governing such domains acting out of 
sequence remain elusive. An alternative scenario including an unknown trans-KR that acts in 
concert with the DH domain in module 15 can currently not be excluded. Module 17 
(KS-KR-ACP) is another split module with the KS located on RizD and KR and ACP located 
on RizE. It catalyzes extension and reduction of the β-keto function to give the expected 
β-hydroxy intermediate. Module 18 (KS0-(O-MT)-ACP) is the fourth module of this type 
which yields a non-extended β-methoxy intermediate. The last elongating module (module 
19) (KS-KR-ACP) yields the full length monomeric chain of rhizopodin which is passed on 
by the non-extending module 20 (KS0-ACP) to the C-terminal TE that is hypothesized to 
catalyze dimerization by formation of two lactone bonds going along with release of the final 
product from the assembly line. The presented model for rhizopodin biosynthesis shows good 
overall agreement with the colinearity rule.  
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Table 2. Putative functions and domain organisation of proteins within the rhizopodin biosynthetic gene 
cluster and the contiguous surrounding region. 
Protein
/gene 
Length 
(bp/aa) Description Modules Domains (coordinates in protein sequence (aa)) 
RizA/ 
rizA 855/285 AT AT AT (1-285) 
RizB/ 
rizB 
36942/ 
12314 
NRPS/PKS Loading 
Module 1 
 
Module 2 
 
Module 3 
Module 4 
Module 5 
 
Module 6 
Module 7 
Module 8 
FTL (6-342), MTL(509-778), AL (905-1415), PCPL(1420-1504) 
KS1 (1561-1996), DH1 (2120-2419), KR1 (2428-2904), ACP1 
(2906-2985) 
KS2 (3019-3449), KR2 (3624-4110), MT2 (4174-4485), ACP2 
(4511-4589) 
KS3 (4630-5055), MT3 (5215-5551), ACP3 (5576-5655) 
KS4 (5694-6121), ACP4 (6317-6395) 
KS5 (6436-6851), DH5 (6969-7269), KR5 (7273-7749), MT5 
(7810-8121), ACP5 (8152-8231), ER5 (8276-8594) 
KS6 (8626-9052), KR6 (9222-9705), ACP6 (9723-9801) 
KS7 (9843-10255), MT7 (10386-10729), ACP7 (10748-10830) 
KS8 (10857-11281), KR8 (11445-11923), MT8 (11989-12309) 
RizC/ 
rizC 
6237/ 
2079 
PKS Module 8 
Module 9 
Module 10 
ACP8 (24-103) 
KS9 (151-577), KR9 (747-1222), ACP9 (1236-1314) 
KS10 (1354-1777), ACP10 (1957-2036) 
RizD/ 
rizD 
23415/ 
7805 
NRPS/PKS Module 11 
 
Module 12 
Module 13 
Module 14 
Module 15 
Module 16 
 
Module 17 
HC11a (37-460), HC11b (488-911), A11 (928-1442), PCP11 
(1443-1529), Ox11 (1539-1765) 
KS12 (1784-2198), ACP12 (2371-2454) 
KS13 (2486-2913), KR13 (3083-3567), ACP13 (3568-3646) 
KS14 (3676-4091), MT14 (4226-4559), ACP14 (4579-4658) 
KS15 (4684-5109), DH15 (5216-5521), ACP 15 (5546-5624) 
KS16 (5669-6101), DH16 (6219-6551), KR16 (6555-7045), 
ACP16 (7058-7136) 
KS17 (7178-7606) 
RizE/ 
rizE 
11883/ 
3961 
PKS Module 17 
Module 18 
Module 19 
Module 20 
KR17 (55-540), ACP17 (544-622) 
KS18 (665-1097), MT18 (1228-1573), ACP18 (1590-1670) 
KS19 (1711-2136), KR19 (2323-2801), ACP19 (2802-2881) 
KS20 (2930-3357), ACP20 (3544-3624) TE (3665-3952) 
RizF/ 
rizF 861/287 AT AT AT (1-287) 
orf Length (bp/aa) 
Accession 
number of 
closest 
homologue 
Similarity/ 
Identity [%] Putative function/homologue 
1 1764/588 ZP_06890144 44/25 ABC-1 domain protein 
2 606/202 ZP_0445617 56/33 hypothetical protein 
3 1443/481 CBK82307 64/43 ATPase component of ABC transporter 
4 720/240 ZP_07267895 54/32 cobalt transport protein 
5 966/322 CAM75127 58/39 Acyltransferase 
6 1689/563 ZP_06890144 58/41 ABC-1 domain protein 
7 537/179 YP_003953239 96/93 transcription elongation factor GreB 
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 Scheme 1. Rhizopodin biosynthetic pathway. A) Organisation of the rhizopodin biosynthetic gene 
cluster. B) Model for the biosynthesis of rhizopodin in S. aurantiaca Sg a15. NRPS domains are marked 
in gray, PKS domains in white and non-elongating KS0 domains in black. 
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Support of the biosynthetic model by feeding experiments 
For experimental support of our biosynthetic model we performed feeding experiments with 
L-serine-13C3,15N and L-methionine-(S-methyl-13C) using liquid cultures. Due to its high 
molecular weight (elemental composition: C78H124N4O22; monoisotopic mass: 1468.8707), 
rhizopodin exhibits in MS analysis at least four apparent isotopic signals, with the 
monoisotopic and the +1 Da signal of equal intensity. Since rhizopodin is composed of two 
monomers, feeding with L-serine-13C3,15N would result in increase of either +4 Da (single 
incorporation) and/or +8 Da (double incorporation) in mass. Upon feeding, we observed 
isotopic signals from +1 to +12 Da with the peak of +4 Da and +8 Da of highest intensity 
(Figure 3A), as expected for incorporation of one or two labeled serine residues. These 
results confirm that serine is the origin of the oxazole heterocycle in the rhizopodin structure. 
In the dimeric structure of rhizopodin a total of 18 methyl branches (2xN-, 8xC-, and 
8xO-methyl) are to be found. By feeding L-methionine-(S-methyl-13C), a maximum increase 
of +18 Da could be envisioned. However, total labeling is hard to achieve in a complex 
medium as used in this case to cultivate Sg a15, due to competition with unlabeled 
methionine. In order to maximize the rate of labeled methionine incorporation into 
rhizopodin, it was added at high concentration after the culture reached the stationary phase 
during which secondary metabolites are preferentially produced. Investigation of the mass 
spectra from extracts of the fed cultures showed labeled rhizopodin with a Gaussian 
distribution from +10 Da to +19 Da with a maximum at +15 Da (Figure 3B), in addition to 
small amounts of unlabeled rhizopodin. This result proves that all methyl branches in the 
rhizopodin structure derive from S-adenosyl-L-methionine (SAM) by the action of SAM-
dependent MTs. Of particular importance, C-methyl branches are not derived from 
methylmalonyl-CoA, thus pointing out that ATs encoded in the riz cluster are specific for 
malonyl-CoA. 
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Figure 3. HR-MS spectra of stable isotope labeled rhizopodin. A) Feeding of L-serine13C3,15N.  
B) Feeding of L-methionine-(methyl-13C). 
Investigations on ACP priming 
Both standalone trans-ATs, RizA and RizF, show significant similarity to ATs in other 
trans-AT PKS systems (RizA, 51% identity/72% similarity to BryP involved in bryostatin 
biosynthesis; RizF, 54% identity/70% similarity to BaeE from bacillaene biosynthetic 
pathway). Their substrate specificity for malonyl-CoA was confirmed by sequence alignments 
(Table S1).[49] Two or more discrete ATs are less frequent in trans-AT PKSs, with six 
examples identified to date (bacillaene,[50] pederin,[40] etnangien,[51] sorangicin,[49] 
kirromycin,[52] and elansolid[44]). In some of these cases one of the trans-ATs has substrate 
specificity different from malonyl-CoA (etnangien, sorangicin, and kirromycin), or the AT 
domain is fused to an ER domain which is able to catalyze enoyl reduction in trans 
(bacillaene,[53] elansolid).  Inactivation of rizF, which resulted in a 50-fold decrease in 
rhizopodin production, suggested preferential loading of individual ACPs by one of the ATs, 
which can be complemented by the other (at least by rizA), albeit with lower efficiency. At 
this stage it is impossible to verify the role of rizA in vivo, as insertional mutagenesis is likely 
to generate a polar effect on the downstream megasynthases and in-frame deletions in Sg a15 
have to date not been achieved, despite significant efforts. Therefore, in order to investigate 
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possible loading preferences of trans-ATs for particular ACPs, we expressed both RizA and 
RizF and several ACPs from the riz cluster in Escherichia coli as recombinant proteins for in 
vitro loading experiments. Among the selected ACPs, we included two ACPs from 
non-elongating modules (12 and 18) aiming to investigate their properties concerning 
malonyl-CoA priming. Holo-ACPs were obtained by coexpression with the Ppant-transferase 
MtaA from the myxothiazol gene cluster[54] and their identities were confirmed by ESI-MS 
analysis of intact proteins (Table 3). Incubation of holo-ACP proteins with malonyl-CoA and 
RizA or RizF resulted in a mass shift of 86 Da, corresponding to loading of a malonyl group. 
On the contrary, incubation of holo-ACPs with malonyl-CoA alone or in combination with 
cell lysate of E. coli BL21 (DE3) carrying the empty expression vector pET28b(+) did not 
result in any detectable amount of malonyl-ACPs. Both ATs were found to load malonyl-CoA 
to all tested ACPs with roughly comparable efficiency under the experimental conditions 
chosen.  
Table 3. Results of HPLC-MS analyses of heterologously expressed holo-ACPs from rhizopodin 
biosynthesis upon incubation with heterologously expressed acetyltransferases RizA and RizF in 
presence of malonyl-CoA.[a] 
 
 
The simplified in vitro conditions using free-standing ATs and excised ACP domains may not 
reflect the complex environment within the megasynthase, where multi-domain interactions 
are involved. Therefore, subtle loading preferences of ATs in vivo might be hard to detect in 
vitro. Nevertheless, the observation that ACPs downstream of non-elongating KS0s can be 
primed with malonyl-CoA in vitro is interesting and suggests that these ACPs are catalytically 
Protein 
Down-
stream 
of KS0 
Calc. 
mass 
Obs. 
mass 
RizA 
malonyl-CoA 
loading 
RizF 
malonyl-CoA 
loading 
holo-
RizACP12 
yes 12237 12241 12327(+86)/[87%] 12327(+86)/[54%] 
holo-
RizACP13 
no 11383 11384 11470(+86)/[62%] 11470(+86)/[67%] 
holo-
RizACP17 
no 11648 11650 11736(+86)/[66%] 11736(+86)/[81%] 
holo-
RizACP18 
yes 11676 11692[b] 11778(+86)/[73%] 11778(+86)/[57%] 
[a] All given masses in Da. Given in brackets are the percental conversions from holo-ACP to 
malonyl-ACP. [b] Unknown modification; identity of the protein confirmed by MALDI-ToF MS. 
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active. This finding raises questions regarding mechanisms of chain transfer by non-
elongating modules in trans-AT PKS systems. If these ACPs are indeed primed with 
malonyl-CoA in vivo, two scenarios would be possible. First, KS0 would accept the polyketide 
chain from upstream ACPs and transfer those directly to the next module, a process of module 
skipping similar to that described in the biosynthesis of myxochromide.[55] The second 
possibility is that a type II thioesterase is responsible for unloading the misprimed malonyl 
group from the ACP;[56] yet no such enzyme was identified in the riz cluster. It is also 
possible, that these ACPs are not primed in vivo due to constraints imposed by the modular 
context which prevents their accessibility to the trans-ATs. Thus, the KS0 would channel the 
acyl intermediate to the next module via its downstream ACP. Future investigations are 
required to verify these hypotheses.  
Discussion  
Assignment of orphan biosynthetic pathways 
At present, the identification and correlation of SMs from so far unassigned biosynthetic gene 
clusters represent a significant bottleneck that constrains the exploitation of the genetically 
encrypted bacterial secondary metabolome. Different approaches based on detailed sequence 
information have been developed in order to resolve this problem. The identification of a SM 
by feeding of 15N labelled amino acid building blocks to a culture coupled to 
1H-15N HMBC NMR guided fractionation requires only the prediction of the pathway of 
interest´s A domain specificities, which can be easily extracted from the sequence 
information.[57] However, the restriction to NRPS containing pathways and the drawbacks of 
1H-15N HMBC NMR guided fractionation (compound must be produced in relatively high 
amounts) along with the fact that different pathways present in the strain might incorporate 
the same aa building block, are serious drawbacks of this approach. The proteomics based 
identification of active biosynthetic machineries is helpful to predict the actual presence of the 
unknown secondary metabolite under the given cultivation conditions,[58] but the tedious 
workflow and a lack of sensitivity are major hindrances of this approach. The generation of a 
strain´s in-depth metabolic profile based on HPLC-HRMS data combined with a compound 
identification algorithm allows for statistics aided comparison with metabolic profiles of 
closely related strains. This comprehensive secondary metabolomic approach proved to be a 
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very powerful tool for the identification of nonubiquitous SM candidate compounds.[23;59] 
Further, this approach can also be used to compare the metabolic profile of a wild type strain 
to that of a mutant carrying an inactivation of an unknown biosynthetic gene cluster to 
identify the correlated SM. In this study it was instrumental for the identification of 
rhizopodin (at very low production levels) and the correlation to its biosynthetic gene cluster 
in S. aurantiaca Sg a15. The biggest drawback of this approach is that it requires the 
feasibility of genetic manipulation of the strain of interest. 
Phylogenetic analysis of the rhizopodin cluster 
Rhizopodin joins the family of SMs that are built up by trans-AT PKS systems, which 
currently contains 23 members since the first discovery of such a system from Bacillus 
subtilis in 1993.[60] The trans-AT biosyntheses have recently been reviewed by Piel .[61] 
Trans-AT PKSs show a high degree of divergence from textbook colinearity rules established 
for cis-AT systems. Modular architectures with missing or superfluous domains or unusual 
domain orders are common in trans-AT PKSs, thus making correlation of PKS function to 
product structure a challenge.[51;62;63] Recently, an innovative approach based on phylogenetic 
clustering of KS sequences in relationship to their substrate specificity was developed and 
allowed prediction of core structures from trans-AT systems with a significantly improved 
reliability.[49;64] For further validation of the proposed biosynthetic model for rhizopodin, we 
performed a phylogenetic analysis of the19 KS-domains in the riz gene cluster with a large 
subset of KS sequences used in the initial publication.[64] The grouping of the rhizopodin KS 
domains in the respective clades of the resulting tree (Figure S2) has been evaluated and 
deduced substrate predictions have been checked for conformity with the above presented 
biosynthetic model. Indeed, except for KS1, KS2 and KS5, predicted substrate specificities of 
the remaining KSs matched in general the ones postulated in the model. For example, the 
non-extending KS12 subclusters within clade X with KS10 from the chivosazol, KS1 from 
the leinamycin and KS9 from the disorazol biosynthetic gene clusters, all of which are 
non-elongating and accept β-oxazole or β-thiazole intermediates. Similarly, non-extending 
KS3, KS7, KS14 and KS18 that channel β-hydroxylated acyl chains to downstream domains, 
form a subclade within  clade X. Four riz KSs (KS4, KS8, KS15 and KS19) form a new 
subclade within clade I (Figure 4), reflecting their specificity for β-methoxylated 
intermediates which are not found in any other trans-AT biosynthetic machineries so far. 
B. Publications – Chapter 7 
 
74 
 
Figure 4. Resolved tree of Bayesian cladogram of 116 full length KS domains from trans-AT PKSs (for 
the complete cladogram see Figure S2) showing clade I which accepts α-branched or β-methylene and 
β-branched substrates.[64] Riz KS4, Riz KS8, Riz KS15 and Riz KS19 (highlighted in gray) which all 
accept β-methoxylated substrates form a subclade within clade I. Abbreviations for members of this 
clade: Bae, bacillaene; BT, thailandamide; Chi, chivosazol; Dif, difficidin; Dsz, disorazol; Lnm, 
leinamycin; Mmp, mupirocin; Onn, onnamide; Ped, pederin; Riz, rhizopodin; TA, myxovirescin. 
Besides phylogenetic analysis of KS domains, prediction of product stereochemistry by each 
KR domain according to the conserved motifs[32;65;66] is in full agreement with the actual 
rhizopodin structure (Figure S3), lending further weight to our proposed biosynthetic model.  
Introduction of methoxy groups 
 The biosynthetic logic for the synthesis of methoxy groups in rhizopodin is special among 
trans-AT systems. 11 core structures (myxovirescin, pederin, onnamide, bryostatin, disorazol, 
rhizoxin, chivosazol, oxazolomycin, etnangien, kirromycin and thailandamide) out of the 23 
reported metabolites produced by trans-AT PKS systems, incorporate between one and three 
methoxy groups. For all of these SMs, except for etnangien and thailandamide, the methoxy 
groups are introduced into the molecules by free-standing O-MTs in post-assembly line 
tailoring reactions. According to our analysis rhizopodin biosynthesis deviates from this logic 
by the employment of non-extending modules of KS0-(O-MT)-ACP architecture, which are 
solely dedicated to methylation of the β-hydroxyl group. A similar organization is found in 
module 12 of the etnangien assembly line (KS-(O-MT)-ACP). Although the KS domain in 
this module retains the conserved residues required for activity, no elongation step would be 
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expected.[51] In thailandamide biosynthesis TaiN ((C-MT)-ACP-KS0-(O-MT)-ACP-TE) 
exhibits a module of identical architecture. However, the O-MT is speculated to attack, 
instead of a β-hydroxyl group, a β-keto-function to form an enol ether which will be 
subsequently reduced.[61]. Interestingly, the KS0 in this module (BT KS16) clusters with Riz 
KS3, KS7, KS14 and KS18 (Figure S2). The putative benefit of using embedded O-MTs in 
rhizopodin biosynthesis is that the final product is uniformly methylated at all eight relevant 
positions. This would avoid production of partially desmethylated derivatives which is 
observed for many SM with methoxy groups that are introduced by freestanding MTs. Indeed, 
no partially desmethylated rhizopodin derivatives have been observed in the extract of Sg a15.  
Phylogenetic and sequence analysis of tandem HC-domains 
Interestingly, in every reported case where SMs are build up by trans-AT PKS/NRPS hybrid 
systems and contain oxazoline/oxazole or thiazoline/thiazole rings the heterocycles are 
introduced by tandem HC domains (with oxazolomycin as outstanding exception employing 
no HC domain at all). Examples include leinamycin,[67] disorazol,[43] rhizoxin,[68] 
chivosazol,[69] and virginamycin.[70] In NRPS or cis-AT PKS-NRPS systems a single HC 
domain is involved in heterocyclization of a serine or cysteine residue tethered on a PCP such 
as in  tubulysin,[71] epothilone,[72] and ajudazol biosynthesis.[73] However, two rare incidences 
of tandem HC-domains exist for biosynthesis of the siderophores vibriobactin[74] and 
anguibactin.[75] Biochemical characterization of VibF in vitro revealed that HC2 is responsible 
for the condensation reaction, whereas HC1 catalyzes the heterocycle formation.[76] In order 
to predict functions of both HC domains in the rhizopodin assembly line, phylogenetic 
analysis of several HCs domains (tandem and single) were conducted (Figure 5). 
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Figure 5. Bayesian cladogram of tandem HC domains from trans-AT PKS-NPRSs, single HC domains 
from cis-PKS-NRPSs, and tandem HC domains found in nonlinear siderophore NRPSs. For tandem HC 
domains the N-terminal HC domain is labeled HC1 and the following domain is abbreviated as HC2. 
Abbreviations for members of this tree: Aju, ajudazol; Ang, anguibactin; Chi, chivosazol; Dkx, 
DKxanthene; Dsz, disorazol; Epo, epothilone; Lnm, leinamycin; Mta, myxothiazol; Rhi, rhizoxin; Riz, 
rhizopodin; Tub, tubulysin; Tug, thuggacin; Vib, vibriobactin; Vir, virginiamycin. 
This analysis shows clearly that HC1s and HC2s are grouped separately, indicating that 
tandem HCs in trans-AT systems function in a similar manner as in VibF. Intensive sequence 
analysis of both groups of HCs was performed aiming to identify possible conserved residues 
that could explain their disctinct functions (condensation or heterocyclization). This revealed 
certain sequence differences between the members of the HC1s and HC2s (for additional 
discussion and alignments see Figure S4). Interestingly, the tandem-HCs from the trans-AT 
systems cluster tighter with the “single”-HCs than with the tandem-HCs from vibriobactin 
and anguibactin. Due to the observed phylogenetic distance between the trans-AT tandem 
HCs and the tandem HCs from vibriobactin and anguibactin biosynthesis it seems likely that 
they resulted from convergent evolution. 
TE-mediated dimerization 
Dimeric (or even trimeric) products are very rare among bacterial secondary metabolites, 
including gramicidin S, enterobactin, thiocoraline (NRPS),[77] disorazol (NRPS-PKS-hybrid), 
the marinomycins and vermiculine (PKS; biosyntheses not yet elucidated).[78;79] TE-mediated 
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formation of the dimeric final product has been demonstrated in vitro for gramicidin,[80] 
enterobactin,[81] and thiocoraline.[82] In analogy to these biosyntheses, the following model 
can be proposed for rhizopodin; The first monomer is transferred to the TE active site serine 
followed by nucleophilic attack of this acyl-O-TE intermediate by the hydroxyl group at C-18 
of the second monomer which is tethered to the upstream ACP, yielding a linear dimeric 
intermediate. The linear dimer would then be transferred to the TE active site, where 
intramolecular cyclization and product release by formation of a dilactone are catalyzed. 
Studies on TEs involved in the biosyntheses of gramicidin S and enterobactin showed that 
there are no obvious sequence differences accounting for their divergent catalytic capabilities. 
However, it was observed that the linker region between the ACP and the TE was longer than 
usual in the case of GrsB (41 aa compared to ~15-20 aa).[80] A related long linker is conserved 
in the rhizopodin and disorazol assembly line (36 aa in RizE/~60 aa in DszC). Furthermore, in 
both cases a non-elongating KS0 domain is found upstream of the terminal ACP which may 
also play a role in the process of dilactone formation. A panel of disorazol derivatives 
differing in the size of dilactone macrocycles have been identified, indicating that the DszTE 
exhibits relaxed substrate specificity for dimerization (Buntin, K. and R.M., unpublished 
results).[83] In the case of rhizopodin biosynthesis, no derivatives of varying macrocycle size 
have been identified to date. However, in-depth HPLC-MS analysis of extracts from the more 
prolific  rhizopodin producer Myxococcus stipitatus Mx s11 (approximately 100-fold higher 
production compared to Sg a15) revealed the presence of a second peak at a different 
retention time (7.57 min) of identical mass as rhizopodin (7.70 min), which is upon thorough 
inspection also seen in the chromatograms from Sg a15 (Figure 1; for chromatogram of 
Mx s11 see Figure S5A). Both compounds show the characteristic +1 and +2 charge states, 
which led us to the assumption that the earlier eluting compound might correspond to a 
rhizopodin isomer with lactone bonds between the carboxylic groups at C-1 and C-1' and the 
hydroxyl groups at C-16 and C-16’ instead of those at C-18 and C-18', resulting in a 34- 
instead of a 38-membered dilactone (Figure S5B). The minute amount of this compound 
prevented further isolation and structural characterization. Neither was it possible to confirm 
the size of the macrocycle by MS/MS fragmentation experiments. The high degree of 
methylation on hydroxyl groups in rhizopodin may have emerged in order to constrain the 
formation of more isomers differing in size of the macrocycle, a feature obviously crucial for 
biological activity. 
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Conclusion 
The identification of S. aurantiaca Sg a15 as producer of rhizopodin by means of genome 
mining in combination with sophisticated analytical and statistical methods and the 
subsequent elucidation of its biosynthetic gene cluster demonstrate the power of this approach 
to assign orphan biosynthetic pathways to their respective SMs. We have recently used an 
analogous approach to identify three novel secondary metabolite classes from M. xanthus.[84] 
This also holds true for very low abundant SMs that might escape visual inspection of the 
data, as shown for this example. 
The rhizopodin assembly line includes several special features, such as an unusual 
biosynthetic logic for the introduction of methoxy groups and the presence of members of a 
new KS phylogenetic subclade, both not reported to date from other trans-AT PKSs. The 
provided data will help to expand the knowledge about trans-AT PKSs which is still far less 
comprehensive than that compiled for cis-AT systems over many years. 
Experimental Section 
Bacterial strains and culture conditions 
 Escherischia coli strains for plasmid preparations were grown in LB at 37 °C. Stigmatella 
aurantiaca Sg a15 and its descendants were cultured in Tryptone-Starch (TS) medium (1% 
tryptone, 1.19% HEPES, 0.4% soluble starch, 0.2% MgSO4·7H2O; pH adjusted to 7.2) at 30 
°C on an orbital shaker. Kanamycin sulfate 50 µg·mL-1 was added for selection whenever 
necessary.  
Sequence analysis 
The DNA sequence of Sg a15 was screened for PKS and NRPS coding sequence using a 
complete genome scanning pipeline provided by Jacques Ravel (available at: 
http://nrps.igs.umaryland.edu/nrps/2metdb/Genome_scanning_download.html). 
DNA preparations and PCR 
S. aurantiaca Sg a15 genomic DNA was prepared with the Puregene® Genomic DNA 
Purification Kit (Gentra) according to the manufacturer´s protocol. Plasmid DNA was either 
purified by standard alkaline lysis or by using the NucleoSpin Plasmid Kit (Macherey-Nagel). 
B. Publications – Chapter 7 
 
   79 
For inactivation constructs ~750 bp internal fragments of the target genes were amplified 
using Taq polymerase (Fermentas) and a set of specific forward and reverse primers. The 
respective forward primer contained a base pair insertion that caused a frame-shift. The PCR 
reactions contained 5% dimethylsulfoxid and were carried out in a peqSTAR 96 Universal 
Gradient (Peqlab) thermocycler. Conditions for PCR reactions: initial denaturation step for 2 
min 95 °C, 40 cycles consisting of denaturation at 95 °C  for 18 s, annealing at 68 °C for 14 s, 
elongation at  72 °C for 14 s with  terminal  a final elongation step at 72 °C for 5 min. The 
PCR products were cloned into pCR2.1-TOPO (Invitrogen) and sequenced. Primers were 
rizB_KS1ko_for (5´-GCGGATCTCTCCTTGAAGTGGT-3´), 
rizB_KS1ko_rev (5´-TCATCTGCAACAGCACCCTC-3´), 
rizB_KS7ko_for (5´-GCTTCATCGACTGACGTGGAT-3´), rizB_KS7ko_rev 5´-GGAATGACACCC
TGGCGCAT-3´), rizA_ko_for (5´-GTTCTCAGCATGTGGAGGATG-3´), rizA_ko_rev (5´-GCTGCTG
CAGCAAGTATTGGA-3´), rizF_ko_for (5´-CGAGCTGTTTCGACGAGTTTC-3´), rizF_ko_rev (5´-G
ATGAGGGGCGTCAGGAATTT-3´), riz_orf5_ko_for (5´-CCTTGTGACTCACAACTCAAGGA-3´) 
and riz_orf5_ko_rev (5´-CGAGGATCTCTATCGCCAGAAC-3´). The resulting plasmids were 
introduced into S. aurantiaca Sg a15 by electroporation as described previously.[22] The 
integration of the plasmids in the respective mutants was verified by PCR control (for details 
see Figure S6). Primers riz_connect_for (5´-CTCACGTGCCGCCTGTTATCT-3´) and 
riz_connect_rev (5´-CGCGGATCTGGACCTCTTCT-3´) were used to provide a PCR fragment 
which was cloned into pCR2.1-TOPO and sequenced in order to close the gap in continuous 
sequence.  
Analysis of SMs 
For secondary metabolite production strain Sg a15 and its descendants were cultivated in 
shake flasks in TS-medium in presence of amberlite XAD-16 (1%; Sigma-Aldrich) for 7 days. 
Cells and XAD were separated from the culture broth by centrifugation, extracted with 
methanol and the extracts were concentrated in vacuo. To compare the SM profile of the 
mutants with that of the wild-type strain, the extracts were analyzed on a Dionex Ultimate 
3000 RS LC connected to a Thermo Fisher Orbitrap XL operated in positive ionization mode 
with R = 30000. The HPLC-system was coupled to the Orbitrap by a Triversa Nanomate from 
Advion, a chip-based nano-ESI interface. Chromatographic conditions: A Waters BEH C18 
column (50 x 2 mm, 1.7 µm dp, flow 600 µL · min-1) was used for separation with a mobile 
phase made up of water/acetonitrile (both solvents containing 0.1 % formic acid) with a 
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gradient from 5 - 95% acetonitrile in 9 min, total runtime 14 min. Since no obvious 
differences between the SM profiles of mutant versus wild-type were observed, cultures of the 
KS inactivation mutants and the wild-type were prepared in quintuplicate and extracted and 
analyzed as described above. 
Statistics facilitated data analysis 
Briefly, the obtained data were used to calculate a MS-PCA model using the ProfileAnalysis 
software (version 2.0, Bruker Daltonic GmbH) as described by Cortina et. al.[84] Bucket 
generation was performed for the retention time range from 2 to 11 min and for mass ranges 
of 200 - 1000 and 1000 – 2000 m/z employing an advanced compound-based bucketing 
approach allowing for deviations of ∆m/z = 30 ppm and ∆RT = 30 s. Parameters for 
compound detection were a signal-to-noise (S/N) ratio of 5, a minimum compound length of 
10 spectra and a smoothing width of 2. In the loadings plot of the resulting MS-PCA model 
data points (representing buckets) which were located far away from the central cloud were 
picked and the respective masses were checked.  
Feeding experiments 
Feeding experiments with L-serine-13C3,15N (Sigma-Aldrich) and 
L-methionine-(S-methyl-13C)(Cambridge Isotope Laboratories) were performed in TS 
medium with reduced culture volumes (20 mL) in the presence of XAD adsober resin (1%). 
Starting on the third day of cultivation, 10 mg of L-serine-13C3,15N were fed in three fractions 
(every 24 hours) to the culture, which was harvested and extracted after five days. For 
L-methionine-(S-methyl-13C), 20 mg were fed following the same schedule. 
Construction of expression constructs and protein expression 
RizA was amplified from genomic DNA by using Phusion DNA polymerase (Finnzymes) 
with primer rizA_for_NdeI (5´-TTGACATATGCGGATCCAGATTTTTCC-3`) and rizA_rev_EcoRI 
(5´-TTGAGAATTCTCATGACGCCCCCTTCCGCC-3´). Restriction sites are underlined. The 
resulting PCR product was purified, digested with NdeI and EcoRI, and ligated into likewise 
digested pET28b(+) resulting in pET28b(+)-rizA, designed for expression of the heterologous 
protein with a N-terminal hexahistidine tag. The ligation was electroporated into E. coli 
DH10B and positive clones were selected on LB agar plates containing 50 µg mL-1 
kanamycin. The identity of the plasmids was confirmed by restriction analysis and 
sequencing. Constructs pET28b(+)-rizF, pET28b(+)-ACP12, pET28b(+)-ACP13, 
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pET28b(+)-ACP17, and pET28b(+)-ACP18 were prepared analogous with primers 
rizF_for_NdeI (5´-TTGACATATGACGAAGATCTTCGTATTT-3´), rizF_rev_EcoRI (5´-TTGAGAA
TTCCTACACGCCCGCAGTCCGTTT-3´), ACP12_for_NdeI 
(5´-TTGACATATGCGCCCTGCGGCGACCGACCT-3´), ACP12_rev_EcoRI 
(5´-TTGAGAATTCTCAGTGCCTTTCGCTCAGGTACT-3´), ACP13_for_NdeI 
(5´-TTGACATATGGCGCAGGATGCGCTCCAGGA-3´), ACP13_rev_EcoRI (5´-TTGAGAATTCTCA
CTGGCGCGAGGCGAGATGGC-3´), ACP17_for_NdeI (5´-TTGACATATGCGAGAGGCGCTGAACTC
CCG-3´), ACP17_rev_EcoRI (5´-TTGAGAATTCTCAGTGGTGCTTGAAGAGGTAGT-3´), 
ACP18_for_NdeI (5´-TTGACATATGACTGCTTCGTCGGCGGATAT-3´), ACP18_rev_EcoRI (5-TT
GAGAATTCTCATTCCGCCGCACCGAGGTGG-3´). For production of N-terminal His-tagged 
fusion proteins, E. coli BL21(DE3) harbouring the respective expression plasmid was grown 
at 37 °C in 250 mL LB medium containing 50 µg · mL-1 kanamycin to an OD600 of 
approximately 0.8 units. In order to obtain the heterologous ACP proteins as holo-ACPs they 
were expressed in the presence of pSUMtaA.[85] For protein expression the culture was 
induced with 0.2 mM isopropyl β-D-thiogalactopyranoside (IPTG) and incubated at 16 °C for 
16 h. The cells were harvested by centrifugation at 7300 · g for 12 min at 4 °C in a Beckman 
Coulter Avanti J-E centrifuge. All following steps were carried out at 4 °C. The cell pellet 
was resuspended in 25 mL binding buffer (50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 
20 mM imidazole, glycerol 10 % (v/v)) and lysed with a French press. Cell debris was 
removed by centrifugation at 25000 · g for 45 min. The supernatant was filtered through 
1.2 µm Acrodisc syringe filters (PALL Life Sciences) before being loaded onto a 1 mL 
Hi-Trap His column using the Äkta purifier system (both from GE Healthcare) at a flowrate 
of 1 mL · min-1. The unbound sample was washed away with 5 column volumes binding 
buffer. For elution of the His-tagged heterologous proteins a stepwise gradient with 7%, 16%, 
40% and 100% elution buffer (50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 500 mM imidazole, 
glycerol 10% (v/v)) with 6 column volumes for each step was applied. The fractions 
containing heterologous protein were buffer exchanged to 50 mM Tris-HCl, pH 8.0, 150 mM 
NaCl, glycerol 10% (v/v) using PD10 columns (Amersham Biosciences) and further 
concentrated using Amicon ultracentrifugal filter devices. Concentrated protein solutions 
were frozen in liquid nitrogen and stored at -80 °C. Protein concentrations were determined 
with Bio-Rad protein assay kit according to the manufacturer’s instructions using bovine 
serum albumin (BSA) as a standard (0.5 – 8 µg · mL-1). Protein fractions were separated on a 
15 % sodium dodecyl sulfate (SDS)-polyacrylamide gel by electrophoresis. Proteins were 
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visualized in the gel by staining with Coomassie Brilliant Blue R-250 (for protein 
preparations used see Figure S6). For matrix assisted laser desorption ionisation time of flight 
mass spectrometry (MALDI-ToF-MS) protein bands were cut from the SDS-polyacrylamide 
gel and in gel digestion with trypsin was performed. Samples were prepared using Zip-Tips 
(Milipore). 
ACP loading assays 
Holo-ACPs from different modules of the rhizopodin assembly line were incubated with 
recombinant RizA or RizF protein in order to investigate malonyl priming activities. 
Incubations contained 50 mM Tris-HCl pH 8.0, 1 mM malonyl-CoA, 20 µM holo-ACP and 
0.2 µM trans-AT (either RizA or RizF). Reactions were incubated for 30 min at 30 °C and 
then analyzed by HPLC-MS on a Jupiter 5 micron  C4 300A column (50 x 1.0 mm; 
Phenomenex) with a water/acetonitrile (both solvents containing 0.1% formic acid) gradient 
(5 to 50% organic fraction over 20 min), coupled to a HCT-Ultra (Bruker Daltonics) mass 
spectrometer operating in positive ionization mode. Average MS-spectra were computated 
and deconvoluted using DataAnalysis software (Bruker Daltonics). 
Sequence analysis 
Prediction of open reading frames was performed with FramePlot 4.0 
(http://nocardia.nih.go.jp/fp4/) and the resulting hits were analyzed by tblastx search.[86] 
Annotation of the rhizopodin biosynthetic gene cluster and sequence alignments were carried 
out using Geneious Pro 5.3.4.[87] Computation of phylogenetic trees was performed by 
Bayesian estimation with the program MrBayes.[88] Settings used: rate matrix: wag; rate 
variation: gamma; gamma categories: 4; Markov chain Monte Carlo (MCMC) chain length: 
1.000.000 generations; heated chains: 4; subsampling frequency: 500 generations. 
Accession number  
The nucleotide sequence reported here is accessible at the EMBL Nucleotide Sequence 
Database under accession number FR854394. 
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Supporting information 
Table S1. Alignment of conserved residues (active-site residues underlined) which correlate with 
domain specificity of RizA and RizF with those of the malonate specific trans-ATs ChiA, DszD and 
LnmG [a] 
Protein 11 63 90 91 92 93 94 11
7 
20
0 
20
1 
23
1 
25
0 
25
5 
15 58 59 60 61 62 70 72 
19
7 
19
8 
19
9 
ChiA Q Q G H S L G R F H N Q V R Q T Q Y T A S S G A 
DszD Q Q G H S L G R F H N Q V A Q T Q F T A S S A A 
LnmG Q Q G H S L G R F H S Q V R R T E Y A A S S A A 
RizA Q Q G H S L G R F H N Q V H Q T A W T A A S A A 
RizF Q Q G H S L G R F H N Q V K R T E F T A A S A A 
[a] Residue numbering according to Yadav et al. [1] from where the consensus active-site residues for malonate specific AT domains were distilled. 
 
 
Figure S1. HPLC-MS data of rhizopodin from an extract of Sg a 15. A) HPLC-MS chromatogram of an 
extract of Sg a15 wild type. Shown in black is the base peak chromatogram (BPC) in positive mode 
from 200-2000 m/z. Shown in red is the combined extracted ion chromatogram (EIC) of 735.44 and 
1469.88 m/z (masses of doubly and singly charged rhizopodin). The low abundant rhizopodin signal is 
marked by an arrow. B) MS-spectrum of retention time 7.70 min, showing the intensities of myxalamide 
B signals in comparison to that of rhizopodin (marked by a red box). 
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Figure S2. Bayesian cladogram of 116 KS sequences composing from selected members of previously 
described substrate specific clades and the sequences of the 19 KS domains from the rhizopodin 
biosynthetic gene cluster (marked in red). Ery KS4 from the canonical erythromycin PKS was used as 
outgroup. The numbers of the KS domains indicates their position within the respective gene cluster. 
The subsequent roman numbers indicate their membership to a certain substrate specific clade. 
Substrate specificities of the respective clades: I : α-branched + either β-OH or β-methylene and 
β-branched; II : β-OH; III : KS0s, mixed substrates; IV : β-OH (D-configuration); V : ethylene; VI : 
acetyl starter units; VII : double bond + α-methyl; VIII : β-OH (D-configuration); IX : double bond or 
heterocycle; X : KS0s, mixed substrates; XI : double bond; XII : double bond; XIII : vinyl or propy; XIV 
: β-OH, nonelongating KS in dehydrating module; XV : double bond generated by module lacking a 
DH; XVI : glycine. Abbreviations used for KS domains from biosynthetic gene clusters: Bae, 
bacillaene; BT, thailandamide; Chi, chivosazol; Dif, difficidin; Dsz, disorazol; GU, uncharacterized 
PKS from Geobacter uraniumreducens; Kkc, lankacidin; Lnm, leinamycin; Mln, macrolactin; Mmp, 
mupirocin; Onn, onnamide; Ped, pederin; Riz, rhizopodin; Ta, myxovirescin. 
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KR domain Conserved 
LDD 
Corresponding 
position in 
rhizopodin 
Predicted 
stereochemistry 
Observed 
stereochemistry 
KR1 (+DH1) IRD 28 and 28´ 
B-type 
 reduction to 
 E-double bond 
 
E-double bond 
KR2 LRD 26 and 26´ 
B-type 
C2 > C4  R R 
KR5 
(+DH5+ER5) 
LRD 22 and 22´ 
B-type 
 complete reduction - 
KR6 VRD 20 and 20´ 
B-type 
C4 > C2  S S 
KR8 IRI 18 and 18´ 
A-type 
C2 > C4  S S 
KR9 LRD 16 and 16´ 
B-type 
C4 > C2  S S 
KR13 LRD 11 and 11´ 
B-type 
C4 > C2  S S 
KR16 LRD 
9 and 9´ 
 
 
7 and 7´ 
B-type 
 reduction to  
E-double bond 
 
B-type 
 reduction to  
E-double bond 
 
E-double bond 
 
 
 
E-double bond 
KR17 AAQ 5 and 5´ 
A-type 
C4 > C2  R R 
KR19 IDS 3 and 3´ 
A-type 
C2 > C4  S S 
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Figure S3. Prediction of stereospecificities of reduction in rhizopodin biosynthesis.  
Previous work on correlation of observed stereospecificity of ketoreduction with conserved sequence 
motifs revealed a highly predictive residue.[2;3] The presence of a conserved Asp residue within a LDD 
motif correlates with B-type ketoreduction (3R, when C2 > C4; 3S when C4 > C2) whereas its absence 
correlates with A-type ketoreduction (3S, when C2 > C4; 3R when C4 > C2). Further predictive 
residues, W141 for A-type ketoreduction and P144 and N148 for B-type ketoreduction,[3] are not 
conserved in the ketoreductase sequences of the rhizopodin biosynthtetic gene cluster. 
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Figure S4.Alignment of HC1 and HC2 domains from tandem HC domains from trans-AT PKS-NRPSs, 
anguibactin and vibriobactin biosynthesis and the “single” HC domain from myxothiazol. 
Abbreviations: Ang, anguibactin; Chi, chivosazol; Dsz, disorazol; Lnm, leinamycin; Mta, myxothiazol; 
Rhi, rhizoxin; Riz, rhizopodin; Vib, vibriobactin; Vir, virginamycin. 
Sequence Analysis of HC domains in order to assign condensation and cyclization 
half-reactions 
The Cy5-motif is much better conserved for the HC2s than for the HC1s, whereas the 
opposite holds true for the Cy6-motif. Since there are no crystallographic data on 
HC-domains present we were in our investigations limited to structural data of C-domains[4-6] 
and data on point mutation experiments performed on HC-domains. Directed amino acid 
exchanges of the second aspartate in the DXXXXDXXS C3-motif of VibF HC1 and HC2 
have shown that this residue is crucial for domain functionality for either condensation or 
cyclization activity.[7] Both the HC1- and the HC2-domains show a strict conservation of this 
aspartate residue. By site-directed mutagenesis experiments of specific residues in the 
HC-domain of the bimodular model system BacA1-2-TE (A-PCP-HC-A-PCP-TE) it has been 
possible to identify single residues that are absolutely necessary for the condensation or the 
cyclization half-reactions.[8] The consensus threonine or serine residue at the start of the 
Cy4-motif and a conserved arginine residue between the Cy4- and the Cy5-motif seem to be 
essential for the condensation since the respective alanine mutants produced neither linear nor 
cyclic products. The HC1s show a conserved serine at this postion whereas in the HC2s there 
is no good conservation. Both HC1s and HC2s show a strict conservation of the just 
mentioned arginine residue. In the same study it has been shown that a conserved asparagine 
residue between Cy4 and Cy5 as well as a conserved serine residue within the Cy6-motif are 
essential for cyclization since the respective alanine mutants produce only linear but no cyclic 
products. The respective asparagine residue is conserved neither in the HC1s nor in the HC2s 
but the HC1s show a strictly conserved FTS motif whereas the HC2s show a FTX motif. 
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Figure S5. Postulated rhizopodin isomer. A) Combined EIC of 735.44 and 1469.88 m/z of an extract of 
Myxococcus stipitatus Mx s11. The chromatogram reveals two peaks with slight differences in retention 
time. B) Chemical structures of rhizopodin (38-membered dilactone) and the postulated isomer with a 
34-membered dilactone macrocycle. 
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Figure S6. SDS-PAGE of heterologously expressed and purified proteins used for in vitro ACP loading 
assays. RizA, calc. size: 33.2 kDa; RizF, calc. size: 34.5 kDa; holo-RizACP12, calc. size: 11.8 kDa; 
holo-RizACP13, calc. size: 11.4 kDa; holo-RizACP17, calc. size: 11.6 kDa, holo-RizACP18, calc. size: 
11.7 kDa. 
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C. Final discussion 
1. Tubulysin: new structures and new biosynthetic insights 
The tubulysins are a family of secondary metabolites produced by a number of myxobacterial  
strains  including Angiococcus disciformis An d48, Cystobacter sp. SBCb004, and 
Archangium gepyhra Ar315.[111;112] These natural products are characterized by the presence 
of a linear tetrapeptide core, consisting of N-methyl pipecolic acid (Mep), isoleucine (Ile), a 
novel amino acid named tubuvaline (Tuv), which is biosynthetically derived from an acetate 
bridged valine-cysteine building block, and a chain-extended analogue of either phenylalanine 
or tyrosine, termed tubuphenylalanine (Tup) or tubutyrosine (Tut), respectively. Further 
modifications by different O-acylations expand this tetrapeptide sequence to the naturally 
occuring tubulysins A-I.  
The tubulysins belong to a select group of natural products that are able to interact with 
the eukaryotic microtubule network.[27;33] Unlike the epothilones that induce tubulin 
polymerization, the tubulysins inhibit polymerization at concentration lower than 
50 pg mL-1.[32] Interestingly, tubulysins show 20 to 100-fold more potency in inhibiting the 
growth of cancer cells when compared to those of other tubulin modifiers such as epothilones, 
vinblastine, and taxol. Moreover tubulysins seem to be less affected by multiple drug 
resistance (MDR) effects, since they present poor substrates for the cellular transporters 
mainly conferring MDR.  Altogether these facts have stimulated significant research into the 
chemistry and biology of the tubulysins to exploit their potential for therapy of multi 
drug-resistant tumors. Structure-activity relationship (SAR) studies with tubulysin synthetic 
analogues have identified the essential structural features related to the cytotoxic activity, as 
well as suggesting strategies for optimizing the metabolite’s pharmacological 
properties.[113-118] These studies explored the acetoxy moiety at C5 of Tuv, the bis-acyl 
N,O-acetal substituent, the Mep heterocycle and the C-terminal Tup/Tut residue for their 
respective influence on bioactivity (results are sumarized in Figure C-1). 
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Figure C-1. Combined insights gained from several SAR studies on tubulysins presented for tubulysin 
D. The pretubulysin core structure is indicated by bold bonds. 
These results show that the N-terminal tertiary amine within the piperidine heterocycle is very 
important for activity. However, the piperidine heterocycle is not essential for activity and can 
be simplified. R-configuration of the alkyl substituent at the Mep α-carbon it is also important 
for activity. Only a moderate loss of activity was observed upon omission of the chemically 
labile O-acyl N,O-acetal group or its replacement with stable alternatives. The same holds 
true for omission of the Tuv C5-acetoxy group. On the other hand a change in the 
stereochemistry at the Tuv C5 position decreases activity. Both the benzyl and the 
2-methylpropionyl moiety can be deleted without detriment on activity, as long as they are 
not deleted simultaneously. The recent elucidation of the tubulin-bound structure of tubulysin 
A allowed for rationalization of these SAR data.[119] In the tubulin-bound state, the thiazole 
nitrogen atom and the phenyl ring form a basal platform at the bottom of the molecule upon 
which the O-acyl N,O-acetal side chain of Tuv packs to form a hydrophobic core. In this 
conformation the alkyl backbone of the Mep piperidine ring, the benzyl and 
2-methylpropionyl moieties of Tut and the O-acyl N,O-acetal group, which all have been 
shown to be not essential for activity, are all situated on the same side of the molecule. The 
hydrophobic core composed of the thiazole ring, the valine side chain of Tuv and the Ile side 
chain, seems to be essential, as indicated by the relevance of the stereochemistry at the Tuv 
C5 atom. The hydrophilic tail of the Mep residue which is situated on the opposite side of this 
T-shaped core is likely to form a hydrogen bond with side chains of tubulin. Therein it was 
also shown that simplification of the N-terminal Mep in combination with loss of both the 
acetoxy and the O-acyl N,O-acetal substituent and the loss of Tup C2-methyl resulted in a 
drastic decrease of activity, suggesting the importance of these functionalities in the absence 
of the acetoxy and the N,O-acetal substituents. In addition the importance of the thiazole 
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heterocycle for activity has been demonstrated as substitutions against phenyl and phenoxy 
moieties dramatically decreased activity.[120] 
In light of these SAR results the previously postulated first enzyme free tubulysin 
intermediate,[121] termed pretubulysin, should be investigated for its cytotoxic activity. 
Pretubulysin presents the polyketide-nonribosomal peptide core minus the four post-assembly 
line oxidative and acylation modifications (structure highlighted by bold bonds in 
Figure C-1). These modifications are most likely introduced by the action of freestanding 
enzymes, since no corresponding functionalities have been identified in the tubulysin 
megasynthetases. Pretubulysin was prepared synthetically and the availability of this 
reference material allowed for the reliable identification of low levels of pretubulysin in 
culture extracts of A. disciformis An d48 by comparison of retention time and MS/MS 
fragmentation patterns upon HPLC-HRMS analyses, supporting its intermediacy in the 
pathway. The compound was tested on HL-60 cells to compare its cytotoxicity to that of a 
Tup C2-desmethyl pretubulysin variant, as well as to tubulysins A and D (Table C-1). 
Tubulysin D is known to be the more toxic than tubulysin A, with an approximately 6-fold 
higher potency.[32] As predicted from the earlier SAR studies, pretubulysin retained good 
cytotoxic activity in comparison to those of tubulysins A and D (3- and 5-fold lower 
cytotoxicity, respectively), while removal of the Tup C2-methyl group led to a 13-fold 
relative reduction in cytotoxicity. Based on these results, the cytotoxic activity of tubulysins 
A and D, and pretubulysin and Tup C2-desmethyl pretubulysin was evaluated against two 
more cell lines, L929 (mouse connective tissue fibroblast) and U937 (human histiocytic 
lymphoma).  
Table C-1. Cytotoxicity of tubulysins and analogues evaluated by MTT assay.   
IC50 (ng mL-1) 
Cell line Tubulysin A Tubulysin D Pretubulysin 
Tup C2-desmethyl 
Pretubulysin 
HL-60 0.01 0.006 0.03 0.39 
L929 0.19 0.015 6.5 74 
U937 0.003 0.0004 0.08 0.41 
 
Both pretubulysin and Tup C2-desmethyl pretubulysin exhibited activity against both cell 
lines, albeit reduced relative to tubulysin A, with pretubulysin being reproducibly the more 
potent. These results reveal several important SAR results, in addition to previously reported 
data. Notably, the good potency of pretubulysin confirms that neither the N,O-acetal nor the 
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acetoxy functionality of Tuv are necessary for cytotoxicity, although there is a modest 
reduction in activity (ca. 10-fold) relative to a previously characterized analogue which beared 
the acetoxy group. Comparison of the data obtained on pretubulysin and its Tup 
C2-desmethyl analogue reveals that the methyl group in Tup also provides an approximately 
10-fold enhancement in biological activity. In conclusion, it was demonstrated that the 
complex structure of the tubulysins can be significantly simplified without a dramatic drop in 
the biological activity. Pretubulysin, which was identified as a direct biosynthetic precursor of 
the tubulysins, is less reactive compared to tubulysin A and D, but retains sub-nanomolar 
activity. Due to the absence of both the acetoxy and the N,O-acetal substituents, pretubulysin 
is much easier accessible by chemical synthesis than the elaborate tubulysins. These findings 
should aid in future efforts to design simplified, yet highly potent analogues of the tubulysins 
for evaluation as anticancer agents. 
As the synthesis of novel tubulysin analogues still remains a laborious procedure, the 
known tubulysin producing myxobacterial strains A. disciformis An d48 and 
Cystobacter sp. SBCb004 were screened for new tubulysin derivatives. By analyzing 
HPLC-HRMS/MS fragmentation patterns, 23 novel tubulysins derivatives were identified 
revealing new aspects of the biosynthesis and supporting earlier proposals. The meanwhile 
achieved isolation of pretubulysin A and its structure elucidation by NMR delivered final 
proof for the previous structural postulations. The predicted structures of the novel tubulysin 
derivatives were established based on HRMS/MS data and show that several steps in the 
tubulysin biosynthetic pathway do not go to completion. The presence of pretubulysins, and 
compounds 12, 13, 19, 20 and 23, 24, 30, 31 (for numbering see Chapter 2) missing one or 
more of the oxidation and acylation reactions, demonstrates that the post-assembly line 
modifications are not perfectly efficient. This observation is consistent with the absence of 
genes coding for obvious tailoring functionalities (oxidases and perhaps an acyltransferase) 
within the biosynthetic gene clusters, arguing for a lack of co-evolution of this portion of the 
pathways. The N-methyltransferase domain of subunit TubC also operates only imperfectly, 
giving rise to the N-desmethyl compounds (14–18) and (25–29). Apparently, the lack of 
N-methylation of the Tuv building block somehow induces skipping of some, if not all, of the 
reductive steps carried out by the adjacent PKS module. However, these enzymatic activities 
seem to function occasionally, as the corresponding hydroxyl (15, 26) and methylene (16, 27) 
analogues are produced at low levels. Processing by post-assembly line enzymes at Tuv C5 
occurs to some extent, and seems to be more efficient when full reduction has taken place at 
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the adjacent C12 position. This mechanism is inconsistent, however, with the discovery 
N-hydroxymethyl 12-keto pretubulysins (21, 32), as the reductive steps have been bypassed 
even though the N-methyl group was added. One possible explanation is that, in a small 
number of cases, the N-methyl is hydroxylated while the intermediate is attached to the 
assembly line, and this modification also disrupts reductive processing by the PKS module. 
Finally, the truncated analogues (22, 33) appear to arise from failure of the final chain 
extension step with malonate, catalyzed by TubF. At this stage it is not clear whether 
premature release from the assembly line is spontaneous due to stalling of the intermediate at 
the TubE/TubF interface, or alternatively enzyme-catalyzed, for example by the TE domain, 
as demonstrated in pikromycin biosynthesis.[122] Unfortunately the yields of these novel 
tubulysin variants were too low to allow for their isolation and the determination of their 
respective cytotoxic activities. 
It is intriguing to consider if the apparent ‘failure’ of various enzymes in the tubulysin 
pathway is in fact favored by evolution to increase the diversity of structures generated by the 
strain, a proposal known as the ‘screening hypothesis’.[123] Indeed, the production of 
sometimes large families of metabolites which differ in modifications of their core structures 
appears to be a general feature of myxobacterial secondary metabolism, in which 
post-assembly line processing is not very abundant.[124] However, relevant information on the 
biological roles of the various tubulysins for the producing organisms is lacking so far. The 
fact that the PKS-NRPS can process a range of structurally divergent intermediates 
encourages the prospect to modify the assembly line by genetic engineering to produce 
further non-natural tubulysin variants. Similar observations have been made for the epothilone 
assembly line, from which multiple epothilone derivatives have been generated by directed 
modification.[125] In the meantime, the novel analogues can be targeted for total synthesis, in 
order to obtain sufficient material to extend the ongoing structure-activity studies of the 
tubulysin metabolites.  
The comparison of the tubulysin biosynthetic gene clusters in An d48 and SBCb004 
revealed the presence of two conserved open reading frames (ORFs), orf17 and orf18, 
downstream of the last PKS gene tubF. The ORFs further downstream did not show any 
correlation between the strains. Orf17 and orf18 both encode patatin-like proteins, which 
show high mutual sequence homology (in the range of 60% identity and 70% similarity) and 
suggest evolution by gene duplication. Patatin-like proteins are known to exhibit lipid acyl 
hydrolase activity,[126] a function not apparently required in the tubulysin pathway. However, 
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it is worth mentioning that genes encoding patatin-like proteins are also present in the 
DKxanthene gene clusters of the myxobacteria Myxococcus xanthus DK1622 and 
Stigmatella aurantiaca DW4/3-1,[127] as well as in the leupyrrin gene cluster of Sorangium 
cellulosum So ce690,[128] suggesting that these enzymes may play an unexpected role in 
natural product biosynthesis. The inactivation of orf18 in An d48 resulted in a mutant that 
almost abolished tubulysin D production but accumulated an unknown compound instead, 
that was not identified in the wild type. This compound was isolated and structure elucidation 
by 1D- and 2D-NMR experiments identified it as a glycerol ester derivative of tubulysin D. 
The thereby deduced assumption that the patatin-like proteins encoded downstream of tubF 
are responsible for cleavage of the ester bond between the C-terminal carboxy group of 
tubulysin D and glycerol was verified by heterologous expression and purification of the 
patatin-like proteins and in vitro incubation with tubulysin D glycerol ester. This procedure 
resulted in the release of tubulysin D. So far it remains unknown how the glycerol moiety is 
attached to the C-terminal carboxy group of tubulysin D in the first place. Due to the site of 
attachment it is conceivable that this reaction would be catalyzed by the thioesterase (TE) 
domain, which normally releases the product under hydrolysis or macrolacton/macrolactam 
formation from the assembly line. However, sequence analysis of the thioesterase domain 
located at the C-terminus of TubF did not reveal obvious differences in amino acid sequence 
when compared to TE domains from other assembly lines. The only noticeable feature was 
the fact that the tubulysin TE domain was slightly longer. Besides the so far incompletely 
resolved biosynthesis of the tubulysin D glycerol ester, also the biological function of this 
compound remains unknown up to date. Assumptions that the glycerol moiety might be 
further acylated with fatty acids and thereby serve for membrane associated storage of 
tubulysin D could not be confirmed experimentally. 
The fact that the producer strains dedicate special enzymes to the cleavage of a previously 
attached glycerol ester to yield tubulysins A and D, is astonishing since the same product 
could be obtained by hydrolytic release from the TE. The maintenance of this genetic 
organization suggests a so far not comprised biological function of the tubulysin glycerol 
esters.  
Despite the potent in vitro activity of tubulysins against various cancer cell lines, their 
therapeutic use is hindered due to severe toxicity. Therefore different approaches for targeted 
delivery of tubulysin derivatives are pursued in order to improve their therapeutic benefits. At 
the moment tubulysin folate conjugates,[129;130] polymeric tubulysin-peptide nanoparticles,[131] 
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and tubulysin analogue-dendrimer conjugates[132] are under investigation. For all these 
approaches the tubulysin core is covalently linked to its carrier via the C-terminus of the 
molecule. For the connections various tubulysin derivatives and linker chemistries are used. 
In this context the glycerol moiety might present a promising alternative for linkage to a 
macromolecular carrier, since the ester bond can most likely be cleaved by human esterases to 
release the cytotoxic tubulysin agent in situ. 
2. Biosynthesis of the quinoline alkaloids aurachins in 
Stigmatella aurantiaca Sg a15 
The aurachins are quinoline alkaloids produced by the myxobacterium Stigmatella aurantiaca 
Sg a15. They exhibit a broad range of biological activities including antimicrobial[133] and 
anti-plasmodial[134] properties. The targets underlying these properties are the mitochondrial 
respiration complexes I (aurachin A and aurachin B) and III (aurachin C and aurachin D)[46] as 
well as the cytochrome b6/f-complex,[45] both of which are inhibited by the aurachins due to 
their structural similarity to vitamin K. The structure of the aurachins is composed of an 
oxygen substituted 2-methylquinoline core and a farnesyl side chain. Aurachins can be 
classified into two structural types based on the position of the farnesyl substitution. 
Aurachin A and aurachin B are A-type aurachins with the farnesyl residue at position C4 
whereas the C-type aurachins, aurachin C and aurachin D, feature the farnesyl side chain at 
position C3. A previous study demonstrated the involvement of a type II PKS in formation of 
the 2-methyl-4-hydroxyquinoline core.[86] The various aurachins are connected via a 
biosynthetic sequence from aurachin D to aurachin A involving diverse oxidation reactions 
and an exceptional 3,4-migration of the farnesyl side chain. The biochemical steps involved in 
the biosynthesis of the quinoline core, as well as the downstream oxidations and the alkyl 
migration display atypical reactions remote from textbook biochemistry. Both in vivo 
inactivation experiments and in vitro characterization of particular enzymes revealed an 
unprecedented starter unit priming mechanism (Chapter 4). The identification of the 
complete set of genes required for biosynthesis up to the most highly elaborated aurachin A 
was accomplished by in vivo inactivation experiments in Sg a15 (Chapter 5). Based on these 
findings it is now possible for the first time to postulate a comprehensive model for the 
biosynthesis of all aurachins (Figure C-2). 
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Figure C-2. Proposed biosynthetic pathway of aurachins. 
Aurachin biosynthesis is initiated by the priming of an anthranilate starter unit to the sole 
ACP (AuaB) encoded within the aua genes. This proceeds via a novel non-acetate priming 
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strategy never before observed in thiotemplated biosynthetic machineries. Besides holo-AuaB 
two homologues of aryl:CoA ligases, AuaEII and AuaE, catalyze substrate activation and 
ACP loading, respectively. AuaEII activates anthranilate in presence of Mg2+, ATP and 
CoASH via an adenyl (AMP) intermediate to anthraniloyl-CoA, which in turn functions as the 
substrate for AuaE mediated transfer of anthranilate to holo-AuaB by transthioesterification to 
complete starter unit priming. There is experimental proof that AuaE can also transfer the 
anthraniloyl-AMP intermediate, formed by AuaEII, to holo-AuaB, although with 
approximately 1000 fold lower efficiency. Based on the homologies of AuaC and AuaD to 
condensing enzymes it is expected that anthraniloyl-AuaB is extended by two malonyl 
building blocks, supplied either as malonyl-CoA or malonyl-ACP (-AuaB). The quinoline 
core is assumed to be formed by nucleophilic attack of the aromatic amine at the β-carbonyl 
carbon of the twice extended polyketide intermediate, most likely while it is still attached to 
AuaB and presumably assisted by the AuaC/AuaD complex. Subsequent hydrolytic release 
and decarboxylation of the terminal carboxyl group yields 2-methyl-4-hydroxyquinoline. 
Alternative scenarios based on hydrolytic release of the polyketide intermediate from the 
carrier protein and spontaneous heterocycle formation either prior to, during, or after 
decarboxylation, cannot be excluded as long as the reaction has not been thoroughly 
investigated in vitro. Complete in vitro validation of these steps has been hampered so far by 
difficulties in obtaining soluble AuaC protein despite numerous efforts. Aurachin biosynthesis 
proceeds with the membrane-bound prenyltransferase AuaA catalyzing the transfer of a 
farnesyl moiety from farnesylpyrophosphate (FPP) to position C3 of 2-methyl-4-
hydroxyquinoline to yield aurachin D.[135] The Rieske oxygenase AuaF accounts, in 
conjunction with a still unidentified reductase partner, for the transformation of aurachin D to 
aurachin C by N-hydroxylation. The migration of the farnesyl side chain from C3 to C4 
involves monooxygenation, reduction, and subsequent elimination of water to trigger the 
alkyl rearrangement. The involvement of an oxidation reaction has been established 
previously by exhaustive feeding experiments. Feeding of [4-13C18O] aurachin C, that was 
isolated beforehand from cultures of Sg a15 fed with [1’-13C18O2] anthranilic acid, to a fresh 
culture of Sg a15 and subsequent isolation of the final product aurachin A revealed that the 
oxygen label was lost during the rearrangement.[136] Assuming that the oxygen at position 4 is 
eliminated in the rearrangement reaction, the introduction of another oxygen atom in the 
course of the farnesyl migration is required to account for the two oxygen atoms found in 
aurachin B and aurachin C. Further feeding experiments with 18O2 oxygen revealed that the 
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oxygen substituent at position C3 of aurachin A is derived from molecular oxygen and not 
from the carbonyl oxygen originating from the anthranilate starter unit.[136] In more detail: 
AuaG is suspected to catalyze epoxidation of the 2,3 double bond to form an aurachin C 
2,3-epoxy intermediate. Subsequent reduction of the C4-keto group by AuaH yields an 
aurachin C 2,3-epoxy,4-hydroxy intermediate (I), for which a tautomeric aurachin C N-oxide 
3,4-diol intermediate (II) can be postulated. Upon protonation of the 4-hydroxy group this 
intermediate (III) is expected to eliminate water, yielding a C4-carbocationic intermediate 
(IV). IV is expected to be the direct precursor undergoing the actual alkyl migration from C3 
to C4 (V) to give the A-type product aurachin B after deprotonation. From a chemical point of 
view this series of reactions is akin to a pinacol rearrangement.  The sequence of reactions is 
expected to be assisted by the AuaH active site as it is very unlikely to drain of spontaneously 
without a favorable environment. This reaction mechanism strongly differs from the one 
postulated by Höfle and Kunze who predicted a migration of the farnesyl side chain to the C4 
carbonyl prior to elimination of water, which should be brought about by a push-pull effect 
between the nitrogen and the carbonyl group.[136] However, with our additional knowledge 
about the involved functionalities of AuaG and AuaH, the newly postulated mechanism seems 
to be more likely. For the last biosynthetic conversion AuaJ is expected to catalyze 
epoxidation of the 2’,3’ double bond of the aurachin B farnesyl side chain. This 2’,3’-epoxy 
aurachin B intermediate is supposed to undergo intramolecular nucleophilic attack of the 3-
hydroxy group at C2’, leading to formation of the dihydrofuran heterocycle. The simultaneous 
opening of the epoxide yields a 3’-hydroxy group and thereby the final product aurachin A. 
This hypothesis is supported by the feeding studies with 18O-labelled oxygen,[136] although the 
proposed intermediate III has not been discovered from the cell extracts, either due to its 
instability in complex solutions, or due to rapid enzymatic turnover.  
The completion of the puzzle of aurachin biosynthesis affirmed once more the 
outstanding features of this biosynthetic pathway. The anthranilate priming is reminiscent of 
EncN-mediated loading of benzoate in enterocin biosynthesis,[137] however involvement of 
two distantly located CoA ligase homologues has so far been unprecedented. CoA ligases and 
A domains of NRPSs, that both belong to the ANL superfamily of adenylating enzymes, carry 
out the synthesis of acyl- or aryl-thioesters in a two-step reaction. The first half-reaction 
consists of the adenylation of the carboxylic group of the substrate to form an acyl- or 
aryl-AMP intermediate. In the second half-reaction, the thiol group of CoA or of the 
phosphopantetheinyl arm of the PCP attacks the acyl carbon with subsequent elimination of 
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AMP. Biochemical characterization of recombinant AuaE and AuaEII revealed that only 
AuaEII was capable to form anthraniloyl-CoA. The inactivity of AuaE could be justified by a 
C-terminal truncation of the enzyme sequence compared to homologous enzymes, leading to 
a lack of a conserved lysine residue, which is known to be essential in the adenylate forming 
half-reaction, and therefore accounts for the enzymes inactivity. The absolute requirement of 
AuaE for aurachin biosynthesis established by in vivo inactivation of the gene in Sg a15 could 
be rationalized by in vitro experiments demonstrating that AuaE mediates anthranilate 
priming of holo-AuaB from either anthraniloyl-AMP or anthraniloy-CoA. The biochemically 
relevant pathway was determined by kinetic studies, which revealed a 1000 fold higher Km 
value for anthraniloyl-AMP compared to anthraniloyl-CoA. AuaE is the first enzyme 
described in the ANL superfamily that catalyzes a transthioesterification reaction for the 
loading of a carrier protein involved in polyketide biosynthesis. AuaE, which has obviously 
evolved from an aryl-CoA ligase ancestor, is functionally equivalent to PKS ATs which 
belong to the unrelated α/β hydrolase superfamily.[138] Such convergent evolution may be 
advantageous as existing substrate specificity can be maintained. This view is supported by 
analysis of the 10-amino acid (aa) code that predicts specificity of NRPS A domains.[61;62] The 
specificity conferring aa-residues of AuaE are in very good agreement with those extracted 
from known bacterial anthranilate-activating enzymes. 
Polyketide biosynthesis has many parallels to fatty acid biosynthesis. Phylogenetic studies 
have revealed complex evolutionary relationships among PKSs themselves and prokaryotic 
and eukaryotic fatty acid synthases.[139;140] The type II fatty acid synthetic pathway found in 
bacteria and plants consists of a set of discrete proteins, that catalyze discrete steps in chain 
elongation.[141] In this pathway three different types of condensing enzymes, called β-keto-
ACP synthases I, II and III, also known as 3-oxoacyl-(acyl-carrier protein) synthases I, II, and 
III, or FabB, FabF, and FabH respectively, are involved which perform different condensation 
reactions on the route to fatty acids.[142] Polyketide synthases show highest homology to 
KASII (FabF) enzymes. AuaC and AuaD were originally identified as a putative KSα/KSβ 
pair of type II PKS, presenting the first instance of such a system to be reported from a 
Gram-negative bacterium.[86] This is still exceptional, as to date only one further example for 
a type II PKS from a Gram-negative bacterium has been described (ant-gene cluster from 
Photorhabdus luminescens).[87] However, the similarities of AuaC and AuaD to KSα and KSβ 
from actinomycetes are not convincing and based on recent sequence updates in the public 
sequence databases, the closest homologues identified for AuaC and AuaD were found to be a 
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pair of proteins encoded by neighbouring genes in Candidatus Kuenenia stuttgartiensis 
CAJ74368 (43% identity/63% similarity) and CAJ74369 (32% identity/49% similariy) 
respectively, both annotated as β-keto-ACP synthases (KASII). These homologues are part of 
a cluster, which based on its annotations (CAJ74365, similar to isocitrate dehydrogenase; 
CAJ74366, ACP; CAJ74367, similar to hydroxymyristoyl ACP dehydratase; CAJ74370, 
similar to phytoene dehydrogenase), seem to be involved in fatty acid metabolism. In order to 
assign the phylogenetic relationships of AuaC and AuaD sequence alignments with members 
of the KASII family and KSα/KSβ pairs have been performed and a phylogenetic tree was 
generated (Figure C-3). KSαs conserve the Cys-His-His catalytical triad identified for 
KASII,[142] whereas in the KSβs the respective residues are replaced by Gln, Asp, and Arg. 
The sequence of AuaC shows perfect conservation of the Cys-His-His triad, whereas the 
AuaD sequence features Thr, Ser, and Glu at the respective positions, thereby differing from 
the residues usually found in the sequences of KSβs. Remarkably CAJ74369 (Val, Asn, and 
Glu) and RemB[143] (KSβ from resistomycin biosynthesis; Arg, His, and His) neither show 
conservation of these residues. The conserved Gln residue, which replaces the active site Cys 
in KSβs, has previously been postulated to be involved in acetate starter unit priming by 
promoting the decarboxylation of a malonyl building block. [78;144] This role was recently 
challenged by the inspection of the crystal structure of the actinorhodin KSα/KSβ 
heterodimer, attributing this activity rather to the KSα.[92] Thereby the duty of the KSβ is 
assumed solely in complex formation with KSα to form an amphipatic tunnel at the 
heterodimer interface that can accommodate the growing polyketide intermediate. 
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Figure C-3. Sequence alignment of AuaC, AuaD and their closest homologues with KASII from 
different species and KSα/KSβ pairs from actinorhodin (act), R1128 substances (zhu), tetracenomycin 
(tcm) and resistomycin (rem) biosynthetic pathways. Identifiers of sequences with reported crystal 
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structures that have been included in the analysis are shown in bold. Active site residues are indicated 
by asterisks. Further catalytically important residues are marked in red. Residues that have been shown 
to be involved in dimerization are marked in blue.  
In contrast KASII enzymes form homodimers with each monomer capable of growing an acyl 
chain into a tunnel created by the dimer interface.[145] Structural features accounting for 
dimerization have been deduced from the crystal structures of both KASII and KSα/KSβ. For 
KASII it has been described that mainly hydrophobic residues of the loops between α2 and β3 
and between β8 and α13, the helices α6, α7, and α8 and the strands β8 and β12 are involved in 
dimerization (residues marked in blue in the sequence of Thermus thermophilus HB8 (T. the) 
KASII).[145] A principle contact is thereby made by a Met or Ile (part of a highly conserved 
His-(Met/Ile)-Thr motif) that is inserted into a hydrophobic pocket of the other monomer. 
This His-(Met/Ile)-Thr motif is also conserved for AuaC and the members of the KSα family. 
The members of the KSβ family on the other hand show no conservation of this motif. The 
crystal structure of the actinorhodin KSα/KSβ heterodimer revealed that the KSα employs this 
motif to make contact to the KSβ, whereas the KSβ uses a Trp from a different loop to 
connect to the KSα. 
Current hypothesis is that the KSβs arose from an ancient KSα gene by duplication and 
subsequent evolution of the KSβ into a structural partner for the KSα resulting in a 
heterodimer that is able to shield the binding pocket for a highly reactive polyketide 
intermediate up to a defined maximum size.[146] The fact that KSα and KSβ sequences form 
distinct clades in phylogenetic analyses suggests that all KSα/KSβ heterodimers are 
descendants of a common ancestor.[146]  
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Figure C-4. Phylogenetic relationships of AuaC and AuaD (framed) with selected members of the 
KASII (marked in grey), KSα (marked in red), and KSβ (marked in blue) families, inferred by Bayesian 
estimation. Sequence of DEBS KS1 has been used as outgroup. The tree is unrooted. 
Phylogenetic analysis of sequences of KSα/KSβ pairs and KASIIs along with sequences of 
AuaC, AuaD, CAJ74368, and CAJ74369 (Figure C-4) revealed as expected a clustering of 
KSα, KSβ, and KASII sequences, respectively. Both AuaD and CAJ74369 fall into the KSβ 
clade although they form the most distant branch. It has been noted before that KSβ sequences 
show a higher degree of divergence than KSα sequences, probably in response to formation of 
products of different chain length.[147] This is supported by the fact that a wider branching of 
KSβ sequences compared to the KSα sequences is observed. AuaC and CAJ74368 cluster 
neither with the KSαs from actinobacteria nor with the KASII sequences. Based on these 
results it can be envisioned that AuaC (and CAJ74368) are not derived from actinobacterial 
KSαs but stem from an independent convergent evolution originating from KASII. In order to 
clarify the exact roles of AuaC and AuaD in the formation of the 
2-methyl-4-hydroxyquinoline in vitro experiments reconstituting its biosynthesis are 
absolutely required. This approach has been hampered so far by difficulties in obtaining 
recombinant AuaC protein due to solubility problems. These problems could not be resolved 
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neither by the use of numerous fusion tags aiming at the improvement of solubility, nor by the 
screening of several expression conditions. Even attempts to co-express AuaC with its 
designated partner AuaD were not met with success. 
In the transformation of aurachin D to aurachin C, AuaF marks another precedent for the 
rare cases where Rieske oxygenases are involved in secondary metabolite biosynthetic 
pathways. Known examples from the literature comprise the biosyntheses of ambruticin,[148] 
jerangolid,[148] leupyrrin,[128] pyrrolnitrin,[149] streptorubin,[150] and metacycloprodigiosin.[151] 
The fact that 4 out of the 7 known cases are derived from myxobacteria, further highlights 
their exploitation of exceptional biochemical reactions for secondary metabolite biosyntheses. 
Besides the Rieske oxygenase AuaF two FAD-dependent monooxygenases are involved in 
the late stage oxidations transforming aurachin C via aurachin B to aurachin A. Particularly 
the conversion of aurachin C to aurachin B, that includes epoxidation of the quinoline core 
(mediated by AuaG) and subsequent reduction of the C4-carbonyl group (mediated by AuaH) 
which after elimination of water culminates in the migration of the farnesyl moiety, is 
unprecedented in secondary metabolite biosynthesis. The investigation of the biochemical 
details and the putative cooperation of AuaG and AuaH present a very interesting topic for 
further investigations. The transformation of aurachin  B to aurachin A, which is expected to 
proceed via double bond epoxidation of the farnesyl side chain followed by an intramolecular 
epoxide opening with simultaneous cyclization is expected to involve AuaJ and AuaI and is 
both chemically and enzymatically reminiscent of polyether ring formation during monensin 
biosynthesis.[152] The successive character of tailoring reactions seems to be strict, since the 
auaF mutant accumulated only aurachin D but no aurachin B and aurachin A derivatives 
missing the N-oxide function were found. This indicates that the N-hydroxyl/N-oxide function 
might be crucial for acceptance by the downstream tailoring functionalities.  
All in all biosynthesis of the aurachins is striking in that it requires the concerted 
expression of many functionalities encoded at various genetic loci. Besides loci I-III the 
expression of the previously identified DAHP synthase[153] and presumably the anthranilate 
synthase complex (TrpE/TrpG) from primary metabolism[154] have to be coordinated. The 
DAHP synthase gene is part of the operon coding for the biosynthetic machinery of the 
siderophore myxochelin.[100] This may implicate iron homeostasis in the regulation of 
aurachins biosynthesis. Additional enzymes such as the reductase partner of AuaF and a 
malonyl-CoA:ACP transacylase putatively required for 2-methyl-4-hydroxyquinoline 
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formation remain unidentified. Such split cluster organization raises the question of how these 
genes are regulated to function together which has yet to be elucidated.  
The aurachin gene cluster organization in different loci is most likely the result of 
successive acquisition by horizontal gene transfer and adaptation of the functionalities that 
were originally dedicated to other pathways. In support of this hypothesis, biosynthetic genes 
of aurachins on loci I-III do not have orthologues in S. aurantiaca DW4/3-1 (non-producer of 
aurachins) which is closely related to Sg a15, albeit both genomes share high synteny. In 
contrast, regions flanking each locus are well conserved in both genomes. In summary, the 
split organization may not only represent an advantage to facilitate differentiated regulation, 
but also facilitate acquisition or loss of tailoring genes to generate new aurachin structures. In 
the future, it will be instructive to study the regulatory mechanism and evolution aspect of 
aurachins biosynthesis in order to contribute to the general understanding of secondary 
metabolism.   
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3. Biosynthesis of the quinoline HHQ in P. aeruginosa as potential 
target for therapeutic interference to attenuate virulence 
Pseudomonas aeruginosa is one of the most clinically important pathogens, causing a 
multitude of nosocomial infections, especially in cystic fibrosis (CF) patients, where it is the 
main perpetrator of the shortened lifespans of patients.[106] The evoked lung infections can be 
both acutely life threatening and cause long-term lung damage due to lingering colonization. 
Therapy of P. aeruginosa infections is complicated by widespread antibiotic resistance [155] 
and the formation of small colony variants and biofilms that contribute to persistence. 
Biofilms display an unspecific antibiotic resistance mechanism based on greatly reduced 
penetration of the antibiotic agent into the biofilm matrix. The formation and maturation of 
these biofilms,[156] as well as the production of the bulk of the many different virulence factors 
excreted by P. aeruginosa, like alkaline proteases, elastase, lipase, lectins A and B, hydrogen 
cyanide and pyocyanin,[157;158] to name only a few, is controlled by small molecule 
intercellular signalling, referred to as quorum sensing (QS). QS is based on the production 
and release of small signalling molecules, called autoinducers, that increase in concentration 
as a function of cell density and activate corresponding transcriptional regulators after a 
threshold concentration has been reached.[102] QS is widespread among bacteria, though the 
nature of specific autoinducers is quite diverse. Gram-positive bacteria mainly use processed 
oligopeptides, whereas Gram-negative bacteria use acylated homoserine lactones.[103] In P. 
aeruginosa, three different QS systems are known. The las and rhl systems use 
acyl-homoserine lactone (AHL) autoinducers and belong to the LuxI/LuxR type systems. The 
third system is rather unique and restricted to particular Pseudomonas and Burkholderia 
strains. Here, 2-alkyl-4(1H)-quinolones (AQ) autoinducers such as 
2-heptyl-3-hydroxy-4(1H)-quinolone (Pseudomonas quinolone signal, or PQS) and its direct 
precursor 2-heptyl-4(1H)-quinolone (HHQ) are used.[104] These systems are interconnected 
with each other and arranged in a certain hierarchy. To sum it up very briefly and simply, the 
las system positively regulates both the rhl and pqs systems, whereas the pqs system 
positively regulates the rhl system, which in turn negatively regulates the pqs system (see 
Figure C-5). [159;160] 
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Figure C-5. Simplified hierarchy of the las, rhl, and pqs quorum sensing systems in P. aeruginosa 
including chemical structures of the autoinducers used by the respective systems. Possible targets for 
interference with the pqs system to either inhibi biosynthesis of the autoinducer or its binding to the 
receptor are also indicated. 
Transcriptional and proteomics studies have shown that around 400 genes, corresponding to 
6-7% of the total genome, are regulated by these three QS systems.[161] The las, rhl, and pqs 
systems regulate the timing and production of multiple virulence factors and biofilm 
formation. In several models, las and pqs signalling deficient mutants were unable to form 
structurally normal biofilms.[156;162] These effects make the QS system a highly attractive 
target for drug development through interference with P. aeruginosa pathogenicity and 
biofilm formation. Compounds capable of inhibiting QS signaling could represent the next 
generation of anti-infective therapeutic agents.[163] It is hoped that an attenuation of bacterial 
virulence (i.e., inhibition of virulence factor production) without necessarily threatening the 
single cell would ease pressure on the evolution of resistance mechanisms.[164] The 
attenuation of virulence may also enable the host`s immune system to eliminate the pathogen 
on its own. Further, an adjunction with classical antibiotics will most likely exhibit synergistic 
effects. However, the development of bacterial resistance to QS signalling inhibitors can only 
be evaluated once such compounds are in broad clinical use. Such drugs might also be of 
major therapeutic value when used to coat of medical devices that tend to be colonized by 
QS-signalling pathogens to prevent biofilm formation.  
The general validity of QS as target for anti-infective therapy in P. aeruginsosa is 
supported by several animal infection models in which QS-deficient mutants of every 
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respective system exhibit attenuated virulence levels compared to P. aeruginosa wild 
type.[158;165;166] The assumption that these three QS systems also play a role in P. aeruginosa 
colonization and chronical infection of CF patients is supported by the fact that all three 
autoinducer molecules 3-oxo-C12-HSL, C4-HSL and PQS have been detected in sputum of CF 
patients in significant concentrations.[167;168] These results seem to contradict the finding that 
QS-deficient P. aeruginosa mutants are often isolated from infected CF patients.[169] Thereby, 
the importance of QS for P. aeruginosa during CF infections may be brought into question. 
The enrichment of QS-deficient mutants during chronic infections in CF patients can be 
explained by the phenomenon of “social cheating”.[170] Although the bacterial population 
benefits from the concerted gene transcription mediated by QS, the single cell incurs an 
enormous metabolic burden. Individuals that cease the production of public goods due to a 
lack of QS signal transduction, called cheaters, can still benefit from the cooperative actions 
of the remaining population and display a gain in individual fitness. However, “social 
cheaters” are dependent on a sufficient fraction of QS participants to maintain the overall 
population benefits, a situation also observed in infected CF patients, where the QS deficient 
mutants never completely replace the wild type. Therefore, complete interruption of 
P. aeruginosa QS in chronic CF infections by drug therapy should be beneficial for 
eradication.  
In general, there are several strategies for QS signalling interference. Firstly, inhibition of 
enzymes that catalyze autoinducer synthesis and inhibition of the receptors that bind the 
autoinducers and mediate the downstream processes are together known as “signal 
interference”. “Quorum quenching” represents the degradation of autoinducer molecules by 
dedicated enzymes such as AHL acylases and AHL lactonases.[103] While enzyme-dependent 
“quorum quenching” is, for obvious reasons, likely not a viable therapeutic strategy, both 
“signal interference” strategies have great potential for the development of small molecule-
derived inhibitors.  
Biosynthesis of AHLs has been elucidated in detail. They are synthesized by LuxI 
homologues from acyl-ACP derivatives and S-adenosyl-L-methionine (SAM).[103] The most 
promising strategy for LuxI-mediated AHL biosynthesis inhibition might therefore be to 
utilize SAM analogs. However, it is questionable if this approach can provide valuable drug 
candidates for human therapy, since SAM is vital for several processes in both bacterial and 
human cells and may lead to both rapid emergence of bacterial resistance and severe side 
effects in humans. The development of receptor antagonists based on AHL derivatives might 
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be hampered as long as they are recognized as substrates for the above mentioned AHL 
acylases and AHL lactonases, which are expressed by a broad range of Gram-negative 
bacteria. Resistance to small molecule inhibitors are more likely to emerge if a broad 
spectrum of bacteria is affected. Aiming at selective QS interference against P. aeruginosa, it 
should therefore be most promising to target the pqs system, which employs HAQ 
autoinducer molecules and thereby eliminates the aforementioned problems. A first proof of 
principle that the pqs system can be targeted by small molecules was obtained from a mouse 
infection model, where animals infected with P. aeruginosa were treated with halogenated 
anthranilic acid derivatives inhibiting PQS biosynthesis. This treatment led to a significant 
increase in survival in comparison to the control group.[171] Knowledge of HAQ biosynthesis 
compared to that of the AHLs has so far been only rudimentary. Further exploration of this 
target requires profound knowledge of PQS formation in P. aeruginosa. It is known that 
pqsA-D are absolutely required for HHQ biosynthesis,[105] encoding an anthranilate:coenzyme 
A (CoA) ligase (pqsA) and three β-ketoacyl-acyl carrier protein synthase III (KAS III) 
homologues.[172] An additional gene (pqsH) located apart from pqsA-D is responsible for the 
hydroxylation of HHQ to form PQS. Feeding studies in vivo have demonstrated that HHQ 
most likely arises from “head-to-head” condensation of an anthraniloyl precursor and a β-keto 
fatty acid derivative.[173] However, the details of the enzymatic mechanism of this reaction and 
the nature of the β-keto fatty acid remained elusive. The formation of 2,4-dihydroxyquinoline 
(DHQ), another secondary metabolite of P. aeruginosa has been reconstituted in vitro with 
recombinant PqsA and PqsD proteins.[174] Based on the structural similarity between DHQ 
and HHQ, it was rationalized that PqsD might be involved in a similar condensation reaction 
in HHQ biosynthesis. Indeed, it was shown that recombinant PqsD protein was capable of 
forming HHQ from anthraniloyl-CoA and β-ketodecanoic acid. Considering the molecular 
mechanism of HHQ formation by PqsD, two possible reaction mechanisms are conceivable. 
Either the reaction would proceed via an imine intermediate of anthranilate and β-
ketodecanoate followed by decarboxylative Claisen condensation to form the heterocycle and 
release the final product from the enzyme, or the sequence of reactions would start with 
decarboxylative Claisen condensation of the β-keto fatty acid and anthraniloyl-CoA, followed 
by heterocycle formation via intramolecular condensation and elimination of water, 
presumably assisted by PqsD in anology to the reactions catalyzed by chalcone synthases.[175] 
By an elaborate experimental approach, it was demonstrated that the latter holds true.  
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The in vitro reconstitution of HHQ biosynthesis by means of recombinant PqsD protein 
formed the basis for the further development of an in vitro assay to screen for inhibitors of 
PqsD function. For this purpose, PqsD, anthraniloyl-CoA, β-ketodecanoic acid and increasing 
concentrations of the potential inhibitor were mixed, incubated for a defined time period, and 
HHQ formation quantified by HPLC-MS/MS. Comparison of HHQ levels formed in presence 
of various concentrations of putative inhibitors to that formed in control reactions without 
inhibitor allowed the determination of the half maximal inhibitory concentration (IC50) of the 
tested compound. The feasibility of this in vitro approach was experimentally validated with 
well-known synthetic FabH inhibitors that were chosen on the basis of structural and 
functional homologies between FabH and PqsD. 
The advantages of this in vitro assay are its uncomplicated read-out, since it bypasses the 
complex and interconnected QS networks in P. aeruginosa that would complicate initial hit 
identification in vivo. Further, it enables testing without the opportunistic pathogen, which 
permits a reduction of safety measures. The assay delivers results quickly and has the 
potential for adaptation to high-throughput screening (currently under development at our 
collaborators from Sanofi-Aventis). In addition, it is possible to test compounds with inherent 
antibiotic activity, such as FabH inhibitors, for inhibition of HHQ formation which is neither 
possible in P. aeruginosa nor in the established reporter gene coupled in vivo assays.[176] 
Though antibiotic activity of a QS inhibitor might not be desirable with regards to the 
development of bacterial resistance, a PqsD inhibition assay that allows the screening of 
compounds with inherent antibiotic activity in the initial compound hit identification phase is 
highly beneficial. This assay might therefore prove to be a valuable tool in the development of 
small molecule inhibitors of PqsD function. 
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4. Rhizopodin biosynthesis: Identification and characterization of 
a trans-AT PKS molecular assembly line 
The steady rise of accessible bacterial whole genome sequences in combination with the facile 
in silico identification of NRPS and PKS biosynthetic gene clusters revealed for all so far 
investigated secondary metabolite (SM)-producing bacteria a much higher genetic potential 
for SM-biosynthesis then realized by production of the SMs known from the respective 
strains (Figure C-6).[19;20;22;23] At present, the identification and correlation of SMs from so 
far unassigned biosynthetic gene clusters represent a significant bottleneck that constrains the 
exploitation of the extensive potential bacterial secondary metabolome.  
 
Figure C-6. Genetic potential for secondary metabolite biosynthesis of selected fully sequenced 
prokaryotes. The bars indicate in silico identified PKS and/or NRPS biosynthetic gene clusters. The red 
fractions indicate secondary metabolites known to be produced by the strain at the time of genome 
sequencing (figure modified from Wenzel and Müller, Nat. Prod. Rep., 2009, 26, 1385-1407). 
In this context the myxobacterial strain Myxococcus xanthus DK1622 presents a prominent 
example. Prior to the availability of its genome sequence DK1622 was not known to produce 
any secondary metabolites at all. Only after in silico analysis of its genome it turned out that 
DK1622 holds a huge genetic potential for SM biosynthesis, encoding for a total 18 
biosynthetic gene clusters of NRPS, PKS, and NRPS-PKS hybrid systems,[177] which 
corresponds to 8.5% of the total genome size. Until recently only 5 out of the potential 18 
SMs from DK1622 were identified (the myxalamids, myxochelins, myxochromides A, 
myxovirescins, and DKxanthenes; all initially isolated from different myxobacterial strains), 
leaving 13 unassigned biosynthetic pathways. Transcriptomic and proteomic studies attested 
the presence of transcripts and/or proteins for all of those 13 assembly lines, thereby 
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implementing their activity, at least on a very low level.[178;179] The elaboration of an 
approach, wherein targeted gene inactivations were coupled with a global metabolite mining 
approach consisting of HPLC-HRMS analysis and data evaluation supported by statistical 
tools, culminated in the recent identification, isolation, and structure elucidation of the 6th SM 
from DK1622, called myxoprincomide (Cortina et al. in preparation). In addition, masses 
corresponding to SMs could be assigned to another two biosynthetic pathways. One can 
assume that most of the 10 remaining unassigned clusters also produce SMs, at least at very 
low levels, which have so far escaped detection for unknown reasons (e.g. low abundance, 
instability, extreme (a)polarity, bad ionization). The solely “manual”, or more precisely 
visual, comparison of HPLC-HRMS data from extracts of a mutant versus a wild type 
(especially in the case of myxobacteria) is a very tedious process that may remain fruitless 
even for a skilled operator, due to the stunning complexity of the data and the huge 
differences in signal intensities that easily mask low abundant compounds. The 
implementation of statistical tools proved instrumental in the elimination of this constraint 
towards comprehensive comparative HPLC-HRMS data evaluation. Statistical supported 
HPLC-HRMS data evaluation requires several biological replicates to fade out random 
variations. The raw data are processed with an algorithm which, based on the presence or 
absence of isotopic patterns, is able to distinguish between “true” MS signals (molecular 
features) and background noise. Based on the combination of m/z values of molecular 
features and the respective retention time, so called buckets are created. These buckets present 
the input values for the statistical evaluation of the data sets. The ProfileAnalysis software 
interface (Bruker Daltonics) provides two independent methods for classification of these 
preprocessed HPLC-HRMS data sets, the principal component analysis (PCA) and the 
Student`s t-test. PCA is a mathematical projection technique designed to extract, display and 
rank the variance in a data matrix. The goal of this operation is to reduce the dimensionality 
of multivariate data sets without losing relevant information. Thereby PCA allows identifying 
the variables that are most influential to the variance of two data sets instead of being obliged 
to look at a larger number of variables in the original data matrix. In the so called loadings 
plot, every bucket calculated for the data set (represented by a small sphere) is spotted in a 
two-dimensional space spanned by PC1 and PC2 (the principal components that explain for 
the highest variance) based on its relation to the principal components. The further a bucket is 
away from the central cloud, the more responsible it is for the variance between two data sets.  
In contrast to the largely unsupervised data evaluation by PCA, the Student`s t-test is a 
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hypothesis driven statistical tool. The t-test also requires preprocessing of the data sets into a 
bucket format, from which it computes a sample inventory listing p-values, maximum 
intensities, average ratios and value counts for each bucket within a sample set. This 
inventory table is extremely useful since a biosynthetic pathway knockout mutant will exhibit 
a value count of zero for the bucket corresponding to the respective SM whereas the wild type 
will exhibit a value count equal to the number of replicate samples analyzed. So far both 
methods still produce quite a number of false positive hits and therefore require another round 
of manual verification of the results. However, they greatly reduce the number of molecular 
features to check, from up to 5000 in the original data set to usually around 30-50 after 
statistical analysis.  
This comprehensive secondary metabolomic approach proved to be a very powerful tool 
for the identification of non-ubiquitous SM candidate compounds.[180;181] Other approaches 
for genomics driven secondary metabolite mining described in the literature have severe 
drawbacks and cannot compete with the output of the approach described above.[182;183]  
Chapter 7 of this thesis describes how this approach was adapted for the SM correlation of a 
so far unassigned biosynthetic gene cluster from Stigmatella aurantiaca Sg a15, identified 
from in silico analysis of the draft genome sequence of Sg a15. The SM was identified as 
rhizopodin, which was previously isolated from Myxococcus stipitatus Mx s11[184] and whose 
biosynthetic gene cluster was unknown so far. Neither was S. aurantiaca Sg a15 previously 
known as producer of rhizopodin. 
Rhizopodin is produced by a trans-AT PKS/NRPS assembly line. Currently 23 SMs are 
reported to be produced by such special variants of PKS that use freestanding instead of 
integral AT domains.[185] The trans-AT PKSs show a high degree of divergence from 
textbook colinearity rules established for cis-AT systems. Modular architectures with missing 
or superfluous domains or unusual domain orders are common in trans-AT PKSs, thus 
complicating correlation of PKS function to product structure.[186-188] Recently, an innovative 
approach based on phylogenetic clustering of KS sequences in relationship to their substrate 
specificity was developed and allowed prediction of core structures from trans-AT systems 
with a significantly improved reliability.[84;189] Phylogenetic analysis of the 19 KS-domains in 
the rhizopodin (riz) gene cluster with a large subset of KS sequences used in the initial 
publication revealed good agreement between substrate prediction based on phylogenetic 
clading and the postulated biosynthetic intermediates. Besides phylogenetic analysis of KS 
domains, prediction of product stereochemistry by each KR domain according to the 
C. Final discussion 
 
120 
conserved motifs [76;190;191] was in full agreement with the actual rhizopodin structure. The 
biosynthetic logic for the introduction of methoxy groups in rhizopodin is outstanding among 
trans-AT systems. Eleven (myxovirescin, pederin, onnamide, bryostatin, disorazol, rhizoxin, 
chivosazol, oxazolomycin, etnangien, kirromycin and thailandamide) out of the 23 reported 
core structures produced by trans-AT PKS systems, incorporate one or up to three methoxy 
groups. For all of these SMs, except for etnangien and thailandamide, the methoxy groups are 
introduced into the molecules by free-standing O-methyltransferases (MTs) in post-assembly 
line tailoring reactions. Rhizopodin biosynthesis deviates from this logic by the employment 
of non-extending modules of KS0-(O-MT)-ACP architecture, which are solely dedicated to 
methylation of the β-hydroxyl group (Riz KS3, KS7, KS14, and KS18). Interestingly, the 
respective downstream KS domains (Riz KS4, KS8, KS15, and KS19), that will accept 
β-methoxylated intermediates, form a new subclade in the trans-AT KS phylogenetic tree. 
The benefit of using embedded O-MTs in rhizopodin biosynthesis consists in occurrence of 
only one final product, which is uniformly methylated at all eight relevant positions. Thereby 
the production of partially desmethylated derivatives, a case observed for many SMs featuring 
methoxy groups that are introduced by freestanding MTs, is avoided. In accordance with this 
theory, no partially desmethylated rhizopodin derivatives could be detected in extracts of 
Sg a15.  
In every reported case where SMs are built up by trans-AT PKS/NRPS hybrid systems 
and contain oxazoline/oxazole or thiazoline/thiazole rings the heterocycles are introduced by 
tandem HC domains, a so far in the literature overlooked circumstance. Examples include 
leinamycin,[192] disorazol,[193] rhizoxin,[194] chivosazol,[195] virginamycin,[196] and rhizopodin. 
In NRPS or cis-AT PKS-NRPS systems generally a single HC domain is involved in 
heterocyclization of a serine or cysteine residue tethered on a PCP such as in  tubulysin,[121] 
epothilone,[197] and ajudazol biosynthesis.[198] However, two rare incidences of tandem 
HC-domains exist from the biosyntheses of the siderophores vibriobactin and anguibactin. 
[199;200] Biochemical characterization in vitro of VibF revealed that HC2 is responsible for the 
condensation reaction, whereas HC1 catalyzes the heterocycle formation.[201] Phylogenetic 
analysis revealed formation of distinct subclades for HC1 and HC2 sequences from trans-AT 
PKS/NRPS hybrid systems, both separated from single HCs and the HC1 and HC2 sequences 
related to siderophore biosynthesis. Due to the observed phylogenetic distance between the 
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trans-AT PKS/NRPS tandem HCs and the tandem HCs from vibriobactin and anguibactin 
biosynthesis it seems likely that they resulted from convergent evolution. 
The dimeric nature of rhizopodin is a very rare feature among bacterial secondary 
metabolites, including gramicidin S, enterobactin (trimer), thiocoraline (NRPS),[202] disorazol 
(NRPS-PKS-hybrid), the marinomycins and vermiculine (PKS; biosyntheses not yet 
elucidated).[203;204] TE-mediated formation of the dimeric (or trimeric) final product has been 
demonstrated in vitro for disorazol (Buntin K., unpublished results), gramicidin,[205] 
enterobactin,[206] and thiocoraline.[207] In analogy to these biosyntheses, the following model 
can be proposed for rhizopodin: The first monomer is transferred to the TE active site serine 
followed by nucleophilic attack of this acyl-O-TE intermediate by the hydroxyl group at C-18 
of the second monomer which is tethered to the upstream ACP, yielding a linear dimeric 
intermediate. The linear dimer would then be transferred to the TE active site, where 
intramolecular cyclization and product release by formation of a dilactone are catalyzed. 
Studies on TEs involved in the biosyntheses of gramicidin S and enterobactin showed that 
there are no obvious sequence differences accounting for their divergent catalytic capabilities, 
but it was observed that the linker region between the ACP and the TE was longer than usual 
in the case of GrsB (41 aa compared to ~15-20 aa).[205] Similarly, extended linkers are 
conserved in the rhizopodin and disorazol assembly lines (36 aa in RizE/~60 aa in DszC). 
Furthermore, in both cases a non-elongating KS0 domain is found upstream of the terminal 
ACP which may also play a role in the dimerization process.  
The rhizopodin assembly line includes several special features, such as an unusual 
biosynthetic logic for the introduction of methoxy groups and the presence of members of a 
new KS phylogenetic subclade, both not reported to date from other trans-AT PKSs. The 
provided data will help to expand the knowledge about trans-AT PKSs which is still far less 
comprehensive than that compiled for cis-AT systems over many years. 
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